Predicting Disease Progression in Scleroderma with Skin and Blood Biomarkers

Maureen D. Mayes, M.D., M.P.H.

E-Mail: Maureen.D.Mayes@uth.tmc.edu

The University of Texas
Health Science Center at Houston
7000 Fannin St., UCT 1006
Houston, TX 77030-5401

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for Public Release; Distribution Unlimited

Scleroderma (Systemic Sclerosis, SSc) is a chronic, incurable autoimmune disease associated with high morbidity and mortality primarily due to lung disease. There is a large variability in individual patients' courses and current predictors of disease progression are inadequate. The overall objective of the proposed research is to develop reliable predictors for clinical outcomes in scleroderma, utilizing the biospecimens and longitudinal clinical data in the GENISOS cohort combining data from multiple areas to develop robust prediction models for ILD progression. The GENISOS cohort is a unique and valuable resource for biomarker development; no other early SSc cohort exists that has serial biological samples linked to longitudinal clinical data and genetic markers. GENISOS is an inception cohort that avoids survival bias inherent in studies of prevalent cases (mean disease duration at GENISOS entry = 2.5 years, eligibility criterion mandates disease duration ≤ 5 years). The cohort was originally established in 1998 and this funding support permitted us to enroll additional patients, continue follow-up on previously enrolled subjects, collect bio-specimens (DNA, RNA in PAXgene tubes, serum, plasma, skin biopsies), perform laboratory studies and analysis as detailed in the Overall Project Summary section of the final report.
Predicting Disease Progression in Scleroderma with Skin and Blood Biomarkers
Proposal Log Number PR120687 (HRPO Log Number A-17770.1)
Award Number W81XWH-13-1-0452

PI: Maureen D. Mayes, M.D., M.P.H. Org: University of Texas Health Science Center at Houston Award Amount: $1,127,763.00

Study/Project Aim(s)
• Aim 1. To study genetic susceptibility variants (DNA) (identified from our previous GWAS, Immunochip and HLA studies) as predictors of progressive disease, in the GENISOS cohort
• Aim 2. To identify blood and skin gene expression profiles (RNA) predictive of progressive disease
• Aim 3. To identify the cytokines/analytes (protein) predictive of disease course utilizing multiplex assays
• 4. To build multivariable models with identified clinical and molecular predictors, utilizing advanced variable reduction and longitudinal analysis strategies

Approach - Funding for this project started 23 Sep 2013. The GENISOS (early scleroderma disease) cohort provides the subjects from which sample collection (DNA, RNA [PAXgene], skin biopsies, monocytes, and serum), clinical characterization and autoantibodies are obtained. Data collection is captured in an electronic database for analysis.

Timeline and Cost

<table>
<thead>
<tr>
<th>Activities</th>
<th>CY</th>
<th>13</th>
<th>14</th>
<th>15</th>
<th>16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Text (Major aim/study/milestone)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Text (Major aim/study/milestone)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Text (Major aim/study/milestone)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Text (Major aim/study/milestone)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated Budget ($K)</td>
<td>$85.3</td>
<td>$85.3</td>
<td>$85.3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Updated: 19 DECEMBER 2016

Goals/Milestones (relevant to this period):
Task 1: IRB & DOD HRPO approvals – Completed initial approvals, ongoing annual reviews up to date
Task 2a: Collection of DNA samples: 86 samples
Task 3a: Collection of Skin biopsy samples: 238 biopsies
Task 4a: Collection of monocyte samples: 355
Task 7: Calculation of fibrosis score of HRCTs (months 0-36) Dr. Ferguson has reviewed and scored a total of 98 HRCTs.
Task 8: Expansion of the GENISOS cohort: Cumulative 91 new enrollees, 405 follow-up visits.
Task 9: Maintenance and expansion of the GENISOS data base (months 0-36) tracking of all skin biopsies and blood samples has been added to the database, all visit data has been checked for quality (through our data quality measures) and entered.

Budget Expenditure To-Date
Projected Expenditure: $1,127,763.00 (Years 01-03)
Actual Expenditure: $1,122,056.58 (23 Sept 2013 thru 22 Sept 2016)
1. Introduction.............................................................................. 1
2. Keywords................................................................................. 1
3. Overall Project Summary...................................................... 1
4. Key Research Accomplishments........................................... 8
5. Conclusion............................................................................... 9
7. Inventions, Patents and Licenses............................................ 14
8. Reportable Outcomes............................................................. 14
9. Other Achievements.............................................................. 14
10. References.............................................................................. 14
11. Appendices............................................................................. 15
1. INTRODUCTION:

Scleroderma (Systemic Sclerosis, SSc) is a chronic, incurable autoimmune disease associated with high morbidity and mortality primarily due to lung involvement (1). There is a large variability in individual patients’ courses and current predictors of disease progression are inadequate (2). The overall objective of the proposed research was to develop more reliable predictors for clinical outcomes in scleroderma, utilizing the bio-specimens and longitudinal clinical data in the GENISOS cohort combining data from multiple areas to develop prediction models for ILD progression. The GENISOS cohort is a unique and valuable resource for biomarker development; no other early SSc cohort exists that has serial biological samples linked to longitudinal clinical data and genetic markers (3). GENISOS is an inception cohort that avoids survival bias inherent in studies of prevalent cases (mean disease duration at GENISOS entry = 2.5 years, eligibility criterion mandates disease duration $\leq$ 5 years). The cohort was originally established in 1998 and this funding support permitted us to enroll additional patients, continue follow-up on previously enrolled subjects, collect bio-specimens (DNA, RNA in PAXgene tubes, serum, plasma, skin biopsies), perform laboratory studies and analysis as detailed below in OVERALL PROJECT SUMMARY.

2. KEYWORDS:

Scleroderma
Systemic Sclerosis
GENISOS (Genes versus Environment in Scleroderma Outcome Study)
Interstitial Lung Disease
Predictors of Outcome
Cytokines
DNA
RNA

3. OVERALL PROJECT SUMMARY:

This report summary is divided into 4 sections – the first (3.a.) is a tally of cumulative subjects enrolled and followed up; the second section (3.b.) summarizes sample collection which supports the experimental sections; section 3.c. summarizes the meeting schedules necessary to coordinate this multi-step research project; and the fourth and longest section (3.d.) provides a summary of the data resulting from this work as they pertain to each Task separately.

3.a. Recruitment and follow-up of subjects in the GENISOS cohort (Task 8)
Recruitment of new subjects (Task 8) has continued throughout all 36 months of this project. The total number of new enrollees since the initiation of this project is 91 new subjects. In addition, 405 follow-up visits have been conducted. The proposed recruitment estimate was 120
new subjects. Although we have fallen somewhat short of this goal, we have collected more samples (see Table below) than originally proposed which provides us with additional statistical power to analyze changes over time and predictors of these changes.

3.b. Sample Collection (Tasks 2 through 4).
Cumulative sample collection to support the experiments in Tasks 2 through 4 is summarized in the Table below. Note that the number of skin biopsies (both initial biopsy at baseline entry into the cohort as well as follow-up biopsies) exceeded the proposed/estimated number. Along with this, the collection of monocytes, DNA, serum and PAXgene (for RNA gene expression) samples also exceeded our initial proposed/estimated number.

TABLE: Cumulative Sample Collection for GENISOS patients from 23 SEP 2013 through 23 SEPT 2016

<table>
<thead>
<tr>
<th>CUMULATIVE 1st through 12th Quarter</th>
<th>Proposed Sample Collection – GENISOS Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quarter</td>
<td>Time/ Months</td>
</tr>
<tr>
<td>1 thru 0-36</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CUMULATIVE 1st through 12th Quarter</th>
<th>ACTUAL Sample Collection – GENISOS Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quarter</td>
<td>Time/ Months</td>
</tr>
<tr>
<td>1 thru 0-36</td>
<td></td>
</tr>
</tbody>
</table>

F/U = Follow-Up; Bx = biopsy.

3.c. Coordination of projects and personnel
Weekly laboratory meetings and monthly research data meetings have been held to discuss the results of this project and to review current and future plans. The weekly laboratory meetings are attended by the PI (Mayes), the Co-Investigator (Assassi), the lab manager (Charles), the research assistant (Hau), the project coordinator (Theodore) and the Rheumatology Division manager (Gurtovnik) to review administrative issues regarding laboratory supplies and other issues. The monthly research data meetings are attended by investigators Drs. Mayes, Assassi, Pedroza and Ferguson as well as Mr. Theodore and Mr. Charles.

3.d. SUMMARY of PROGRESS per SOW TASKS:

Task 1: Institutional Review Board (IRB) (in months 1-2) and DOD Human Research Protection Office (HRPO). The initial IRB approvals were obtained early in Year 1 and annual reviews and renewals were obtained. Documentation has been provided to the DOD HRPO. There have been no substantive modifications to the protocol and no unanticipated problems involving risk to the subjects were encountered.

“Task 2: Collection of DNA samples, genotyping and analysis of genetic data (Specific Aim 1)”
“2.a. Collection of DNA samples (months 1-36): Forty new patients will be enrolled annually by Drs. Mayes and Assassi into the GENISOS cohort at UTHealth. DNA will be extracted from baseline blood samples by the Research Assistant in the laboratories of Division of Rheumatology at UTHealth.”

A total of 91 new subjects have been enrolled which, as noted in section 3.A. above, is less than initially estimated. DNA has been extracted from all blood samples and is stored in the Rheumatology Research Laboratory at UT Houston. These samples, as well as previously collected DNA samples, serve as the basis for the studies performed below.

“2.b. Genotyping by Taqman Assay: Genotyping data are available on the majority of patients in the GENISOS cohort through (previous) genome wide association study and Immunochip efforts. Genotyping by Taqman assays will be performed for selected susceptibility loci in the newly enrolled patients (120 by the end of funding period).”

“2.c. Analysis of genetic data.”

“2.d. Manuscript on genetic predictors of disease progression.”

We genotyped thirteen idiopathic interstitial pneumonia (IIP)-related single nucleotide polymorphisms (SNPs) by Taqman assay and analyzed them for their association with SSc overall or for the presence and severity of SSc-related lung disease (ILD). Surprisingly, we did NOT find an association with any of these SNPs. Our results add new evidence that SSc and SSc-related ILD are genetically distinct from IIP even though they share phenotypic similarities. (PMID 26792595)

In a related study, we continued analysis of SNPs associated with SSc and reported, along with our international colleagues and additional SSc cases and controls, that a polymorphism in CCR6 was associated with Scl-70 (antitopoisomerase or ATA) positive SSc. The CCR6 gene encodes for a chemokine receptor which plays a critical role in IL-17 driven autoimmunity. Scl-70 is the autoantibody that is associated with severe and progressive interstitial lung disease in SSc. Thus SSc-cases with this polymorphism may benefit from agents that block the IL-17 pathway. (PMID26314374)

“Task 3: Collection of skin samples, RNA extraction, gene expression analysis (Specific Aim 2)”

“3.a. Collection of skin biopsy samples. Drs. Mayes and Assassi will perform 60 skin biopsies per year at UTHealth.”

“3.b. RNA extraction and global gene expression study in skin samples. Purified RNA will be extracted from stored skin biopsy samples by the Research Assistant using commercially available kits in the laboratories of Division of Rheumatology at UTHealth. The RNA quantity and quality will be assessed by Nanodrop and Bio-analyzer in the CTSA Microarray Core Laboratories at UTHealth. Global gene expression profiling will also be performed in the Microarray Core Laboratories.”
“3.c. Analysis of skin global gene expression data. The analysis of skin gene expression data will be completed by Drs. Assassi and Gorlova in consultation with Dr. Michael Whitfield at Dartmouth Medical School (Dartmouth, NH).”

“3.d. Manuscript on skin gene expression predictors of disease progression.”

The cumulative number of skin biopsies is 238 (75 on newly enrolled subjects and 163 repeat/follow-up biopsies as noted in the Table above) which exceeded our initial target (note: this number of biopsies is approved by IRB) and which strengthens our ability to determine differences between normal and SSc and among the subsets of SSc.

This project has been divided into two sections – the first involved 61 GENISOS subjects and 36 controls (reported in a manuscript discussed in the following paragraph) and the second part (skin biopsies on 127 unique GENISOS subjects some of whom have serial/follow-up biopsies) will expand and confirm our previous findings and permit longitudinal analysis with prognostic implications. This second phase is in process. This is the largest and most comprehensive study of this type in SSc and indeed in any autoimmune connective tissue disease. Results of gene expression studies on the initial 61 GENISOS patients identified 2,754 differentially expressed transcripts when compared to controls. Clustering analysis revealed 2 prominent transcriptomes in SSc patients: the keratin and fibro-inflammatory signatures. Higher keratin transcript scores were associated with shorter disease duration and interstitial lung disease, while higher fibro-inflammatory scores were associated with diffuse cutaneous involvement and a higher modified Rodnan skin thickness score. There was considerable heterogeneity across patients. These findings may be useful in stratifying patients for targeted therapies or for predicting the response to immunosuppression (PMID 26238292).

The second phase of our gene expression studies will examine changes over time within individual patients and across patients to identify predictors for better/worse clinical course.

“Task 4: Collection of monocyte samples, RNA extraction, gene expression analysis (Specific Aim 2)”

“4.a. Collection of monocyte samples: Blood samples will be collected in CPT tubes from newly enrolled patients and patients seen at year 1 visit. 80 monocyte samples have been already collected. Drs. Mayes and Assassi will conduct the GENISOS visit and collect the clinical data. The monocyte samples will be purified and the RNA will be extracted by the Research Assistant in the laboratories of Division of Rheumatology at UTHealth. The purified RNA samples will be stored in -80 freezer.”

“4.b. Global gene expression study in monocyte samples”

“4.c. Analysis of monocyte global gene expression data”

Total collection of CPT tubes for monocyte isolation is 355 (72 at baseline and 352 in follow-up). Purified RNA from these samples are stored in -80 freezers.

Regarding analysis approaches, Drs. Mayes and Assassi have communicated with our consultant, Dr. Michael Whitfield, Associate Professor in the Department of Genetics at Dartmouth Medical School and Director of the Translation Genomics Laboratory at the Dartmouth Institute for Quantitative Biomedical Sciences through multiple emails and phone
calls. Several face-to-face meeting have occurred between Drs. Mayes, Assassi and Whitfield to discuss approaches to analysis of microarray gene expression data. These meetings have been scheduled to coincide with the annual American College of Rheumatology Conference, at the bi-annual Scleroderma Research Workshop meeting (August 2015) and at several other meetings so as to save costs since travel to these meetings was already planned. In addition, multiple discussions have been conducted through electronic communication.

Global gene expression studies of the monocyte samples will await the gene expression data from our skin biopsy study (Task 3 above) as the results of the skin biopsies gene expression will inform the monocyte studies. These further studies will be funded from non-DOD sources.

“Task 5: Cytokine level determination and data analysis”

“5.a. Multiplex assays in rapid/slow progressor groups. Human DiscoveryMAP v 1.0 multiplex assays for the analyte determination in already collected 62 samples (rapid and slow progressor samples-Stage I of Specific Aim 3) has been performed by Myriad Ruled Based Medicine (Austin, TX).”

“5.c. Design of custom-made multiplex assay. Custom-made multiplex assays will be designed in collaboration with Myriad Ruled Based Medicine (Austin, TX) based on the identified cytokines in the Subtask 5.b.”

“5.d. Determination of cytokine levels by custom-made assays. The levels of selected cytokines will be determined in all collected baseline samples (currently available 331 + newly enrolled 80= 411) utilizing custom-made assays. These assays will be performed by Myriad Ruled Based Medicine (Austin, TX).”

The levels of 72 plasma cytokine/analytes were measured in 91 patient samples and 40 age-, gender- and ethnicity matched controls. All patients had SSc-ILD based on imaging. The main focus of this analysis was to identify plasma cytokine/analytes which predict the course of SSc-ILD. Plasma samples were investigated by highly sensitive multiplex assays including Simoa in Myriad-Rule Based Medicine (Austin, TX). In this important analysis, four plasma cytokine/analytes were predictive of ILD progression. Higher levels in the below cytokines were associated with slower ILD progression as measured by annualized rate of change in FVC% predicted:

- B Lymphocyte Chemoattractant (BLC) \( \rightarrow p=0.009 \)
- Beta-2-Microglobulin (B2M) \( \rightarrow p=0.015 \)
- Macrophage Migration Inhibitory Factor (MIF) \( \rightarrow p= 0.033 \)
- Macrophage Inflammatory Protein-1 beta (MIP-1 beta) \( \rightarrow p= 0.044 \)

BLC, MIF, and MIP-1 are important inflammatory cytokines. BLC is selectively chemotactic for B-cells while MIF and MIP-1 are prominent interferon inducible chemokines. These cytokines cumulatively represent an inflammatory subset of SSc that are more amendable to immunosuppression, thus are associated with better ILD outcome. This finding is also supported by our observation at the whole blood gene expression level. In those studies, patients with a prominent interferon signature were more likely to respond to immunosuppression.
We also have measured levels of the aforementioned cytokines in the baseline serum samples from SCOT trial. Longitudinal FVC% data from this trial will be shared with us next month (January 2017). We plan to publish the combined results of the GENSISOS cohort (discovery cohort) and SCOT (validation) in a manuscript.

In addition, and as reported in our last progress report we investigated the role of pneumoprotein predictors of early ILD progression in the subjects in the GENISOS cohort who had ILD verified by imaging. Specifically, we studied CCL18 (also known as pulmonary activation-regulated chemokine or PARC, as we had previously observed that PARC had a significant correlation with short-term decline in functional vital capacity (FVC) as a surrogate of ILD progression. However, in this cohort of patients with verified ILD there was no statistical significant relationship between CCL18/PARC levels and FVC progression \( (p=0.45) \). We also measured KL-6 by a commercially available, validated ELISA kit. Baseline KL-6 levels were higher in patients than in controls \( (p<0.0001) \). Baseline higher KL-6 levels (as a continuous variable) were predictive of a faster rate of FVC% decline at the one year follow-up \( (b=-0.03, p=0.04) \). Upon categorizing KL-6 using a cut-off of 1273 u/mL based on the optimal cut-off previously determined by a Japanese study \( (4) \), the predictive significance of KL-6 remained in both the univariate \( (p=0.01) \) and multivariable analyses after accounting for race, disease duration, age, and treatment with immunosuppressive agents. Although CCL-18 was higher in patients than controls \( (<0.0001) \), its levels did not predict rate of FVC decline \( (p=0.4) \). These data were presented at the 2016 American College of Rheumatology meeting and the manuscript is currently being prepared.

In this very select cohort we also analyzed whether autoantibodies and other various clinical and demographic variables could predict FVC decline and observed that Scl-70 performed by immunodiffusion was the only variable that predicted faster FVC decline in patients with SSc related ILD. Interestingly, the same antibody performed by a chemoluminescent or a line-blot immunoassay were not predictive of FVC decline. The discrepancy observed between different methods of Scl-70 determination is important as it might have relevant implications for enrichment strategies in clinical trials of SSc-ILD. These data were presented in an abstract form at the 2016 Scleroderma World Congress (Lisbon, Portugal February 2016) and the manuscript is under preparation for submission.

“Task 6: Multivariable models with identified clinical and molecular predictors (Specific Aim 4)

6.a. Random forest and longitudinal analyses (months 32-34)

6.b. Manuscript on multivariable models predictive of disease progression (months 35-36)”
For this aim, we have conducted a novel multi-level analysis combining whole blood gene expression data with plasma proteins. This analytic method is called Similarity Network Fusion analysis (Wang et al. Nature Methods 2014). As shown in Figure 1, networks of patient and control samples are generated at each molecular level (e.g. whole blood gene expression and proteins in the circulation) and then combined into a single network. We are currently analyzing the skin gene expression data from the GENISOS cohort which will provide a third level of molecular data. After addition of the skin gene expression data, we will create clusters of patients and link those patient groups to pulmonary outcomes.

Figure 1: Similarity network fusion analysis of multilevel molecular data. A. Whole blood gene expression data; B. Protein data in the circulation; C. Combined molecular data
Red: SSc and blue: controls
“Task 7: Calculation of fibrosis score of high resolution chest CTs (months 0-36)”
“Dr. Ferguson will determine the fibrosis score on the high resolution chest CTs obtained in the GENISOS cohort.”

Cumulatively, our radiology co-investigator, Dr. Ferguson, has reviewed and scored 98 high resolution chest computed tomography scans (chest HRCTs). The degree of fibrosis correlates with the pulmonary function testing in terms of stabilization or decline. These scores are used in our evaluation of SSc-related interstitial lung disease (ILD) in subjects in the GENISOS cohort and are used, in addition to pulmonary function test results, to confirm the presence or absence of ILD in the cohort.

“Task 8: Expansion of the GENISOS cohort (months 0-36)”

“The baseline and follow-up GENISOS visits will be conducted by Drs. Mayes and Assassi at UTHealth. This is necessary for capturing the longitudinal clinical data and collecting the bio-specimens for the proposed research.”

The cumulative total since the initiation of this project is 91 newly recruited subjects and 405 follow-up visits. All longitudinal clinical data have been obtained and bio-specimens have been collected (See Table above)

“Task 9: Maintenance and expansion of GENISOS data base (months 0-36)”

“The Data Base Manager at UTHealth in close collaboration with Mr. Tony Mattar (Computer Task Force, Inc., Troy, MI) will maintain the GENISOS data base. The data base will also be expanded to accommodate the genetic and cytokine data. They also will establish an interface for connecting the gene expression data with the clinical data base.”

In the twelfth quarter of this project, Ms. Deepthi Nair (database manager) and Mr. Samuel Theodore (Study Coordinator) have continued to work together, as they have through all 12 quarters, to ensure that the clinical data entry is accurate and complete. Quality control (QC) checks are in place. It is only after the QC process has been completed on data for each visit that the visit data are uploaded into the “permanent” database and available for use in analyses. In collaboration with Mr. Tony Mattar (database consultant) they have reviewed, verified and uploaded the clinical information on cohort subjects both new enrollees and those with follow-up visits. The link between clinical and laboratory data and the skin biopsy specimen tracking (as established in the first quarter) is working well. The clinical and laboratory data have been queried repeatedly to provide the data field values (for example, pulmonary function test data over time) to correlate with the genetic (Task 2), gene expression (Tasks 3 and 4) and cytokine data (Task 5).

4. KEY RESEARCH ACCOMPLISHMENTS:

- Skin gene expression patterns: Prominent fibro-inflammatory and keratin gene expression signatures are present in SSc skin which show significant heterogeneity within this patient population; this finding will be useful for stratifying
patients for targeted therapies or predicting response to immunosuppression. (PMID 26238292)

- Anti-Ku antibodies characterize a group of SSC patients who are more likely to have SSC-related lung disease and muscle inflammation but whose survival is no different from the overall SSC population. (PMID 267583908)

- Meta-analysis of genetic risk factors identified a novel shared locus, IRF4, for the risk of SSC and RA highlighted the usefulness of a cross-disease GWAS meta-analysis strategy in the identification of common risk loci for autoimmune disease. (PMID 27111665)

- Genetic susceptibility loci of idiopathic interstitial pneumonia (IIP) do NOT represent risk for SSC-interstitial lung disease (SSC-ILD) – this is an important finding with implications for therapy in that agents which have been shown to be effective in IIP may not be effective in SSC-ILD. (PMID 26792595)

- CCR6 genetic polymorphisms are associated with Scl-70 positive SSC which implicates the IL-17 immune pathway as being important in at least some cases of SSC and, thus, these subjects may benefit from IL-17 blocking strategies. (PMID26314374)

- In our cytokine studies we have found that KL6 and not CCL-18 is a predictor of early progression in systemic sclerosis related interstitial lung disease.

5. CONCLUSION:

Scleroderma (systemic sclerosis, SSc) is a markedly heterogeneous disease ranging from mild symptoms that do not affect survival to severe and rapid disease with significant morbidity and the highest mortality of all of the autoimmune diseases. The importance of our work lies in the potential of precision medicine, that is, the accurate characterization of SSC subsets at the onset of disease in order to target treatment to the individual’s particular pathway responsible for disease activity and progression.

By expanding and following the GENISOS cohort, we have collected detailed clinical data in this inception cohort that characterizes and documents clinical course.

We have identified – through our skin gene expression studies described above – that there are different gene expression signatures in SSC skin which will be helpful in stratifying patients for targeted therapies. Our future and expanded gene expression studies (underway) will further refine and develop this approach.

We have identified – through our cytokine studies – that the secreted protein KL6 and not CCL-18 (as reported by others) is a predictor of early progression in SSc-related ILD. Our full cytokine profile is pending.

FUTURE DIRECTIONS

It has become clear from our current and ongoing genotyping results, gene expression studies and cytokine analysis that the complexity of SSc is even greater than we at first anticipated. New and sophisticated statistical methods that have recently been developed will help in analysis and interpretation of these data in a combined fashion.
Specifically, future directions include the following: 1) completion of our skin biopsy gene expression studies which will be the largest and most detailed such study in SSC; 2) completion of cytokine analysis including changes over time in serial serum samples; 3) analysis of these combined data sets to develop (and then publish) predictive models.

6. PUBLICATIONS, ABSTRACTS AND PRESENTATIONS:

a. All Manuscripts:

(1) PUBLICATIONS – Lay Press

Nothing to report.

(2) PUBLICATIONS – Peer-Reviewed Scientific Journals (n=10)


(3) PUBLICATIONS: INVITED ARTICLES (N=2)


(4) ABSTRACTS and PRESENTATIONS:


6.b – PRESENTATIONS – see Abstracts 1 through 8 above; all abstracts were presented at national or international meetings.

7. INVENTIONS, PATENTS AND LICENSES:

Nothing to report.

8. REPORTABLE OUTCOMES:

a. CCR6 genetic polymorphisms are associated with Scl-70 positive SSc which implicates the IL-17 immune pathway as being important SSc.
b. Identification of a SNP in IRF4 that is a novel risk factor for SSc.
c. KL6 and not CCL-18 is a predictor of early progression in systemic sclerosis related interstitial lung disease.
d. Identification of the keratin signature as being important in SSc-related skin gene expression.
e. Publication of the largest skin gene-expression in SSc with implications for stratifying subjects by disease pathway and potentially as a means to determine response to therapy.
f. Publication of the first microRNA whole blood profiling in SSc.
g. The discovery of the keratin signature in SSc skin described in Abstract # 2 above.
h. The discovery that the susceptibility genes of idiopathic interstitial lung disease are quite distinct from those of SSc-related ILD.

9. OTHER ACHIEVEMENTS:

A repository of DNA, RNA, serum and plasma has resulted from the sample collection for this study. This repository is linked to longitudinal detailed clinical data for access and analysis of future predictors of outcome.

10. REFERENCES:


11. APPENDICES:

(1) List of personnel (not salaries) receiving pay from the research effort:

<table>
<thead>
<tr>
<th>Personnel</th>
<th>Role</th>
<th>Percent Effort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Maureen Mayes</td>
<td>Principal Investigator</td>
<td>20%</td>
</tr>
<tr>
<td>Dr. Shervin Assassi</td>
<td>Co-Investigator</td>
<td>0% (K-award)</td>
</tr>
<tr>
<td>Dr. Claudia Pedroza</td>
<td>Co-Investigator</td>
<td>10%</td>
</tr>
<tr>
<td>Dr. Emma Ferguson</td>
<td>Co-Investigator</td>
<td>2.5%</td>
</tr>
<tr>
<td>Samuel Theodore</td>
<td>Research Coordinator</td>
<td>100%</td>
</tr>
<tr>
<td>Hau Pham (who replaced Kelley Liao as of 5/23/2016)</td>
<td>Research Assistant</td>
<td>50%</td>
</tr>
<tr>
<td>Kelley Liao (who replaced Miranda Taing as of 5/26/2015)</td>
<td>Research Assistant</td>
<td>50%</td>
</tr>
<tr>
<td>Miranda Taing</td>
<td>Research Assistant</td>
<td>50%</td>
</tr>
</tbody>
</table>

(2) Copies of Journal Articles
Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations

S. Hoa, MD\textsuperscript{a,b}, M. Hudson, MD, MPH\textsuperscript{a,b,c,*}, Y. Troyanov, MD\textsuperscript{d,e}, S. Proudmant, MBBS\textsuperscript{i,g}, J. Walker, MBBS, PhD\textsuperscript{i}, W. Stevens, MBBS, PhD\textsuperscript{1}, M. Nikpour, MBBS, PhD\textsuperscript{i}, S. Assassi, MD\textsuperscript{k}, M.D. Mayes, MD\textsuperscript{k}, M. Wang, MSc\textsuperscript{i}, M. Baron, MD\textsuperscript{a,b,c}, M.J. Fritzler, MD, PhD\textsuperscript{i}, Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS)

Abstract
Autoantibodies directed against the Ku autoantigen are present in systemic sclerosis (SSc) and have been associated with myositis overlap and interstitial lung disease (ILD). However, there is a paucity of data on the clinical correlates of anti-Ku antibodies in the absence of other SSc-specific antibodies. The aim of this study was to assess the clinical correlates of single-specificity anti-Ku in SSc.

An international (Canada, Australia, USA, Mexico) cohort of 2140 SSc subjects was formed, demographic and clinical variables were harmonized, and sera were tested for anti-Ku using a line immunoassay. Associations between single-specificity anti-Ku antibodies (i.e., in isolation of other SSc-specific antibodies) and outcomes of interest, including myositis, ILD, and survival, were investigated.

Twenty-four (1.1%) subjects had antibodies against Ku, and 13 (0.6%) had single-specificity anti-Ku antibodies. Subjects with single-specificity anti-Ku antibodies were more likely to have ILD (58% vs 34%), and to have increased creatine kinase levels (>3x normal) at baseline (11% vs 1%) and during follow-up (10% vs 2%). No difference in survival was noted in subjects with and without single-specificity anti-Ku antibodies.

This is the largest cohort to date focusing on the prevalence and disease characteristics of single-specificity anti-Ku antibodies in subjects with SSc. These results need to be interpreted with caution in light of the small sample. International collaboration is key to understanding the clinical correlates of uncommon serological profiles in SSc.

Abbreviations: ACA = anticientromere antibodies, ACR = American College of Rheumatology, ANA = antinuclear antibodies, ARNAP = anti-RNA polymerase III antibodies, ASIG = Australian Scleroderma Interest Group, ATA = antitopoisoforms I

Editor: Francesco Carubbi.

Financial disclosures: The CSRG received funds and/or gifts in kind from the Canadian Institutes of Health Research (CIHR) (grant n. FRN 83518), the Scleroderma Society of Canada and its provincial Chapters, Scleroderma Society of Ontario, Sclérodermie Quebec, Cure Scleroderma Foundation, Scleroderma Society of Saskatchewan, INOVA Diagnostics Inc. (San Diego, CA), Euromimmun (Lübeck, Germany), Fonds de la recherche en santé du Québec (FRSQ), the Canadian Arthritis Network (CAN), the Arthritis Society Research Chair (University of Calgary) and the Lady Davis Institute for Medical Research of the Jewish General Hospital, Montreal, QC.

The CSRG has also received educational grants from Pfizer and Actelion pharmaceuticals. The ASIG receives unrestricted grants from Actelion, Pfizer and GSK, and is also supported by Scleroderma Australia. The GENISOS cohort receives funding from DoDW81XWH-13-1-0452.

Conflicts of interest: SH is funded as a clinical fellow by the Université de Montréal Rheumatology Program Abbvie educational grant. MH is funded by the Fonds de la recherche en Santé du Québec. NN holds an NHMRC research fellowship (APP1071735). SA is funded by the NIH/NIAMS K23AR061436. MDM is funded by the NIH/NIAMS AR055258.

The funding sources had no role in the design of the study, analysis of the data, preparation of the manuscript and decision to submit for publication.

The authors report no conflicts of interest.

Supplemental Digital Content is available for this article.

* Department of Medicine, McGill University, Montreal, Quebec, Canada; Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada; Division of Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; Division of Rheumatology, Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada; University of Montréal, Université de Montréal, Montréal, Quebec, Canada; RHEUMATOLOGY Unit, Royal Adelaide Hospital, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Bedford Park, Australia; Department of Allergy and Immunology, Flinders Medical Centre, Bedford Park, Australia; Department of Rheumatology, St. Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia; Department of Medicine, The University of Melbourne at St. Vincent’s Hospital, Melbourne, Victoria, Australia; Division of Rheumatology and Immunogenetics, University of Texas Health Science Centre at Houston, Houston, TX; Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.

† Correspondence: Dr Marie Hudson, Jewish General Hospital, Room A-725, 3755 Côte Sainte-Catherine Road, Montreal, Quebec H3T 1E2, Canada (e-mail: marie.hudson@mcgill.ca).

Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2016) 95:35(e4713)
Received: 29 April 2016 / Received in final form: 3 August 2016 / Accepted: 4 August 2016
http://dx.doi.org/10.1097/MD.0000000000004713
1. Introduction

Systemic sclerosis (SSc) is a heterogeneous disease with varying degrees of skin and organ involvement, and can be classified by extent of skin involvement (limited or diffuse cutaneous SSc), and also by serological subtype. Common SSc-specific autoantibodies, such as anticentromere (ACA), antimitochondrial antibodies, and anti-RNA polymerase III (ARNAP) antibodies, have been associated with specific clinical features. In recent years, less common SSc-associated autoantibodies have been studied and their clinical correlates characterized. A potential limitation of some of those studies is the confounding introduced by the presence of overlapping antibodies. The study of distinct autoantibodies in the absence of other SSc-related autoantibodies, which we will refer to as single-specificity, has allowed us to understand specific clinical correlates of individual autoantibodies. For example, Ro52/TRIM21 autoantibodies were found to be independently associated with the presence of interstitial lung disease (ILD) and poor survival in SSc,[19] and distinct associations were found for single-specificity anti-PM75, anti-PM100, and anti-PM1-1a antibodies.[2,3]

Autoantibodies directed against Ku have been reported in a small percentage of SSc sera. The Ku (p70/p80) antigen is a DNA-binding protein involved in double-stranded DNA repair, through the nonhomologous end-joining pathway.[4–8] It combines with a DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and regulates the phosphorylation of many nuclear proteins, including nuclear enzymes and transcription factors.[9] It also plays a role in V(D)J recombination of receptor genes on B and T lymphocytes,[4–8] immunoglobulin class switching,[10] telomere protection,[11,12] and development of the central nervous system.[13,14] The prevalence of anti-Ku autoantibodies in SSc varies from 1.5% to 16%,[15–23] depending primarily on the detection method and on the genetic and geographical background of the subjects studied.[15,24] They were first described in 1981 by Mimmori et al.[19] as a marker of scleroderma-polymyositis overlap syndrome, but have since been reported in a variety of other autoimmune disorders, including systemic lupus erythematosus (SLE) (0.7%–27%), idiopathic inflammatory myopathies (up to 26%), mixed connective tissue disease and undifferentiated connective tissue disease (up to 8.3%), rheumatoid arthritis (up to 16%), and Sjogren syndrome [<1%–20%], in isolation or as part of overlap syndromes,[13,14,19,23,25–27,47] and only rarely in healthy controls.[19,23,25] In SSc, these autoantibodies have been associated with myositis,[14,19,22,32,48] and ILD,[14,42] and also limited cutaneous involvement,[14,19,22] arthritis,[14,22] and less vascular involvement.[14,20–22] However, results have been conflicting,[13,22,24,25] and conclusions have been limited by small numbers of subjects studied and potentially confounded by the co-presence of other SSc-related autoantibodies.

The objective of this study was therefore to identify the demographic, clinical, and serological characteristics of SSc subjects with single-specificity anti-Ku antibodies in a large international, multicenter cohort.

2. Methods

An international (Canada, Australia, USA, Mexico) retrospective cohort of 2140 SSc subjects was formed, demographic and clinical variables were harmonized, and sera were tested for anti-Ku using a line immunoassay (LIA). Associations between single-specificity anti-Ku antibodies (i.e., in isolation of other SSc-related autoantibodies), baseline characteristics, and mortality were investigated.

2.1. Sources of data

The study subjects were SSc patients enrolled in the Canadian Scleroderma Research Group (CSRG), the Australian Scleroderma Interest Group (ASIG), or the American Genetics versus Environment in Scleroderma Outcome Study (GENISOS) cohorts. Briefly, subjects in the CSRG are recruited from 15 sites across Canada and Mexico, and must have a diagnosis of SSc verified by an experienced rheumatologist, be >18 years of age, and be fluent in English, French, or Spanish. Over 98% of the cohort meets the 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for SSc.[49] Loss to follow-up in the CSRG cohort is 25%. Subjects in the ASIG are recruited by investigators from 12 Australian centers specializing in the care of patients with SSc, according to similar inclusion criteria. All subjects fulfill either the 1980 preliminary ACR criteria for classification of SSc, or the Medsger criteria for limited SSc.[50] Estimated loss to follow-up in the ASIG cohort is 7%. The GENISOS cohort is a longitudinal cohort of subjects with early SSc. Subjects are enrolled within 5 years of disease onset as determined by the first non-Raynaud phenomenon symptom from 3 University of Texas institutions at Houston, San Antonio, and Galveston. All enrolled subjects fulfill the 2013 ACR/EULAR classification criteria for SSc.[51] Estimated loss to follow-up in the GENISOS cohort is 25%.

Ethics committee approval for this study was obtained at McGill University (Montreal, Canada) and at all participating CSRG, ASIG, and GENISOS study sites. All subjects provided informed written consent to participate in the study. The subjects included in this study were those whose baseline visits were between September 2004 and June 2014 for CSRG, between January 2007 and March 2013 for ASIG, and between January 1998 and September 2012 for GENISOS, and who had complete serological profiles for anti-Ku antibodies as detected by the methods described below.

2.2. Clinical variables

Subjects recruited into this study underwent standardized medical evaluation including medical histories, physical
examinations and laboratory investigations, according to the protocols from their respective cohorts, and the following clinical variables were harmonized to create a single dataset with common variable definitions. All study variables were collected at the baseline study visit, except creatine kinase (CK) and mortality, which were also available during follow-up.

Demographic information regarding age, sex, and ethnicity was collected by patient self-report. Disease duration was recorded by study physicians and defined as the interval between the onset of the first non-Raynaud disease manifestation and baseline study visit.

Skin involvement was assessed using the modified Rodnan Skin Score (mRSS), a widely used clinical assessment where the examining rheumatologist records the degree of skin thickening ranging from 0 (no involvement) to 3 (severe thickening) in 17 areas (total score range 0–51). Limited cutaneous disease was defined as skin involvement distal to the elbows and knees with or without facial involvement; diffuse cutaneous disease was defined as skin involvement proximal to the elbows and knees with or without truncal involvement. Those with a clinical diagnosis of SSc but no skin involvement were included with the limited cutaneous subset.

History of inflammatory myositis, calcinosis, inflammatory arthritis, scleroderma renal crisis, and malignancy was recorded by a study physician. The presence of telangiectasias, digital pits, and digital ulcers on physical examination was also recorded by a study physician. CK levels were measured by local laboratories.

To assess gastrointestinal involvement, subjects answered yes/no to 6 questions concerning gastroesophageal reflux disease, dysphagia, antibiotics for bacterial overgrowth, episodes of pseudo-obstruction, fecal incontinence, and hyperalimentation.

The presence of ILD was determined using a clinical decision rule that was recently published.[52] This algorithm considers ILD to be present if a high-resolution computed tomography (HRCT) scan of the lung was interpreted by an experienced radiologist as showing ILD, or, in the case where no HRCT is available, if either a chest x-ray was reported as showing increased interstitial markings (not thought to be due to congestive heart failure) or fibrosis, and/or if a study physician reported the presence of typical "velcro-like crackles" on physical examination. Pulmonary function tests were performed at local respiratory physiology laboratories.

Pulmonary hypertension was defined as an estimated systolic pulmonary artery pressure (sPAP) ≥45 mm Hg measured using the Doppler flow measurement of the tricuspid regurgitant jet on cardiac echocardiography (an estimate that correlates strongly with right heart catheter studies)[53] for CSRG and GENIOSS subjects, or mean pulmonary artery pressure (mPAP) >25 mm Hg with a pulmonary capillary wedge pressure (PCWP) <15 mm Hg on right heart catheterization for ASIG subjects.

In addition, disease overlap with SLE and Sjögren syndrome, history of Raynaud phenomenon, trigeminal neuralgia, and autoimmune thyroid disease, and presence of capillaroscopic alterations on dermatoscopic examination recorded by a study physician were also available in the CSRG dataset.

All subjects were assessed, followed, and classified in the same way, on a similar platform, regardless of anti-Ku antibody status and outcomes. Frequency of missing data was recorded.

2.3. Serology

Autoantibody analysis of the CSRG and GENIOSOS cohorts were performed in a central laboratory—Mitogen Advanced Diagnostics Laboratory, University of Calgary—and the ASIG analyses were performed using an identical immunoassay kit and protocol. Serum aliquots were stored at −80°C until needed for diagnostic assays. Antinuclear antibodies (ANAs) were detected by indirect immunofluorescence (IIF) performed on Hep-2 cells (ImmunonConcepts, Sacramento, CA). Anti-Ku, centromere (CENP-A and CENP-B), topoisomerase I, RNA polymerase III (RP11 and RP155), fibrillarin, NOR-90, Th/To, Ro52/TRIM21, PDGER, PM75, and PM100 antibodies were detected by Euroline SSc profile LIA (Euroimmun GmbH, Luebeck, Germany) according to manufacturer's instructions. With the intent of optimizing specificity, antibodies were reported as absent (negative, equivocal, and low titers) and present (moderate and high titers). Data on ANA titers and patterns were also available for subjects from the CSRG cohort.

2.4. Statistical analysis

Subjects were grouped according to anti-Ku status, either positive (further subdivided into single-specificity or overlapping with other SSc antibodies) or negative at baseline visit. Descriptive statistics were used to summarize the baseline demographic and clinical characteristics of the subjects. Given the exploratory nature of the analysis and the small samples in the subgroups, clinically relevant numerical differences between subgroups were considered informative. Exploratory statistical analyses were performed using chi-square tests, Fisher exact tests, and Mann–Whitney U tests, as indicated. P < 0.05 was considered statistically significant. Bonferroni correction for multiple testing was calculated for statistically significant findings. Missing data, selection bias, and information bias were addressed qualitatively.

Kaplan–Meier analysis and Cox proportional-hazard models adjusting for baseline differences in age, ethnicity, and sex were used to compare survival between autoantibody subsets. Multivariate logistic regression adjusting for baseline differences in age and ethnicity was used to determine the association between anti-Ku antibody groups and ILD. P values <0.05 were considered statistically significant.

All statistical analyses were performed with SAS v.9.2 (SAS Institute, Cary, NC).

3. Results

All cohort subjects were tested for anti-Ku antibodies and were eligible for inclusion. Of the 2140 SSc subjects included in this study, 24 (1.1%) had anti-Ku antibodies. Thirteen (0.6%) had single-specificity anti-Ku antibodies (i.e., in isolation of other SSc-related antibodies), 11 (0.5%) had overlapping anti-Ku antibodies, and 2116 (98.9%) were negative for anti-Ku antibodies (Table 1). Individual clinical and serological characteristics of single-specificity and overlapping anti-Ku-positive subjects are presented in Tables 2 and 3, respectively.

3.1. Clinical correlates of single-specificity anti-Ku-positive subjects

Subjects with single-specificity anti-Ku antibodies tended to be older at disease onset (mean age 51.5 vs 45.3 years), of Hispanic ethnicity (30% vs 7%), and with limited cutaneous disease (77% vs 63%); and less likely to be of white ethnicity (70% vs 81%), have digital pitting (20% vs 49%), digital ulcers (0% vs 15%), and calcinosis (8% vs 25%), compared with anti-Ku-negative subjects.
### Table 1
Baseline characteristics of the study cohort, as a group and according to anti-Ku antibody status.

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Whole group (N=2140)</th>
<th>Anti-Ku-positive (n=24)</th>
<th>Single-specificity anti-Ku-positive (n=13)</th>
<th>Overlapping anti-Ku-positive (n=11)</th>
<th>Anti-Ku-negative (n=2116)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, y</strong></td>
<td>55.1 ± 12.6</td>
<td>55.5 ± 15.1</td>
<td>59.1 ± 12.4</td>
<td>51.3 ± 17.5</td>
<td>55.1 ± 12.6</td>
</tr>
<tr>
<td><strong>Disease duration, y</strong></td>
<td>9.7 ± 4.5</td>
<td>10.2 ± 9.9</td>
<td>8.7 ± 8.5</td>
<td>11.8 ± 11.4</td>
<td>9.7 ± 9.4</td>
</tr>
<tr>
<td><strong>Age at disease onset, y</strong></td>
<td>45.3 ± 13.7</td>
<td>33.2 (2%)</td>
<td>15.3 (2%)</td>
<td>39.4 ± 14.7</td>
<td>45.3 ± 13.7</td>
</tr>
<tr>
<td><strong>Clinical variables</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Modified Rodnan Skin Score (0–61)</strong></td>
<td>10.7 ± 10.0</td>
<td>9.8 ± 9.7</td>
<td>6.5 ± 8.2</td>
<td>13.5 ± 10.2</td>
<td>10.7 ± 10.0</td>
</tr>
<tr>
<td><strong>Histopathology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Calcinosis</strong></td>
<td>523 ± 21 (32%)</td>
<td>11 ± 3%</td>
<td>9 ± 3%</td>
<td>7 ± 4%</td>
<td>11 ± 3%</td>
</tr>
<tr>
<td><strong>Digital ulcers</strong></td>
<td>266 ± 14 (14%)</td>
<td>3 ± 2%</td>
<td>0 ± 0%</td>
<td>3 ± 3%</td>
<td>263 ± 14%</td>
</tr>
<tr>
<td><strong>Gastrointestinal disease</strong></td>
<td>10.7 ± 10.0</td>
<td>9.8 ± 9.7</td>
<td>6.5 ± 8.2</td>
<td>13.5 ± 10.2</td>
<td>10.7 ± 10.0</td>
</tr>
<tr>
<td><strong>SeroLOGY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antinuclear antibody (ANA) positivity</strong></td>
<td>1859 ± 95%</td>
<td>181 ± 8%</td>
<td>23 ± 100%</td>
<td>12 ± 100%</td>
<td>1836 ± 95%</td>
</tr>
<tr>
<td><strong>Overlapping with other antibodies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anticyclic citrullinated peptide</strong></td>
<td>717 ± 34 (23%)</td>
<td>12 ± 10%</td>
<td>7 ± 8%</td>
<td>8 ± 6%</td>
<td>717 ± 34%</td>
</tr>
<tr>
<td><strong>Malignancy</strong></td>
<td>163 ± 8%</td>
<td>8 ± 6%</td>
<td>1 ± 8%</td>
<td>8 ± 6%</td>
<td>163 ± 8%</td>
</tr>
<tr>
<td><strong>Mortality</strong></td>
<td>375 ± 18%</td>
<td>8 ± 6%</td>
<td>4 ± 7%</td>
<td>8 ± 6%</td>
<td>375 ± 18%</td>
</tr>
<tr>
<td><strong>Follow-up duration, y</strong></td>
<td>5.0 ± 3.1</td>
<td>5.5 ± 3.8</td>
<td>5.4 ± 4.0</td>
<td>5.7 ± 3.7</td>
<td>5.0 ± 3.1</td>
</tr>
<tr>
<td><strong>Laboratory tests</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CK at baseline visit</strong></td>
<td>105.8 ± 148.0</td>
<td>122.9 ± 106.5</td>
<td>136.7 ± 144.1</td>
<td>107.4 ± 40.8</td>
<td>105.6 ± 148.4</td>
</tr>
<tr>
<td><strong>% of CK &gt;3x normal at baseline</strong></td>
<td>20.1 ± 423 (10%)</td>
<td>2 ± 6%</td>
<td>1 ± 11%</td>
<td>0 ± 0%</td>
<td>19 ± 1%</td>
</tr>
<tr>
<td><strong>Highest CK during follow-up</strong></td>
<td>145.4 ± 349.2</td>
<td>145.2 ± 350.9</td>
<td>150.6 ± 130.4</td>
<td>173.6 ± 92.2</td>
<td>145.2 ± 350.9</td>
</tr>
<tr>
<td><strong>% of CK &gt;3x normal during follow-up</strong></td>
<td>41 ± 2%</td>
<td>41 ± 2%</td>
<td>41 ± 2%</td>
<td>41 ± 2%</td>
<td>41 ± 2%</td>
</tr>
<tr>
<td><strong>Pulmonary function tests</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DLCO, % predicted</strong></td>
<td>69.0 ± 20.8</td>
<td>65.3 ± 22.1</td>
<td>61.8 ± 23.5</td>
<td>68.9 ± 21.9</td>
<td>69.0 ± 20.8</td>
</tr>
<tr>
<td><strong>FVC, % predicted</strong></td>
<td>91.2 ± 20.4</td>
<td>86.8 ± 18.1</td>
<td>89.4 ± 9.8</td>
<td>87.0 ± 23.8</td>
<td>91.2 ± 20.4</td>
</tr>
<tr>
<td><strong>TLC, % predicted</strong></td>
<td>94.0 ± 23.8</td>
<td>86.8 ± 17.7</td>
<td>88.5 ± 19.0</td>
<td>87.0 ± 18.0</td>
<td>94.0 ± 23.9</td>
</tr>
</tbody>
</table>

All variables represent study baseline characteristics, except for mortality and CK levels observed during follow-up. Variable comparisons with P < 0.05 include the following as described in the footnotes.

The single-specificity anti-Ku antibody positive group was exclusive of antirenal, antitopoisomerase I, anticientromere, Ro/SSA, Th/To, Ro52/TRIM21, Ro52/PM75, and PM100 antibodies.

CI = confidence interval, CK = creatine kinase, DLLCO = diffusion capacity for carbon monoxide, FVC = forced vital capacity, Gastroesophageal reflux disease, GAST = gastrointestinal, OR = odds ratio, PDGF = platelet derived growth factor receptor, SD = standard deviation, TLC = total lung capacity.

Footnotes:
1. Intestinal lung disease: anti-Ku-positive versus anti-Ku-negative (OR 2.5, 95% CI 1.1–5.6, P = 0.03); after Bonferroni correction (95% CI 0.7–9.1). Single-specificity anti-Ku-positive versus anti-Ku-negative (OR 2.7, 95% CI 0.9–8.6, P = 0.09).
2. Malignancy: overlapping anti-Ku-positive versus anti-Ku-negative (OR 4.6, 95% CI 1.2–17.6, P = 0.02); after Bonferroni correction (95% CI 0.6–36.3).
3. Per cent with CK >3x normal at baseline: single-specificity anti-Ku-positive versus anti-Ku-negative (OR 11.1, 95% CI 1.3–82.9, P = 0.03); after Bonferroni correction (95% CI 0.4–294.5).
Table 2
Clinical and serological characteristics of single-specificity anti-Ku-positive subjects.

<table>
<thead>
<tr>
<th>ANA titer (1:x)</th>
<th>ANA pattern</th>
<th>Sex (M/F)</th>
<th>Ethnicity</th>
<th>Age, y</th>
<th>Age at disease onset, y</th>
<th>Limited skin disease</th>
<th>Myositis</th>
<th>Arthritis</th>
<th>Calcinosis</th>
<th>Digital ulcers</th>
<th>ILD</th>
<th>PH</th>
<th>Malignancy</th>
<th>SLE overlap</th>
<th>Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 N/A</td>
<td>N/A</td>
<td>F</td>
<td>White</td>
<td>60</td>
<td>56</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>Y (cause N/A)</td>
<td></td>
</tr>
<tr>
<td>2 5120</td>
<td>Sp</td>
<td>F</td>
<td>White</td>
<td>75</td>
<td>63</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 1280; 640</td>
<td>Nu; Sp</td>
<td>F</td>
<td>N/A</td>
<td>78</td>
<td>76</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 1280; 320</td>
<td>H/Sr; Nu</td>
<td>F</td>
<td>White</td>
<td>57</td>
<td>53</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 N/A</td>
<td>N/A</td>
<td>F</td>
<td>Hispanic</td>
<td>48</td>
<td>42</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>6 N/A</td>
<td>N/A</td>
<td>F</td>
<td>Hispanic</td>
<td>53</td>
<td>49</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 N/A</td>
<td>N/A</td>
<td>F</td>
<td>White</td>
<td>51</td>
<td>46</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8* 1280; 320</td>
<td>H/Sr; Cyto</td>
<td>F</td>
<td>N/A</td>
<td>45</td>
<td>43</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td>Y</td>
</tr>
<tr>
<td>9 5120; 320; 160</td>
<td>Nu; Sp; Cyto</td>
<td>F</td>
<td>Hispanic</td>
<td>40</td>
<td>38</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 N/A</td>
<td>N/A</td>
<td>F</td>
<td>White</td>
<td>79</td>
<td>76</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 N/A</td>
<td>N/A</td>
<td>F</td>
<td>White</td>
<td>57</td>
<td>43</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 N/A</td>
<td>N/A</td>
<td>F</td>
<td>White</td>
<td>65</td>
<td>41</td>
<td>Y†</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 N/A</td>
<td>N/A</td>
<td>F</td>
<td>White</td>
<td>61</td>
<td>34</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 N/A</td>
<td>N/A</td>
<td>F</td>
<td>White</td>
<td>32</td>
<td>21</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

All variables represent study baseline characteristics, except for death.
ANA = antinuclear antibody, Cyto = cytoplasmic, F = female, H/Sr = homogeneous and speckled, ILD = interstitial lung disease, M = male, N/A = not available, Nu = nucleolar, PH = pulmonary hypertension, SCC = squamous cell carcinoma, SLE = systemic lupus erythematosus, Sp = speckled, Y = yes.
* Subject 8 is also positive for anti-U1RNP and anti-Sm, but is classified as single-specificity as these antibodies were not excluded from the definition of single-specificity anti-Ku, and were not routinely tested in all subjects.
† Subject 12 had no skin involvement (SSc sine scleroderma).

Table 3
Clinical and serological characteristics of overlapping anti-Ku-positive subjects.

<table>
<thead>
<tr>
<th>Overlap antibodies</th>
<th>ANA titer (1:x)</th>
<th>ANA pattern</th>
<th>Sex (M/F)</th>
<th>Ethnicity</th>
<th>Age, y</th>
<th>Age at disease onset, y</th>
<th>Limited skin disease</th>
<th>Myositis</th>
<th>Arthritis</th>
<th>Calcinosis</th>
<th>Digital ulcers</th>
<th>ILD</th>
<th>PH</th>
<th>Malignancy</th>
<th>SLE overlap</th>
<th>Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 ACA</td>
<td>N/A</td>
<td>N/A</td>
<td>F</td>
<td>White</td>
<td>69</td>
<td>68</td>
<td>Y</td>
<td>N/A</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>Breast cancer</td>
<td>N</td>
</tr>
<tr>
<td>2 ACA</td>
<td>2560</td>
<td>Cen</td>
<td>F</td>
<td>White</td>
<td>44</td>
<td>21</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N/A</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>3 ACA-Ro52</td>
<td>N/A</td>
<td>N/A</td>
<td>F</td>
<td>White</td>
<td>80</td>
<td>51</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>Skin SCC</td>
<td>N</td>
</tr>
<tr>
<td>4 ACA-Ro52</td>
<td>2560</td>
<td>Sp</td>
<td>F</td>
<td>Asian</td>
<td>40</td>
<td>37</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 ACA-ARNAP-NOR90</td>
<td>N/A</td>
<td>N/A</td>
<td>F</td>
<td>Hispanic</td>
<td>17</td>
<td>15</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 ARNAP</td>
<td>N/A</td>
<td>N/A</td>
<td>F</td>
<td>White</td>
<td>72</td>
<td>48</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>Melanoma</td>
<td>N</td>
</tr>
<tr>
<td>7 ATA</td>
<td>5120</td>
<td>Sp</td>
<td>F</td>
<td>Hispanic</td>
<td>46</td>
<td>45</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>8 ATA</td>
<td>1280; 1280</td>
<td>H/Sr; Nu</td>
<td>M</td>
<td>White</td>
<td>44</td>
<td>31</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>9 ATA-Ro52</td>
<td>5120</td>
<td>Sp</td>
<td>F</td>
<td>White</td>
<td>54</td>
<td>29</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>10 Ro52</td>
<td>N/A</td>
<td>N/A</td>
<td>F</td>
<td>White</td>
<td>45</td>
<td>44</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 PMSc-NOR90:Ro52</td>
<td>2560</td>
<td>Nu; Sp; O</td>
<td>M</td>
<td>Aboriginal</td>
<td>54</td>
<td>44</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>Metastatic rectal cancer</td>
<td>N</td>
</tr>
</tbody>
</table>

All variables represent study baseline characteristics, except for death.
ACA = anticientromere antibody, Cyto = cytoplasmic, F = female, H/Sr = homogeneous and speckled, ILD = interstitial lung disease, M = male, N/A = not available, Nu = nucleolar, OR = organizer region, O = others, PH = pulmonary hypertension, SCC = squamous cell carcinoma, SLE = systemic lupus erythematosus, Sp = speckled, Y = yes.
* Subject 4 had no skin involvement (SSc sine scleroderma).
† Patient 4 had no skin involvement (SSc sine scleroderma).

Table 4
Multivariate logistic model to estimate the association between the presence of anti-Ku antibodies and ILD, adjusting for baseline demographic differences.

<table>
<thead>
<tr>
<th>Odds ratio</th>
<th>95% confidence intervals</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>White ethnicity</td>
<td>0.77</td>
<td>0.61</td>
</tr>
<tr>
<td>Age</td>
<td>1.02</td>
<td>1.01</td>
</tr>
<tr>
<td>Single-specificity versus negative anti-Ku subjects</td>
<td>2.69</td>
<td>0.75</td>
</tr>
<tr>
<td>Overlapping versus negative anti-Ku subjects</td>
<td>2.35</td>
<td>0.71</td>
</tr>
</tbody>
</table>

ILD = interstitial lung disease.
Interstitial lung disease was also more common in single-specificity anti-Ku-positive subjects than in anti-Ku-negative subjects (58% vs 34%; odds ratio [OR] 2.7, 95% confidence interval [CI] 0.9–8.6, \( P = 0.09 \); in logistic regression analysis adjusting for differences in baseline demographic characteristics: OR 2.69, 95% CI 0.75–9.59, \( P = 0.13 \) (Tables 1 and 4).

Pulmonary hypertension was numerically more common in single-specificity anti-Ku-positive subjects compared with anti-Ku-negative subjects (25% vs 14%; OR 2.0, 95% CI 0.4–10.0, \( P = 0.39 \)).

Although there was no difference in inflammatory myositis prevalence (8% vs 9%), subjects with single-specificity anti-Ku antibodies were more likely to have significantly elevated CK levels (>3× normal) at baseline (11% vs 1%; OR 11.1, 95% CI 1.3–92.9, \( P = 0.03 \)) and during follow-up (10% vs 2%).

In a survival analysis adjusted for differences in baseline characteristics, subjects with single-specificity anti-Ku antibodies were not found to be at significantly increased risk of death compared with subjects without anti-Ku antibodies (mean [SD] follow-up of 5.0 [3.1] years) (Table 5 and Supplementary Figure, http://links.lww.com/MD/B244).

### 3.3. Serological characteristics of anti-Ku-positive subjects

All subjects with anti-Ku antibodies had positive ANA by IIF (Table 1). In the CSRG cohort, all subjects with single-specificity anti-Ku antibodies (\( n = 6 \)) had ANA titers of at least 1:320 with speckled patterns, along with nuclear patterns in half of subjects and cytoplasmic patterns in a third of subjects (Table 2 and Supplementary Table 2, http://links.lww.com/MD/B244).

Among subjects with overlapping antibodies, 6 had 1 more (2 ACA, 2 ATA, 1 ARNAP, 1 Ro52/TRIM21), 3 had 2 more (2 ACA-Ro52/TRIM21, 1 ATA-Ro52/TRIM21, and 2 had 3 more (1 ACA-RNAP-Nor90, 1 PM-Scl-Nor90-Ro52/TRIM21) overlapping antibodies. Interestingly, the majority of subjects who had ILD had either ATA or anti-Ro52/TRIM21 overlapping antibodies, whereas most subjects with calcinosis had ACA overlapping antibodies (Table 3).

Of note, 1 CSRG subject classified as part of the single-specificity anti-Ku-positive group also had positive anti-U1-RNP and anti-Sm autoantibodies (which were not among the antibodies tested for the whole sample, and therefore not excluded from the definition of single-specificity anti-Ku-positivity in this study). This subject was diagnosed with SSc-SLE overlap disease and was the only single-specificity anti-Ku-positive subject who had calcinosis (Table 2).

### 4. Discussion

We aimed to describe the demographic, clinical, and serological characteristics of SSc subjects with single-specificity anti-Ku antibodies. In this international, multicenter cohort of 2140 subjects, only 24 (1.1%) had anti-Ku antibodies, and 13 (0.6%) had single-specificity anti-Ku antibodies. These numbers are slightly lower than previously reported frequencies using the LIA technique (Table 6) and might be attributed to our intent of optimizing specificity by using a higher cut-off (moderate and high titers only). Single-specificity anti-Ku-positive subjects in this cohort tended to be older, have more limited skin disease, and less vascular digital complications than anti-Ku-negative subjects. ILD was more frequent in anti-Ku-positive subjects in general, and also in single-specificity and overlapping anti-Ku-positive subjects. CK elevations were also more common in subjects with single-specificity anti-Ku antibodies. Serologically, single-specificity anti-Ku-positive subjects had high-titer speckled ANAs, with or without nuclear staining patterns.

To date, little was known on the clinical correlates of single-specificity anti-Ku antibodies in SSc. In an extensive review of the literature (Table 6, Supplementary Table 4, http://links.lww.com/MD/B244), only 2 studies were identified that examined these antibodies in isolation. The first, by Kuwana et al,[17] reported on
Table 6

Summary of the literature on clinical associations of anti-Ku antibodies in SSc, by method of detection.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Study of single-specificity anti-Ku</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Total study population</td>
<td>2140</td>
<td>505</td>
<td>129</td>
<td>210</td>
<td>560</td>
<td>625</td>
<td>379</td>
<td>N/A</td>
<td>275</td>
<td>66</td>
<td>139</td>
<td>56</td>
<td>N/A</td>
</tr>
<tr>
<td>Subpopulation positive for anti-Ku</td>
<td>2140</td>
<td>505</td>
<td>129</td>
<td>210</td>
<td>560</td>
<td>625</td>
<td>379</td>
<td>N/A</td>
<td>275</td>
<td>66</td>
<td>139</td>
<td>56</td>
<td>N/A</td>
</tr>
<tr>
<td>Subpopulation positive for single-specificity anti-Ku†</td>
<td>24 (1.1%)</td>
<td>14 (2.8%)</td>
<td>6 (5%)</td>
<td>10 (4.7%)</td>
<td>13 (2.3%)</td>
<td>14 (2.2%)</td>
<td>6 (1.6%)</td>
<td>7 (2.5%)</td>
<td>275</td>
<td>66</td>
<td>139</td>
<td>56</td>
<td>N/A</td>
</tr>
</tbody>
</table>

| Sociodemographics | Male, % | 8 vs 14 | N/A | 40 | 23 vs 1 | Sex-matched | 0 vs 11 | N/A | 0 vs 12 | N/A | 22 | 14 | 18 |
| Female, % | 70 vs 81 | N/A | N/A | 100 vs 100 | 100 vs 100 | 100 | N/A | N/A | N/A | N/A | 59 |

| Clinical variables | Limited cutaneous disease, % | 77 vs 63 | N/A | 50 | 60 | 100 vs 99 | 86 vs 72 | N/A | N/A | 100 | 71 | 33 | 100 |
| Skin (mRSS), mean | 6.5 vs 10.7 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inflammatory myositis, % | 8 vs 9 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Elevated muscle enzymes, % | 11 vs 1 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cacanosis, % | 8 vs 25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inflammatory arthritis, % | 25 vs 29 | N/A | N/A | N/A | 39 vs 12 | 43 vs 21 | N/A | N/A | N/A | 43 vs 39 | 13 | N/A | N/A |
| Triangles, % | 69 vs 72 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gastrointestinal disease, % | 92 vs 82 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Scleroderma renal crisis, % | 0 vs 4 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Pulmonary hypertension, % | 25 vs 14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intestinal lung disease, % | 58 vs 34 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Mortality, % | 23 vs 18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
7 Japanese subjects with SSc and single-specificity anti-Ku antibodies; in contrast to our study, they were found to have a younger age of disease onset compared with anti-Ku-negative subjects. All were classified as overlap SSc syndromes, all were associated with skeletal muscle involvement, and none had digital tip ischemia. The second study, by Kaji et al., compared 44 SSc subjects (from 2 Japanese institutions and the University of Pittsburgh) with single-specificity anti-Ku antibodies with anti-RuvBL1/2 and anti-PM-Scl-positive subjects, all considered as related to SSc/myositis overlap; 50% had inflammatory myositis and 43% had ILD. However, no comparison with triple-negative subjects was provided. Three additional studies from European centers reported on anti-Ku-positive SSc subjects in whom the majority (>70%) had single-specificity anti-Ku antibodies. Subjects were found to be older at disease onset, have more limited cutaneous involvement, inflammatory myositis, inflammatory arthritis and trigeminal neuralgia, and less digital vascular complications. ILD was also more frequent, but was characterized by mild functional impairment.

On the contrary, lung disease associated with anti-Ku-positive myositis with or without SSc overlap has been reported to be corticosteroid refractory in 75% of subjects by Rigolet et al. Furthermore, studies of anti-Ku-positive inflammatory myopathy subjects in which at least half had single-specificity autoantibodies have also shown an association with more ILD, inflammatory arthritis, inflammatory arthritis overlap with other rheumatic diseases, and milder inflammatory myopathies, as evidenced by less frequent dermatomyositis rash, modest CK elevations, nonspecific abnormalities on muscle biopsy, and treatment-responsive, monophasic course of muscle disease.

Our findings are generally consistent with previously reported clinical associations between anti-Ku autoantibodies in SSc and limited cutaneous involvement, ILD, and less vascular complications, and strengthen these findings by showing an association with single-specificity anti-Ku autoantibodies in a large multicenter patient sample.

Pulmonary hypertension has been previously reported to be associated with anti-Ku antibodies. Rodriguez-Reyna et al. found that 73% of anti-Ku-positive SSc subjects had pulmonary arterial hypertension, compared with only 23% of anti-Ku-negative SSc subjects. We also found a higher rate of pulmonary hypertension among the single-specificity anti-Ku subjects (25%), although this observation was based on only 2 subjects.

Other features previously associated with anti-Ku autoantibodies, such as higher rates of myositis overlap, were not clearly observed in our cohort: only 8% of single-specificity anti-Ku-positive subjects had inflammatory myositis, which was similar to other subgroups. However, CK elevations were more common in the single-specificity anti-Ku subjects, although this observation was based on only 1 subject. Interestingly, most of the studies that reported very high rates of myositis overlap (71%–90%) identified anti-Ku-positive subjects through screening of sera positive for autoantibodies to extractable nuclear antigens (ENAs). On the contrary, studies that analyzed anti-Ku-positive subjects by screening a SSc population with a LIA technique such as in our study, did not report such a high prevalence of myositis. Furthermore, Cooley et al. previously observed that anti-Ku-positive subjects who met classification criteria for a connective tissue disease tended to meet the minimum number of criteria. This was again demonstrated in the study by Hausmanowa-Petrusewicz.
et al.\textsuperscript{13,16} in which 5 anti-Ku-positive subjects had sclerodactyly and telangectasias, but only 2 were identified as scleromyositis or SSc-polyarthropathy. The other 2 remaining “unclassified,” given that their muscle and SSc-spectrum diseases did not meet classification criteria. As such, it is possible that a number of subjects with anti-Ku-positivity and a diagnosis of inflammatory myositis may present milder clinical features of SSc, such as sclerodactyly, puffy fingers, Raynaud phenomenon, or esophageal dysmotility, which are all suggestive of an overlap disease with SSc, but in isolation may not be classified as SSc disease. Therefore, these subjects may not be referred and captured into a cohort of SSc, which could explain the lower frequency of myositis in association with anti-Ku antibodies in SSc cohort studies.

Interestingly, SSc-SLE disease overlap was more frequent in single-specificity anti-Ku-positve subjects in our cohort; anti-Ku antibodies in SLE subjects have not previously been associated with a particular clinical phenotype, except for African ethnicity.\textsuperscript{13,14,25,33} On the contrary, trigrinal neuralgia and autoimmune thyroid disease were not seen in anti-Ku-positve subjects, contrary to what has been observed with anti-Ku in a few case reports and series.\textsuperscript{22,42,56–58}

Of note, clinical characteristics of single-specificity and overlapping subjects tended to be distinct on many levels: age, cutaneous extent, frequency of digital vascular complications, calcinosis and malignancy, and mortality. This dataset highlights the importance of studying single-specificity autoantibodies, as overlapping subjects may present a different, likely mixed phenotype.

All international subjects with anti-Ku antibodies had ANA by IIF, and all CSRG subjects with single-specificity anti-Ku autoantibodies had titers of at least 1:320, all of speckled with or without nucleolar staining patterns (Table 2). This is consistent with anti-Ku’s serological characteristics previously reported in the literature (Supplementary Table 3, http://links.lww.com/MD/B244). We also observed that anti-Ku-positve subjects generally had less frequent concomitant ACA (21% vs 35%); this is consistent with findings by Rozman et al.\textsuperscript{53} who found decreased concomitant ACA and ATA autoantibodies in anti-Ku-positve subjects. On the contrary, Graf et al.\textsuperscript{61} found increased association between anti-Ku and antiphospholipid (or USCAP) autoantibodies, whereas none of our anti-Ku-positve subjects had this autoantibody (Supplementary Table 3, http://links.lww.com/MD/B244). It is acknowledged, however, that the LIA used in our international cohort has a low sensitivity as compared with immunoprecipitation and other immunomoussays (M.J. Fritzler, unpublished data, April 2016).

The role of anti-Ku in the pathophysiology of autoimmune diseases is not entirely understood. The autoantibody-binding target Ku is known to be involved in double-stranded DNA repair.\textsuperscript{34–38} Schild-Poulter et al.\textsuperscript{21} found that anti-Ku autoantibodies were often associated with autoantibodies directed against other DNA repair proteins, and suggested that B-cell responses to latent or persistent DNA damage may be involved at the onset or during the development of autoimmunity in certain systemic autoimmune rheumatic diseases. Hypoxia has also been reported to induce chromatin modifications, leading to recruitment and activation of the DNA-dependent protein kinase (which includes Ku).\textsuperscript{39} This is of interest given that vasculopathy and tissue hypoxia are thought to be part of the initial pathophysiology of SSc. Ku is also involved in V(D)J recombination of receptor genes on B and T lymphocytes\textsuperscript{44,8} and in immunoglobulin class switching;\textsuperscript{110} one could hypothesize that defective expression of the Ku peptide may lead to altered function of the immune system and result in autoimmunity as well. Genetic background seems to play a role in anti-Ku autoimmunity, as evidenced by its positive association with certain human leukocyte antigen (HLA) class II genotypes.\textsuperscript{15,60} Moleculr mimicry between the Ku antigen and certain fungal proteins has also been postulated as a potential trigger for anti-Ku autoimmunity in genetically predisposed individuals.\textsuperscript{61}

Finally, overlapping anti-Ku antibodies were found to be associated with a history of malignancy in our study. To our knowledge, this association has not been reported previously (Table 6). Interestingly, malignancy has been hypothesized to act as a trigger of autoimmunity in certain cases of SSc, particularly in the ARNAP-positive subset, via mechanisms involving antitumor immunity, molecular mimicry, and epitope spreading.\textsuperscript{62,63} In fact, tumors associated with ARNAP-positive SSc have been shown to harbor mutated forms of the RNA polymerase III autoantigen.\textsuperscript{164} In the same way, genetic alterations of the Ku antigen in tumor cells could explain the association between malignancy and overlapping anti-Ku antibodies in SSc. Alternatively, overexpression of repair proteins (such as Ku) in response to DNA damage intrinsic to cancer cells, or defective expression of Ku leading to both uncontrolled tumor expansion and immune system dysfunction, constitute other hypotheses to link anti-Ku autoimmunity and malignancy.

This study has some limitations. Inflammatory myositis was not defined using specific criteria. Instead, a study physician reported its presence or absence. However, the fact that all study physicians were experienced rheumatologists supports the validity of this diagnosis. Nevertheless, mild myositis may have been overlooked. Similarly, defining ILD in the context of longitudinal observational cohort studies is very complex, given issues of missing data and verification bias. We defined ILD using a clinical decision rule that was recently published.\textsuperscript{52} Data on right heart catheterization was not systematically collected in all subjects. Nevertheless, in those without right heart catheterization, we defined pulmonary hypertension using a high cut-off for pulmonary systolic pressure on echocardiogram that has been shown to correlate strongly with right heart catheter studies.\textsuperscript{53} Still, we acknowledge that pulmonary hypertension based on echocardiogram is not synonymous with pulmonary arterial hypertension, which is one of the criteria used to define ILD. In this study, we could thus still represent a mixture of 2 clinical phenotypes. Further stratifying by reactivity to the 2 subunits could lead to the identification of a “purer” phenotype associated with anti-Ku.
subunits, similar to the findings that anti-PM-75 and anti-PM-100 are associated with distinct phenotypes. However, the rarity of these antibodies poses an enormous challenge to further stratification.

Furthermore, subjects identified as having “single-specificity” anti-Ku antibodies may in fact have had other autoantibodies that were not detected by the LIA employed in this study. This might include some associated with connective tissue disease-related ILD such as anti-Jo-1, markers of overlapping disease such as U1RNP, which were only available for a subset of the cohort. However, in the CSGR cohort, we have previously reported a very low prevalence of anti-Jo1 antibodies (approximately 1%) and previous studies have not reported any association between anti-Ku and anti-Jo1 or other antisynthetase antibodies in SSc.[14,22,23] As for U1RNP, 1 case of overlapping Ku and U1RNP autoantibodies out of 13 anti-Ku-positive subjects (8%) was detected in the CSGR cohort, which is similar to the 7% to 13% frequency reported elsewhere.[17,19,22] This subject was classified as having single-specificity anti-Ku antibodies, and was reported to have calcinosis, SLE overlap, and a fatal outcome (cause unknown). If this subject were to be included in the analysis, the single-specificity anti-Ku-positive group would display absence of calcinosis, increased frequency of SLE (17% vs 3%), and similar mortality (15% vs 18%) as anti-Ku-negative subjects, which is no different from current conclusions. Thus, the presence of these autoantibodies is unlikely to have influenced the results of this study in a meaningful manner.

Additional limitations in cohort studies include missing data (>10% for certain variables, such as pulmonary hypertension, CK levels, and pulmonary function test results) and loss to follow-up. However, given that data collection and follow-up were performed on a similar platform irrespective of anti-Ku status, missing data and loss to follow-up could be considered to be missing completely at random. Also, this cohort was composed predominantly of ambulatory patients with mean disease duration of 9.7 years. Thus, it lacks some generalizability for patients with early-onset disease, for those who may have died earlier in the course of their disease, and for seriously ill patients requiring hospitalization. Nevertheless, about a third of the cohort had disease duration of 5 years or less, and the whole cohort is representative of the majority of SSc patients seen in clinical practice. A final limitation of this study is the fact that most reported associations did not reach statistical significance. Given the exploratory nature of the analysis and the small samples in the subgroups, clinically relevant numerical differences were considered informative. Still, it remains possible that some of our findings occurred by chance alone.

On the contrary, when dealing with uncommon serological profiles (there were only 0.6% of subjects with single-specificity anti-Ku antibodies), large well-phenotyped cohorts are required to begin to fill important gaps in knowledge. In the end, the limitations of our data are counter-balanced by its strengths, which include large sample size and detailed clinical phenotypic data.

In conclusion, this is the largest cohort to date focusing on the prevalence and disease characteristics of single-specificity anti-Ku antibodies in subjects with SSc. In our international cohort, anti-Ku antibodies were rare, being found in only 1.1% of subjects. Nevertheless, as a clinician, if faced with a SSc patient who presents a milder cutaneous, vascular and possibly muscular disease phenotype, and who has strongly positive speckled ANA with or without nucleolar pattern, but has an otherwise negative panel for other tested SSc-specific antibodies anti-Ku could be suspected and tested for. If positive, increased clinical vigilance for ILD screening may be warranted. On the other hand, the usually mild clinical features and lack of survival difference associated with this autoantibody would be reassuring in terms of prognosis. Due to the very rare presence of these antibodies and thus the small size of the single-specificity anti-Ku sample, these results need to be interpreted with caution. International collaborations are key to understanding the clinical correlates of uncommon serological profiles in SSc.

Acknowledgments

Investigators of the Canadian Scleroderma Research Group: J. Pope, London, Ontario; M. Baron, Montreal, Quebec; J. Markland, Saskatoon, Saskatchewan; D. Robinson, Winnipeg, Manitoba; N. Jones, Edmonton, Alberta; N. Khalidi, Hamilton, Ontario; P. Docherty, Moncton, New Brunswick; E. Kaminska, Calgary, Alberta; A. Massey, London, Ontario; E. Sutton, Halifax, Nova Scotia; J-P. Mathieu, Montreal, Quebec; M. Hudson, Montreal, Quebec; S. Ligier, Montreal, Quebec; T. Grodzicky, Montreal, Quebec; S. Leclercq, Calgary, Alberta; C. Thorne, Newmarket, Ontario; G. Gyger, Montreal, Quebec; D. Smith, Ottawa, Ontario; P.R. Fortin, Quebec, Quebec; M. Larché, Hamilton, Ontario; T.S. Rodriguez-Reyna, Mexico City, Mexico; A.R. Cabral, Mexico City, Mexico; M.J. Fritzler, Advanced Diagnostics Laboratory, Calgary, Alberta.

Investigators of the Australian Scleroderma Interest Group: C. Hill, Adelaide, South Australia; S. Lester, Adelaide, South Australia; P. Nash, Sunshine Coast, Queensland; M. Nikpour, Melbourne, Victoria; J. Roddy, Perth, Western Australia; K. Patterson, Adelaide, South Australia; S. Proudhon, Adelaide, South Australia; M. Rischmueller, Adelaide, South Australia; J. Sahhar, Melbourne, Victoria; W. Stevens, Melbourne, Victoria; J. Walker, Adelaide, South Australia; J. Zochling, Hobart, Tasmania.

Investigators of GENISOS: Shervin Assassi, Houston, Texas; Maureen D. Mayes, Houston, Texas; Terry A. McNearney, Galveston, Texas; Gloria Salazar, Houston, Texas.

References


BRIEF REPORT

**IRF4** Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies


**Objective.** Systemic sclerosis (SSc) and rheumatoid arthritis (RA) are autoimmune diseases that have similar clinical and immunologic characteristics. To date, several shared SSc–RA genetic loci have been identified independently. The aim of the current study was to systematically search for new common SSc–RA loci through an interdisease meta-genome-wide association (meta-GWAS) strategy.

**Methods.** The study was designed as a meta-analysis combining GWAS data sets of patients with SSc and patients with RA, using a strategy that allowed identification of loci with both same-direction and opposite-direction allelic effects. The top single-nucleotide
polymorphisms were followed up in independent SSc and RA case–control cohorts. This allowed an increase in the sample size to a total of 8,830 patients with SSc, 16,870 patients with RA, and 43,393 healthy controls.

**Results.** This cross-disease meta-analysis of the GWAS data sets identified several loci with nominal association signals ($P < 5 	imes 10^{-8}$) that also showed evidence of association in the disease-specific GWAS scans. These loci included several genomic regions not previously reported as shared loci, as well as several risk factors that were previously found to be associated with both diseases. Follow-up analyses of the putatively new SSc–RA loci identified IRF4 as a shared risk factor for these 2 diseases ($P_{\text{combined}} = 3.29 \times 10^{-12}$). Analysis of the biologic relevance of the known SSc–RA shared loci identified the type I interferon and interleukin-12 signaling pathways as the main common etiologic factors.

**Conclusion.** This study identified a novel shared locus, IRF4, for the risk of SSc and RA, and highlighted the usefulness of a cross-disease GWAS meta-analysis strategy in the identification of common risk loci.

Genome-wide association studies (GWAS) and immune-focused fine-mapping studies have revolutionized our understanding of the genetic component of complex autoimmune diseases by facilitating the identification of thousands of susceptibility loci associated with autoimmunity (1). The vast majority of these loci are shared risk factors for at least 2 autoimmune diseases, pointing to a common genetic background underlying these autoimmune processes. This genetic overlap was suspected some time ago, given the high rate of co-occurrence of autoimmune diseases and the well-established familial aggregation reported for these immune disorders (1).

Systemic sclerosis (SSc) and rheumatoid arthritis (RA) are complex autoimmune diseases that have similar clinical and immunologic features. Both diseases are rheumatic connective tissue disorders, characterized by an exacerbated inflammatory response, deregulation of innate and adaptive immunity, including autoantibody production, and systemic complications. Because of the establishment of large consortia and international collaborations, the number of confirmed RA susceptibility factors has increased up to a total of 101 loci associated with the disease at the genome-wide significance level (2). With regard to SSc, GWAS, Immunochip, and candidate gene studies have clearly identified various genetic regions involved in susceptibility to SSc (3). However, the knowledge of the genetic predisposition to this disease is relatively limited, in part due to its low prevalence, which impairs the recruitment of large cohorts required to reach a high statistical power and to effectively detect association signals. Interestingly, a considerable proportion of the SSc susceptibility factors also represent RA risk loci (2,3). In addition, although not very common, co-familiarity and co-occurrence between these 2 rheumatic conditions have been observed (4). These observations provide evidence of a genetic overlap of both diseases. Thus, it is expected that additional shared risk factors remain to be discovered.

One approach that has been developed for the identification of common loci in a cost-effective manner is to perform a combined-phenotype GWAS, that is, to combine genome-wide genotype data for 2 autoimmune diseases. This strategy has been successfully applied to the study of not only closely related phenotypes but also nonrelated phenotypes, and thus far the results have been encouraging (5).

Taking into account all of these considerations, the purpose of the present study was to systematically identify new common risk loci for SSc and RA by applying the combined-phenotype GWAS strategy, followed by replication testing in independent case–control data sets.

**PATIENTS AND METHODS**

**Study population.** The first stage of the present study, the discovery phase, included 6,537 patients with either SSc or RA and 8,741 healthy controls. The SSc GWAS panel comprised 4 case–control sets from Spain, Germany, The Netherlands, and the US (2,716 cases and 5,666 controls), whose data had been obtained in previous studies (5–7). The RA case–control GWAS panel included 2 previously published RA GWAS cohorts (the Wellcome Trust Case Control Consortium [WTCCC] and the Epidemiological Investigation of Rheumatoid Arthritis study cohort) from the UK and Sweden (3,821 cases and 3,075 controls) (8).

Subjects included in the second stage of the study, the replication phase, were drawn from independent SSc and RA case–control sets of individuals European ancestry. The SSc

---

Address correspondence to Elena López-Isac, MSc, or to Javier Martín, MD, PhD, IPBLN-CSIC, Parque Tecnológico Ciencias de la Salud, Avenida del Conocimiento s/n 18016-Armilla, Granada, Spain. E-mail: elenalongezisac@ipb.csic.es or martin@ipb.csic.es.

Submitted for publication March 30, 2016; accepted in revised form April 19, 2016.
replication cohort included 6,114 cases and 8,744 healthy controls from 8 different countries (Spain, Germany, Italy, the UK, The Netherlands, Sweden, Norway, and the US). The healthy controls from the UK and US partially overlapped with the control sets of previously published cohorts (the WTCCC and the second North American Rheumatoid Arthritis Consortium [NARAC2]) (8). The RA replication cohort included 9 case-control collections from North America (US and Canada), Spain, The Netherlands, the UK, Sweden, France, and New Zealand, and comprised a total of 13,049 RA cases and 25,908 healthy controls. Of these, 9,711 cases and 24,253 healthy controls were obtained from several previously published studies, including the Brigham Rheumatoid Arthritis Sequential Study, NARAC1, CANADA, studies from the Rheumatoid Arthritis Consortium International (RACI-US, RACI-2b2, RACI-UK, RACI-SE-U, and RACI-NL), Consortium of Rheumatology Researchers of North America, Vanderbilt, Dutch studies (Amsterdam Medical Center, Treatment Strategies for RA [BeSt Study], Leiden University Medical Center, and Dutch Rheumatoid Arthritis Monitoring Registry), Research in Active Rheumatoid Arthritis, and the Anti-TNF Response to Therapy collection (ACR-REF: BRAGGSS, BRAGGSS2, ERA, KI, and TEAR) (2). All of the patients with SSc and patients with RA fulfilled previously described classification criteria for each disease (2,5). All individuals enrolled in the present study provided written informed consent, and approval from the local ethics committees was obtained from all of the centers in accordance with the tenets of the Declaration of Helsinki.

Study design. We performed a 2-stage study to systematically identify SSc–RA shared risk factors, with the first stage being the discovery phase for GWAS meta-analysis of each disease separately and a combined-phenotype GWAS meta-analysis, and the second stage being the replication phase (Figure 1).

Discovery phase. We performed GWAS analysis for each disease separately and in a combined-phenotype GWAS analysis. Two different tests were considered for the combined analysis (5). In the first test, in order to detect common signals for SSc and RA with same-direction allelic effects, the meta-analysis considering both diseases was performed as usual. Those SNPs that showed an association at $P < 5 \times 10^{-6}$ in the combined-phenotype analysis (referred to as $P_{\text{combined}}$) and also showed nominal significance in the association study for each disease ($P < 0.05$) were selected for follow-up in the replication phase.

In the second test, in order to identify common signals with opposite-direction allelic effects, we flipped the direction of association (1/odds ratio [OR]) in the RA data set for the combined-phenotype meta-analysis. To select SNPs for replication, the same selection criteria as stated above were followed. For both sorts of meta-analyses, we only considered for follow-up those SNPs that had not been previously reported as genetic risk factors for SSc and RA, or those that had been reported for one disease but not reported for the other.

Replication phase. The SNPs selected were followed-up in independent replication cohorts. Subsequently, we performed a meta-analysis of the initial GWAS screening and replication stages. The SNP signals that 1) reached the genome-wide significance level for association ($P_{\text{combined}} < 5 \times 10^{-8}$) in the combined-phenotype meta-analysis (GWAS + Replication phases), and that 2) showed, for each disease separately, nominally significant associations ($P < 0.05$) in the replication phase as well as significant associations ($P < 5 \times 10^{-3}$) in the GWAS + Replication meta-analysis were considered shared risk factors for the 2 analyzed diseases.

Quality control and genotype imputation of GWAS data. We applied stringent quality control criteria in all of the GWAS data sets. Cutoff values for the sample call rate and the SNP call rate were set as 95%. Markers with allele distributions deviating from Hardy-Weinberg equilibrium (HWE) ($P < 0.001$) in controls from any of the populations analyzed separately were excluded. Markers with minor allele frequencies lower than 1% were filtered out. After quality control, we performed whole-genome genotype imputation with IMPUTE2 software (9) using as reference panels the CEU (Utah residents with northern and western European ancestry from the CEPH collection) and TSI (Toscani in Italy) populations of the HapMap Phase 3 project (available at http://www.hapmap.org). Imputed SNP quality was assessed by establishing a probability threshold for merging genotypes at 0.9. Subsequently, stringent quality control was applied to the imputed data using the same criteria as stated above. Thereafter, genome-wide genotyping data were available for a total of 219,756 SNPs.

The first 5 principal components were estimated, and individuals deviating more than 6 SDs from the cluster centroids were considered outliers. In addition, duplicate pairs or highly related individuals among data sets were also removed on the basis of pairwise comparisons, using the Genome function in Plink version 1.7 (see http://pngu.mgh.harvard.edu/purcell/plink/) (Pi-HAT threshold of 0.5).

Follow-up genotyping. The genotyping of the replication cohorts was performed with either TaqMan SNP genotyping technology in a LightCycler 480 Real-Time polymerase chain reaction system (Roche Applied Science) or the GWAS and Immunochip platforms.

For the SSc study, all cases were genotyped using the TaqMan genotyping system, with TaqMan 5’ allele discrimination predesigned assays from Applied Biosystems. The genotyping call rate was >95% for the 3 SNPs. The control samples were also genotyped using this technology, with the exception of the UK and US cohorts. For these 2 control
RESULTS

Discovery analysis. In the first phase of this study, we conducted a cross-disease meta-analysis in order to systematically identify new putatively shared loci between SSc and RA. The overall workflow of the study is illustrated in Figure 1.

The meta-analysis combining both data sets identified various SNPs from 7 distinct genomic regions that showed a significant association at the level of $P < 5 \times 10^{-6}$, as well as a nominal signal of association ($P < 0.05$) in the disease-specific analyses. The strongest association was found in the well-accepted SSc- and RA-associated locus IRF5 ($P_{\text{combined}} = 8.44 \times 10^{-17}$; for SSc, $P_{\text{GWAS}} = 1.14 \times 10^{-16}$; for RA, $P_{\text{GWAS}} = 7.86 \times 10^{-16}$). Three additional known SSc-RA loci, namely PTPN22, ATG5, and BLK, were also identified at the initial discovery stage (Figure 2) (see also Supplementary Table 2 and Supplementary Figure 1, available on the *Arthritis & Rheumatology* web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39730/abstract). The remaining SNPs were located in 3 different loci, including FBN2 and HNF1A, neither of which has been previously reported as a genetic risk factor for SSc and RA, and IRF4, which has been found to be associated with RA in previous studies (Table 1 and Figure 2) (see also Supplementary Figure 2 on the *Arthritis & Rheumatology* web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39730/abstract). Interestingly, the regional association plots of the FBN2, IRF4, and HNF1A loci showed that the top SNPs in the combined-phenotype analysis were also the top SNPs in the analyses for SSc and RA separately, or at least were in high linkage disequilibrium with the top signal observed for each disease (see Supplementary Figure 2).

These new putatively shared SNPs were selected for follow-up in additional SSc and RA replication cohorts. For IRF4, 3 SNPs met our criteria for being selected for validation in the replication phase. In this case, we selected the SNP with the lowest $P$ value for association (see Supplementary Table 2).

Replication phase and meta-analysis. According to the established thresholds discussed above in Patients and Methods, we identified 1 new association signal shared between SSc and RA at SNP rs9328192 of IRF4 ($P_{\text{combined}} = 3.29 \times 10^{-12}$). Furthermore, this IRF4 SNP almost reached genome-wide significance in the meta-analysis for each disease separately (for SSc, $P_{\text{GWAS + Replication}} = 2.78 \times 10^{-7}$, OR 0.90; for RA, $P_{\text{GWAS + Replication}} = 1.44 \times 10^{-6}$, OR 1.08) (Table 1).

Regarding the HNF1A and FBN2 genetic variants, despite the initial suggestive association signals found in the first stage, these loci did not show genome-wide significance in our combined-phenotype meta-analysis.
<table>
<thead>
<tr>
<th>Locus (Chr.)</th>
<th>SNP Ref. allele</th>
<th>P for SSc-RA GWAS</th>
<th>SSc GWAS</th>
<th>SSc GWAS Replication (meta-GWAS)</th>
<th>RA GWAS</th>
<th>RA Replication (meta-GWAS)</th>
<th>SSc-RA GWAS + Replication</th>
<th>P Current status</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBN2 (5)</td>
<td>rs6897611 T</td>
<td>(4.79 \times 10^{-7})</td>
<td>2.85 \times 10^{-3}</td>
<td>1.16</td>
<td>0.641</td>
<td>0.98</td>
<td>0.165</td>
<td>1.04</td>
</tr>
<tr>
<td>IRF4 (6)</td>
<td>rs9328192 G</td>
<td>(4.06 \times 10^{-7})</td>
<td>8.86 \times 10^{-6}</td>
<td>0.86</td>
<td>1.89 \times 10^{-3}</td>
<td>0.93</td>
<td>2.78 \times 10^{-7}</td>
<td>0.90</td>
</tr>
<tr>
<td>HNF1A (12)</td>
<td>rs10774577§ T</td>
<td>(7.53 \times 10^{-7})</td>
<td>8.62 \times 10^{-4}</td>
<td>0.89</td>
<td>0.036</td>
<td>0.94</td>
<td>1.64 \times 10^{-3}</td>
<td>0.91</td>
</tr>
</tbody>
</table>

* GWAS = genome-wide association study; SNPs = single-nucleotide polymorphisms; Chr. = chromosome.
† Represents the odds ratio (OR) for the reference (Ref.) allele.
‡ P values and ORs were derived from meta-analysis under random effects due to heterogeneity of the ORs among cohorts.
§ The rheumatoid arthritis (RA) and systemic sclerosis (SSc) replication cohorts from Spain, and the SSc replication cohorts from Italy and The Netherlands were excluded from the analysis of rs10774577 due to issues with Hardy-Weinberg equilibrium.
Nevertheless, *HNF1A* rs10774577 showed suggestive evidence of association in the meta-analysis performed in the SSc data set (\(P_{\text{Replication}} = 0.036\), OR 0.94; \(P_{\text{GWAS + Replication}} = 1.64 \times 10^{-4}\) OR 0.91), and showed an association at the level of \(P = 1.59 \times 10^{-6}\) in the combined-phenotype meta-analysis. Considering that this SNP was not included in those cohorts that were genotyped with Immunochip, the present study had a lower statistical power for the analysis of this genomic region. Therefore, the possibility of a slight or modest genetic effect of *HNF1A* rs10774577 on both diseases cannot be ruled out, and further studies will be required to establish whether this locus is a shared SSc–RA risk factor.

**DISCUSSION**

In the present study, we identified a novel non-HLA susceptibility locus that is shared between SSc and RA, namely *IRF4*, using a combined-phenotype GWAS strategy in large case–control cohorts of patients with SSc and those with RA. This locus, *IRF4*, was already reported to be involved in RA susceptibility, but had not been previously associated with SSc (2).

The cross-disease meta-analysis performed with the SSc and RA GWAS data sets identified various SNPs from 7 different loci that met our stringent selection criteria for the replication phase (\(P_{\text{combined}} < 5 \times 10^{-6}\); for SSc and for RA, each \(P_{\text{GWAS}} < 0.05\)). Four of the 7 SNPs were already known risk factors for SSc and RA (*PTPN22, ATG5, IRF5*, and *BLK*), thus providing support for the effectiveness of this strategy in the identification of shared risk loci (2,3). It is worth mentioning that these loci were detected by the 2 different tests used in the first phase, which were performed in order to detect both same-direction and opposite-direction allelic effects. In fact, the shared *IRF4* SNP newly identified in this study showed opposite effects for SSc and for RA (protective effect and risk effect, respectively). This discrepancy might be attributable to the fact that the actual causal variants for the associations in each disease could be different, and that *IRF4* rs9328192 is tagging them. This discordant phenomenon is particularly common between autoimmune diseases (1). However, to completely understand these discordant effects, the interaction with other genetic variants contributing to disease susceptibility should be considered, in addition to analyzing the precise biologic impact of the associations.

The associated *IRF4* SNP (rs9328192) showed modest effect sizes for SSc and RA. However, we were able to capture this association in our meta-analysis because of the large cohort used in this study, together with the combined-phenotype approach, which allowed us to increase the statistical power. This highlights the capability of the combined-phenotype approach in the identification of shared variants with low penetrance, whose associations might have been missed in disease-specific GWAS due to a lack of power (11).

*IRF4* belongs to the IRF family of transcription factors and plays a pivotal role in the development and function of several autoimmune-associated cells (12). Various genetic and functional studies have pointed to *IRF4* as a master regulator for autoimmunity (12,13). It has been demonstrated that *IRF4* is a crucial factor for the editing and L-chain rearrangements of the B cell receptor, and for pre–B cell expansion, both of which are processes directly related to the development of autoimmunity (14). In addition, *IRF4* is a critical controller of Th17 cell differentiation and the production of interleukin-17 (IL-17) and IL-21 (12), which are components of the immune system that play a key role in the pathogenesis of SSc and RA.

The results of the present study add another *IRF* to the list of *IRFs* associated with SSc (*IRF4, IRF5, IRF7*, and *IRF8*) and RA (*IRF4, IRF5*, and *IRF8*) (2,3), thus providing genetic support for the type I interferon (IFN) signature described in patients with SSc and those with RA (15). Moreover, our pathway enrichment analysis also identified the type I IFN signaling pathway as one of the most relevant common pathways between SSc and RA on the basis of their common genetic background (see Supplementary Methods, Supplementary Table 3, and Supplementary Figure 3, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39730/abstract). Therefore, deregulation of this signaling pathway might be a biologic process that underlies the onset of these 2 autoimmune rheumatic conditions.

In summary, through a cross-disease meta-analysis of GWAS for SSc and RA, we were able to identify *IRF4* as a new shared susceptibility locus for these 2 autoimmune diseases. The results of the present study, taken together with the findings from previous studies, reinforce the idea of a common genetic background between SSc and RA. The identification of these pleiotropic autoimmunity loci may point to common pathogenic pathways, which ultimately may represent a clinical advantage in that it may provide support for drug repositioning on the basis of the true understanding of the pathogenic mechanisms of SSc and RA.

**ACKNOWLEDGMENTS**

We thank Sofia Vargas, Sonia García, and Gema Robledo for their excellent technical assistance, and all of the...
patients and control donors for their essential collaboration. We thank National DNA Bank Carlos III (University of Salamanca, Spain) for supplying part of the control DNA samples. We also would like to thank the following organizations: the European League Against Rheumatism Scleroderma Trials and Research Group, the German Network of Systemic Sclerosis, the US Scleroderma Foundation, and the US Raynauds & Scleroderma Association.

**AUTHOR CONTRIBUTIONS**

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Drs. López-Isac and J. Martin had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Study conception and design.** Fonseca, Radstake, Worthington, Mayes, J. Martin.


**Analysis and interpretation of data.** López-Isac, J.-E. Martin.

**REFERENCES**


**APPENDIX A: MEMBERS OF THE SPANISH SCLERODERMA GROUP**

Members of the Spanish Sleroderma Group include the following: Raquel Ríos and José Luis Callejas (Hospital Clínico Universitario San Cecilio, Granada), José Antonio Vargas Hitos (Hospital Virgen de las Nieves, Granada), Rosa García Portales (Hospital Virgen de la Victoria, Málaga), María Teresa Camps (Hospital Carlos Haya, Málaga), Antonio Fernández-Nebro (Hospital Carlos Haya, Málaga), Maria F. González-Escríbar (Hospital Virgen del Rocio, Seville), Francisco José García-Hernández and Mª Jesús Castillo (Hospital Virgen del Rocio, Seville), Mª Ángeles Aguirre and Inmaculada Gómez-Gracía (Hospital Reina Sofía/IMIBIC, Córdoba), Luis Rodríguez-Rodríguez (Hospital Clínico San Carlos, Madrid), Paloma García de la Peña (Madrid Norte Sanchinarro Hospital, Madrid), Esther Vicente (Hospital La Princesa, Madrid), José Luis Andreu and Mónica Fernández de Castro (Hospital Puerta de Hierro Majadahonda, Madrid), Francisco Javier López-Longo and Lina Martínez (Hospital General Universitario Gregorio Marañón, Madrid), Vicente Fonollosa and Alfredo Guillén (Hospital Valle de Hebrón, Barcelona), Iván Castellví (Santa Creu i Sant Pau University Hospital, Barcelona), Gerard Espinosa (Hospital Clinic, Barcelona), Carlos Tolosa (Hospital Parc Taulí, Sabadell), Anna Pros (Hospital Del Mar, Barcelona), Mónica Rodríguez Carballeira (Hospital Universitari Mutua Terrasa, Barcelona), Francisco Javier Narváez (Hospital Universitari de Bellvitge, Barcelona), Manel Rubio Rivas (Hospital Universitari de Bellvitge, Barcelona), Vera Ortiz-Santamaría (Hospital General de Granollers, Granollers), Ana Belén Madroñero (Hospital General San Jorge, Huesca), Bernardo Díaz and Luis Trapiella (Hospital Central de Asturias, Oviedo), Adrián Sousa (Hospital Xeral-Complexo Hospitalario Universitario de Vigo, Vigo), María Victoria Eguibide (Hospital Universitario Cruces, Barakaldo), Patricia Fanlo Mateo (Hospital Virgen del Camino, Pamplona), Luis Sáez-Comet (Hospital Universitario Miguel Servet, Zaragoza), Federico Díaz and Vanesa Hernández (Hospital Universitario de Canarias, Tenerife), Emma Beltrán (Hospital General Universitario de Valencia, Valencia), José Andrés Román-Ivorra and Elena Grau (Hospital Universitari i Politecnic La Fe, Valencia), Juan José Alegre-Sancho (Hospital Universitari Doctor Peset, Valencia), Francisco J. Blanco García and Natividad Oreiro (INIBIC-Hospital Universitario A Coruña, La Coruña).
RESEARCH ARTICLE

Investigating the Causal Relationship of C-Reactive Protein with 32 Complex Somatic and Psychiatric Outcomes: A Large-Scale Cross-Consortium Mendelian Randomization Study


1 Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, 2 Department of Human Genetics, Wellcome Trust Sanger Institute, Hinxton, United Kingdom, 3 MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, United Kingdom, 4 Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands, 5 Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada, 6 Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada, 7 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, 8 Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, United States of America, 9 Department of Dermatology, Veterans Affairs Hospital, University of Michigan, Ann Arbor, Michigan, United States of America, 10 Department of Genetics, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands, 11 Metabolic Research Laboratories, Wellcome Trust–MRC Institute of Metabolic Science, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, 12 Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 13 Center for Applied Genomics, Division of Human Genetics, Children’s Hospital of Philadelphia, Philadelphia, United States of America, 14 Department of Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom, 15 Department of Molecular Neuroscience, Institute of Neurology, London, United Kingdom, 16 Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom, 17 Neurology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom, 18 Division of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, United States of America, 19 Instituto de Parasitología y Biomedicina Lopez-Neyra, Consejo Superior de Investigaciones Científicas, Granada, Spain, 20 Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece, 21 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, 22 Institut für Integrative und Experimentelle Genomik, Universität zu Lübeck, Lübeck, Germany, 23 Department of Molecular
Mendelian Randomization of CRP in 32 Somatic and Psychiatric Outcomes

Abstract

Background

C-reactive protein (CRP) is associated with immune, cardiometabolic, and psychiatric traits and diseases. Yet it is inconclusive whether these associations are causal.

Methods and Findings

We performed Mendelian randomization (MR) analyses using two genetic risk scores (GRSs) as instrumental variables (IVs). The first GRS consisted of four single nucleotide polymorphisms (SNPs) in the CRP gene (GRS<sub>CRP</sub>), and the second consisted of 18 SNPs that were significantly associated with CRP levels in the largest genome-wide association study (GWAS) to date (GRS<sub>GWAS</sub>). To optimize power, we used summary statistics from GWAS consortia and tested the association of these two GRSs with 32 complex somatic and psychiatric outcomes, with up to 123,865 participants per outcome from populations of European ancestry. We performed heterogeneity tests to disentangle the pleiotropic effect of IVs. A Bonferroni-corrected significance level of less than 0.0016 was considered
statistically significant. An observed p-value equal to or less than 0.05 was considered nominally significant evidence for a potential causal association, yet to be confirmed.

The strengths (F-statistics) of the IVs were 31.92–3,761.29 and 82.32–9,403.21 for GRS\textsubscript{CRP} and GRS\textsubscript{GWAS}, respectively. CRP GRS\textsubscript{GWAS} showed a statistically significant protective relationship of a 10% genetically elevated CRP level with the risk of schizophrenia (odds ratio [OR] 0.86 [95% CI 0.79–0.94]; \(p < 0.001\)). We validated this finding with individual-level genotype data from the schizophrenia GWAS (OR 0.96 [95% CI 0.94–0.98]; \(p < 1.72 \times 10^{-6}\)). Further, we found that a standardized CRP polygenic risk score (CRP\textsubscript{PRS}) at \(p\)-value thresholds of \(1 \times 10^{-4}, 0.001, 0.01, 0.05, \) and 0.1 using individual-level data also showed a protective effect (OR < 1.00) against schizophrenia; the first CRP\textsubscript{PRS} (built of SNPs with \(p < 1 \times 10^{-4}\)) showed a statistically significant (\(p < 2.45 \times 10^{-4}\)) protective effect with an OR of 0.97 (95% CI 0.95–0.99). The CRP GRS\textsubscript{GWAS} showed that a 10% increase in genetically determined CRP level was significantly associated with coronary artery disease (OR 0.88 [95% CI 0.84–0.94]; \(p < 2.4 \times 10^{-5}\)) and was nominally associated with the risk of inflammatory bowel disease (OR 0.85 [95% CI 0.74–0.98]; \(p < 0.03\)), Crohn disease (OR 0.81 [95% CI 0.70–0.94]; \(p < 0.005\)), psoriatic arthritis (OR 1.36 [95% CI 1.00–1.84]; \(p < 0.049\)), knee osteoarthritis (OR 1.17 [95% CI 1.01–1.36]; \(p < 0.04\)), and bipolar disorder (OR 1.21 [95% CI 1.05–1.40]; \(p < 0.007\)) and with an increase of 0.72 (95% CI 0.11–1.34; \(p < 0.02\)) mm Hg in systolic blood pressure, 0.45 (95% CI 0.06–0.84; \(p < 0.02\)) mm Hg in diastolic blood pressure, 0.01 ml/min/1.73 m\(^2\) (95% CI 0.003–0.02; \(p < 0.005\)) in estimated glomerular filtration rate from serum creatinine, 0.01 g/dl (95% CI 0.0004–0.02; \(p < 0.04\)) in serum albumin level, and 0.03 g/dl (95% CI 0.008–0.05; \(p < 0.009\)) in serum protein level. However, after adjustment for heterogeneity, neither GRS showed a significant effect of CRP level (at \(p < 0.0016\)) on any of these outcomes, including coronary artery disease, nor on the other 20 complex outcomes studied. Our study has two potential limitations: the limited variance explained by our genetic instruments modeling CRP levels in blood and the unobserved bias introduced by the use of summary statistics in our MR analyses.

Conclusions

Genetically elevated CRP levels showed a significant potentially protective causal relationship with risk of schizophrenia. We observed nominal evidence at an observed \(p < 0.05\) using either GRS\textsubscript{CRP} or GRS\textsubscript{GWAS}—with persistence after correction for heterogeneity—for a causal relationship of elevated CRP levels with psoriatic osteoarthritis, rheumatoid arthritis, knee osteoarthritis, systolic blood pressure, diastolic blood pressure, serum albumin, and bipolar disorder. These associations remain yet to be confirmed. We cannot verify any causal effect of CRP level on any of the other common somatic and neuropsychiatric outcomes investigated in the present study. This implies that interventions that lower CRP level are unlikely to result in decreased risk for the majority of common complex outcomes.

Introduction

Emerging evidence suggests that persistent dysregulation of the inflammatory response is linked to a plethora of complex somatic and neuropsychiatric disorders [1–18]. Epidemiological
studies have shown that C-reactive protein (CRP), a well-studied biomarker of inflammation, is associated with and exhibits reliable predictive value for cardiovascular disease [19,20], type 2 diabetes [21], immunity-related disorders such as inflammatory bowel disease (IBD) [22], rheumatoid arthritis [23], and all-cause mortality [20,24]. Nevertheless, the evidence for a causal involvement of CRP in these outcomes from traditional experimental or observational studies remains controversial [25,26], fueling the debate surrounding whether CRP contributes to the chain of causality in disease mechanisms [27]. The use of genetically informed instrumental variables (IVs), termed Mendelian randomization (MR), is a complementary approach to epidemiological observations and allows investigation of whether the effect of an exposure (i.e., CRP level) on observed outcome phenotypes is likely to be causal [28].

Recent large-scale MR studies, focusing mainly on cardiovascular disease and metabolic traits, failed to show a causal association between CRP level and these outcomes (S1 Table). This has led to the notion that elevated CRP levels do not causally contribute to these traits and disorders. However, these studies used a single CRP-associated single nucleotide polymorphism (SNP) or a very limited set of CRP-associated SNPs (S1 Table). Common SNPs serving as proxies for CRP level represent only a small effect on CRP level per se and thus require a large enough sample size to detect causal effects on the outcome. Moreover, most studies have generally included a limited range of common complex diseases, often not more than two or three outcomes, or they have been performed in a single or small population, yielding inadequate study power (S1 Table). In other words, the evidence for a causal relationship between CRP and a broad range of common traits or diseases remains inconclusive. This is mostly due to the lack of well-powered MR studies that use optimally informative genetic IVs for CRP. Here, we sought to comprehensively examine the hypothesis that genetically determined CRP level directly contributes to common somatic and psychiatric outcomes. To optimize IV power, we applied a MR approach using summary statistics from large-scale genome-wide association study (GWAS) consortia of 32 somatic and psychiatric phenotypes for the four CRP variants representing 98% of the common variation in the CRP gene and for the largest known set of independent SNPs known to be associated with CRP. We further aimed to confirm the identified association between CRP and schizophrenia using a CRP polygenic risk score (CRPPRS) from individual-level genotype data from the largest consortium of schizophrenia to date. We performed an in silico pathway analysis (see Discussion) to provide insights into the possible mechanism underlying the observed association of CRP level with schizophrenia.

Methods

Study Design and Rationale

The present MR study consists of two key components. First, we used established gene variants associated with CRP level and combined them to build two genetic risk scores (GRSs) for CRP. The first GRS consisted of only four SNPs in the CRP gene (GRSCRP) selected from the largest recent MR study of CRP [29], and the second consisted of 18 SNPs that were associated with CRP level at a genome-wide significance level in the largest GWAS for CRP to date (GRSWAS) [30]. Second, we obtained summary association statistics from GWAS consortia for a panel of 32 common somatic and psychiatric outcomes (Table 1). BPP and BZA selected the studies, and contacted each consortium with a standardized request for study data, including the name of the study or consortium, the number of cases and controls, the number of available CRP SNPs for GRSCRP and GRSWAS, and the estimated effect for each SNP (or its proxy) on outcome, i.e., the per-allele regression coefficient with standard error or the odds ratio (OR) and corresponding 95% confidence interval. Data were available for 32 different outcomes in five broad disease/trait classes (autoimmune/inflammatory, cardiovascular, metabolic,
neurodegenerative, and psychiatric), including at least 1,566, and up to 184,305, participants per outcome from populations of European ancestry (Table 1). These outcomes were selected based on the following two inclusion criteria: (i) the outcome having been associated with CRP level in epidemiological studies and (ii) availability of large meta-GWAS analyses for the outcome (Table 1).

Table 1. Diseases and traits included in this study.

<table>
<thead>
<tr>
<th>Disease or Trait</th>
<th>Cases</th>
<th>Controls</th>
<th>Total</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autoimmune/inflammatory</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Celiac disease</td>
<td>4,533</td>
<td>10,750</td>
<td>15,283</td>
<td>[31]</td>
</tr>
<tr>
<td>IBD (all types)</td>
<td>13,020</td>
<td>34,774</td>
<td>47,794</td>
<td>[32,33]</td>
</tr>
<tr>
<td>Crohn disease</td>
<td>6,333</td>
<td>15,056</td>
<td>21,389</td>
<td>[32]</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>6,687</td>
<td>19,718</td>
<td>26,405</td>
<td>[33]</td>
</tr>
<tr>
<td>Psoriasis vulgaris</td>
<td>4,007</td>
<td>4,934</td>
<td>8,941</td>
<td>[34,35]</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>1,946</td>
<td>4,934</td>
<td>6,880</td>
<td>[34,35]</td>
</tr>
<tr>
<td>Cutaneous psoriasis</td>
<td>1,363</td>
<td>3,517</td>
<td>4,880</td>
<td>[34,35]</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>5,538</td>
<td>20,167</td>
<td>25,705</td>
<td>[36]</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>1,311</td>
<td>3,340</td>
<td>4,651</td>
<td>[37]</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>2,356</td>
<td>5,187</td>
<td>7,543</td>
<td>[38]</td>
</tr>
<tr>
<td>Type 1 diabetes</td>
<td>9,934</td>
<td>16,956</td>
<td>26,890</td>
<td>[39]</td>
</tr>
<tr>
<td>Knee osteoarthritis</td>
<td>5,755</td>
<td>18,505</td>
<td>24,260</td>
<td>[40]</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>60,801</td>
<td>123,504</td>
<td>184,305</td>
<td>[41]</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>—</td>
<td>—</td>
<td>69,368</td>
<td>[42]</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
<td>—</td>
<td>—</td>
<td>69,372</td>
<td>[42]</td>
</tr>
<tr>
<td>Ischemic stroke (all types)</td>
<td>3,548</td>
<td>5,972</td>
<td>9,520</td>
<td>[43]</td>
</tr>
<tr>
<td>Ischemic stroke (cardioembolic)</td>
<td>790</td>
<td>5,972</td>
<td>6,762</td>
<td>[43]</td>
</tr>
<tr>
<td>Ischemic stroke (large vessel)</td>
<td>844</td>
<td>5,972</td>
<td>6,816</td>
<td>[43]</td>
</tr>
<tr>
<td>Ischemic stroke (small vessel)</td>
<td>580</td>
<td>5,972</td>
<td>6,552</td>
<td>[43]</td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index</td>
<td>—</td>
<td>—</td>
<td>123,865</td>
<td>[44]</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>6,698</td>
<td>15,872</td>
<td>22,570</td>
<td>[45]</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>6,271</td>
<td>68,083</td>
<td>74,354</td>
<td>[46]</td>
</tr>
<tr>
<td>eGFRcr</td>
<td>—</td>
<td>—</td>
<td>74,354</td>
<td>[46]</td>
</tr>
<tr>
<td>Serum albumin level</td>
<td>—</td>
<td>—</td>
<td>53,189</td>
<td>[47]</td>
</tr>
<tr>
<td>Serum protein level</td>
<td>—</td>
<td>—</td>
<td>25,537</td>
<td>[47]</td>
</tr>
<tr>
<td><strong>Neurodegenerative</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis</td>
<td>4,133</td>
<td>8,130</td>
<td>12,263</td>
<td>[48]</td>
</tr>
<tr>
<td>Alzheimer disease</td>
<td>4,663</td>
<td>8,357</td>
<td>13,020</td>
<td>[49]</td>
</tr>
<tr>
<td>Parkinson disease</td>
<td>5,333</td>
<td>12,019</td>
<td>17,352</td>
<td>[50]</td>
</tr>
<tr>
<td><strong>Psychiatric</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autism</td>
<td>90</td>
<td>1,476</td>
<td>1,566</td>
<td>[51]</td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>7,481</td>
<td>9,250</td>
<td>16,731</td>
<td>[52]</td>
</tr>
<tr>
<td>Major depressive disorder</td>
<td>9,240</td>
<td>9,519</td>
<td>18,759</td>
<td>[53]</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>3,241</td>
<td>45,604</td>
<td>79,845</td>
<td>[54]</td>
</tr>
</tbody>
</table>

eGFRcr, estimated glomerular filtration rate from serum creatinine.

doi:10.1371/journal.pmed.1001976.t001
Genetic Instruments

Weak IVs yielding insufficient statistical power may have hampered estimation of causal effects of CRP on the outcomes in previous analyses (S1 Table). Our MR approach, by using GWAS data and combining multiple independent SNPs into a GRS (i.e., IV), has the potential to greatly increase power. The selected SNPs have been described elsewhere [30,55,56] and are further detailed in S2–S4 Tables. These IVs were used to test the combined effect of the associations of CRP-level-influencing alleles with the outcomes. Our approach was implemented in such a way that the effects of both independent SNPs in the CRP gene (GRS\textsubscript{CRP}) [55,56] (S1 Methods) and independent SNPs known to be genome-wide significantly associated with CRP levels (GRS\textsubscript{GWAS}) [30], as well as pleiotropic effects of SNPs, could be discriminated [57]. Pleiotropy exists if CRP SNPs influence exposures (risk factors) other than CRP level and therefore violate one of the key MR assumptions.

Statistical Analysis

All analyses were done using the GRS function implemented in the grs.summary module of the R package Genetics ToolboX (version 2.15.1 for Windows). The grs.summary module approximates the regression of an outcome onto an additive GRS, using only single SNP association summary statistics extracted from GWAS results. The method is described in more detail elsewhere [58]. In brief, we performed MR analyses using GRS IVs in two steps. First, we used four individual CRP gene SNPs (i.e., IVs) associated with CRP level [56,59] (S2 and S3 Tables) to create a weighted GRS, named GRS\textsubscript{CRP}, corresponding to the joint effect of the four SNPs within the CRP gene [55]. We extracted \( \omega \) (the estimated coefficient, or weight) for individual SNPs from association results reported by the CRP Coronary Heart Disease Genetics Collaboration (CCGC) [29,55]; \( \omega \) represents a one-unit (in mg/l) increase of the natural log of CRP level (lnCRP) per dose of the coded allele. The four tagging SNPs represent 98% of the common variation in the CRP gene, assuming a minor allele frequency of \( 0.05 \) and an \( r^2 \) threshold of \( 0.8 \), and aggregately explain \( \sim \)2% of the total variation (i.e., phenotypic variance) in serum CRP level in populations of European descent [55,59]. Second, we constructed a multilocus GRS, named GRS\textsubscript{GWAS}, that combined 18 SNPs associated with serum CRP level at a genome-wide significance level (\( p < 5 \times 10^{-8} \); S2 and S3 Tables), derived from a large meta-GWAS analysis of CRP conducted by the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) Consortium [30]. This multilocus GRS explains approximately \( \sim \)5% of the total variation in serum CRP level [30].

We integrated \( \omega \) for each CRP SNP from the reference data of CCGC [55] or meta-analysis of GWASs [30] for CRP level with the summary association statistics extracted from the GWAS consortium data for each outcome (S1 Data; S2 Methods). This MR approach using meta-GWAS summary statistics data is equivalent to an inverse-variance-weighted meta-analysis and has previously been validated in comparison to individual-level data [57,60]. To estimate the causal effect of CRP level on an outcome, we obtained the \( \beta \) values (estimated effects from regression analysis) for the effects of CRP SNPs on the outcome, with standard errors, \( \text{se}_\beta \), from the corresponding GWAS results. Where no summary statistics for a CRP SNP in the GRS IVs were available in the look-up dataset, we chose the proxy SNP that had the highest linkage disequilibrium with the initial SNP (\( r^2 > 0.9 \) in HapMap release 22; S3 Table). If several proxy SNPs had the exact same \( r^2 \) value, we chose the proxy nearest to the original SNP in the instrument. Separate regressions of outcomes on GRSs were performed to calculate \( \alpha_{IV} \) estimators (i.e., causal IV estimators) for each outcome. Correspondingly, the value of a GRS is the sum of the \( \omega \) values multiplied by the allele dosage (i.e., 0, 1, or 2) for each CRP SNP in the CCGC or in the CHARGE Consortium data [30,55]. For uncorrelated SNPs, when maximizing
the likelihood function, the $\alpha_{IV}$ value and its standard error, $se_{\alpha}$, can be approximated with the formula $\alpha \cong (\Sigma \omega \times \beta \times se_{\beta}^{-2}) / (\Sigma \omega^2 \times se_{\beta}^{-2})$, with $se_{\alpha} \cong \sqrt{1 / \Sigma \omega^2 \times se_{\beta}^{-2}}$. InCRP was used as the outcome in reference studies [30,55], so in obtaining the $\omega$ values (i.e., effect sizes) for each of the CRP SNPs, a unit increase in lnCRP equals a 10 symmetric percentage (s%) increase in CRP level, which corresponds to a unit change in the level of a continuous outcome or logit of risk estimate (i.e., beta coefficient) for a dichotomous outcome [61]. The $\alpha_{IV}$ value (i.e., causal estimate) for each CRP SNP is, therefore, presented for each outcome as corresponding to a 10-s% increase in actual CRP level. During the course of this study, an updated, larger GWAS dataset for coronary artery disease (CAD) became publicly available (CARDIoGRAMplusC4D Consortium, release 2015 [41]); we therefore redid the analysis for CAD using the release 2015 data.

To assess which SNPs might have violated the key MR assumption regarding pleiotropy, we performed goodness-of-fit tests to correct both GRSs for the heterogeneity of their corresponding SNPs’ effects on each outcome. Heterogeneity, which indicates the potential presence of pleiotropy, was measured using the $Q$ statistic and was considered statistically significant at a conservative uncorrected $p$-value of $<0.05$. Although heterogeneity could be an indicator of pleiotropy, there are other factors that could introduce heterogeneity in the analyses. Even though the adjustments for heterogeneity that we have made could be overconservative, we have used this method in order to minimize false positives. After stepwise removal of SNPs with potential pleiotropic effects, we repeated the analyses until significant heterogeneity was no longer observed.

To further ensure the strength of these two GRSs as IVs, we generated an $F$-statistic for each outcome. We used variance in lnCRP explained by each set of CRP SNPs (2% and 5%, respectively, for GRS$_{CRP}$ and GRS$_{GWAS}$) to calculate the $F$-statistic using the formula $F$-statistic = $[R^2 \times (n - 1 - K)]/[(1 - R^2) \times K]$, where $R^2$ represents the proportion of variability in CRP level that is explained by the GRS, $n$ represents sample size, and $K$ represents the number of IVs included in model (i.e., for this study $K = 1$) [62]. As a rule of thumb, an $F$-value above ten indicates that a causal estimate is unlikely to be biased due to weak instruments [57].

**Multiple Testing**

The present study included 32 independent sample sets. For each sample set, we did one statistical test, for which a global nominal significance level of $\leq 0.05$ was considered as satisfactory to derive conclusions. The need for correction for multiple testing is debatable. Nevertheless, to ensure the validity of our conclusions, we took a conservative approach and applied a Bonferroni-corrected significance threshold calculated as 0.05 divided by 32 (i.e., 0.0016). We considered a statistical test with an observed $p$-value more than 0.05 as a definitely nonsignificant result, i.e., no association; an observed $p$-value equal to or less than 0.05 as nominally significant evidence for a potential, but yet to be confirmed, causal association; and an observed $p$-value equal to or less than 0.0016 as statistically significant evidence for a causal association.

**CRP Polygenic Risk Score and Schizophrenia Using Individual-Level Data**

In an ancillary follow-up study, inspired by comments by the editors and the reviewers, we aimed further to determine whether GRS$_{GWAS}$ was causally associated with schizophrenia using individual-level data retrieved from the Psychiatric Genomics Consortium (PGC) schizophrenia dataset (S3 Methods) [54]. This dataset consisted of 36 independent cohorts with a combined 25,629 cases and 30,976 controls for which we had ethics approval (S4 Methods). Three family-based samples of European ancestry (1,235 parent–affected offspring trios) were
excluded from our analysis. To evaluate whether the observed protective causal association between GRS\textsubscript{GWAS} and schizophrenia was persistent, we investigated whether the CRP\textsubscript{PRS} was also protectively associated with schizophrenia. Briefly, CRP\textsubscript{PRS} values were calculated for each individual by summing the total effect of the SNP dosages by their effect size. In addition to the 18 genome-wide significant CRP SNPs, we grouped subthreshold CRP-associated SNPs at the following \(p\)-value thresholds: \(1 \times 10^{-4}\), 0.001, 0.01, 0.05, and 0.1. Standardized CRP\textsubscript{PRS} values were tested for association with schizophrenia case status in each cohort with adjustment for ten principal components (PCs). A fixed effects inverse-variance-weighted meta-analysis was performed across all 36 cohorts to obtain the overall effect size estimate as explained in S4 Methods and elsewhere [63]. The variance in schizophrenia case status explained by CRP\textsubscript{PRS} was estimated using the deviation in Nagelkerke’s pseudo-\(R^2\) between a null model (which included ten PCs) and the full model (which included GRS in addition to the ten PCs), calculated in R using the Functions for Medical Statistics Book with Some Demographic Data (fmsb) R package (S3 Methods). Similar to previous studies, the statistical significance of CRP\textsubscript{PRS} values was estimated based on their logistic regression coefficient [64], and reported CRP\textsubscript{PRS} ORs correspond to a 1-SD increase in CRP\textsubscript{PRS} [65].

**Results**

Using GRS\textsubscript{CRP}, we first tested whether a CRP-gene-determined increase in lnCRP was associated with each outcome. In Table 2, the causal effects of lnCRP estimated for each outcome are summarized. We found no heterogeneity in the IV analyses (\(\Phi\)\textsubscript{heterogeneity} \(\geq 0.11\) for all outcomes), and GRS\textsubscript{CRP} was a strong instrument (\(F \geq 31\)). IV analyses provided nominal evidence for potential causal relationships of lnCRP with risk of Crohn disease (OR 0.78 [95% CI 0.65–0.94]; \(p < 0.009\)), psoriatic arthritis (1.45 [1.04–2.04]; \(p < 0.03\)), and schizophrenia (0.90 [0.82–0.99]; \(p < 0.03\)), and with an increase in systolic blood pressure (SBP) (mean increase 1.23 mm Hg per 10-s% increase in CRP level [95% CI 0.45–2.01]; \(p < 0.002\)) and diastolic blood pressure (DBP) (0.70 [0.20–1.19]; \(p < 0.006\)). GRS\textsubscript{CRP} showed no significant effect on any of the other outcomes (Table 2; S1 Fig).

GRS\textsubscript{GWAS} showed a statistically significant protective effect of lnCRP on the risk of schizophrenia (per 10-s% increase in CRP level, OR 0.86 [95% CI 0.79–0.94]; \(p < 0.0010\)) (Figs 1 and S1; Table 3). In a follow-up analysis using the individual-level PGC data, we found that a GRS incorporating the same 18 CRP SNPs used to construct the GRS\textsubscript{GWAS} was again significantly associated with a lower risk of schizophrenia (OR 0.96 [95% CI 0.94–0.98]; \(p < 1.72 \times 10^{-6}\)). This signal persisted when we included all SNPs meeting a less stringent \(p\)-value threshold of \(1 \times 10^{-4}\) (OR 0.97 [95% CI 0.95–0.99]; \(p < 2.45 \times 10^{-4}\)). At less stringent \(p\)-value thresholds, less variance was explained by the logistic model, and the protective effect of CRP risk scores became less significant, but across all \(p\)-value thresholds, the direction of the effect was consistently protective (Figs 2 and 3). To ensure that the association between risk alleles for CRP and schizophrenia was not driven by a small number of genome-wide significant SNPs, we performed a leave-one-out sensitivity analysis of the 18 genome-wide SNPs. In the 18 sets of 17 SNPs, the variance explained (Nagelkerke’s pseudo-\(R^2\)) ranged from 0.012% to 0.034%, with \(p\)-values ranging from 9.3 \(\times 10^{-5}\) to 1.6 \(\times 10^{-2}\), suggesting that the protective effect observed between risk alleles for CRP and schizophrenia was not driven by a small number of SNPs with large effects.

GRS\textsubscript{GWAS} also showed moderate but nominally significant effects of lnCRP on the risk of IBD (OR 0.85 [95% CI 0.74–0.98]; \(p < 0.03\)), Crohn disease (0.81 [0.70–0.94]; \(p < 0.005\)), psoriatic arthritis (1.36 [1.00–1.84]; \(p < 0.049\)), knee osteoarthritis (1.17 [1.01–1.36]; \(p < 0.04\)), and bipolar disorder (1.21 [1.05–1.40]; \(p < 0.007\)), while its effect was statistically significant
Table 2. The effect of the CRP genetic risk score instrument of four SNPs in CRP (GRS_{CRP}) with somatic and neuropsychiatric outcomes.

<table>
<thead>
<tr>
<th>Disease or Trait</th>
<th>M</th>
<th>N</th>
<th>Effect Size (95% CI) (^1)</th>
<th>Goodness-of-Fit Test p-Value</th>
<th>p-Het</th>
<th>F-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autoimmune/inflammatory</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Celiac disease</td>
<td>3</td>
<td>15,283</td>
<td>0.96 (0.77 to 1.21)</td>
<td>0.750</td>
<td>0.19</td>
<td>311.86</td>
</tr>
<tr>
<td>IBD (all types)</td>
<td>3</td>
<td>47,794</td>
<td>0.97 (0.84 to 1.13)</td>
<td>0.700</td>
<td>0.30</td>
<td>975.35</td>
</tr>
<tr>
<td>Crohn disease</td>
<td>4</td>
<td>21,389</td>
<td>0.78 (0.65 to 0.94)</td>
<td>0.009</td>
<td>0.25</td>
<td>436.47</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>4</td>
<td>26,405</td>
<td>1.10 (0.92 to 1.31)</td>
<td>0.290</td>
<td>0.92</td>
<td>538.84</td>
</tr>
<tr>
<td>Psoriasis vulgaris</td>
<td>4</td>
<td>8,941</td>
<td>1.23 (0.96 to 1.57)</td>
<td>0.110</td>
<td>0.95</td>
<td>182.43</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>4</td>
<td>6,880</td>
<td>1.45 (1.04 to 2.04)</td>
<td>0.030</td>
<td>0.92</td>
<td>140.37</td>
</tr>
<tr>
<td>Cutaneous psoriasis</td>
<td>4</td>
<td>4,880</td>
<td>1.10 (0.76 to 1.59)</td>
<td>0.620</td>
<td>0.60</td>
<td>99.55</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>4</td>
<td>25,702</td>
<td>0.94 (0.77 to 1.15)</td>
<td>0.550</td>
<td>0.17</td>
<td>524.55</td>
</tr>
<tr>
<td>Systemic lupus erythematous</td>
<td>3</td>
<td>4,651</td>
<td>1.20 (0.80 to 1.81)</td>
<td>0.380</td>
<td>0.19</td>
<td>94.88</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>3</td>
<td>7,518</td>
<td>1.07 (0.78 to 1.45)</td>
<td>0.680</td>
<td>0.85</td>
<td>153.90</td>
</tr>
<tr>
<td>Type 1 diabetes</td>
<td>2</td>
<td>26,890</td>
<td>1.15 (0.90 to 1.47)</td>
<td>0.260</td>
<td>0.34</td>
<td>548.73</td>
</tr>
<tr>
<td>Knee osteoarthritis</td>
<td>4</td>
<td>24,260</td>
<td>0.94 (0.78 to 1.13)</td>
<td>0.500</td>
<td>0.23</td>
<td>495.06</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAD</td>
<td>4</td>
<td>184,305</td>
<td>1.00 (0.93 to 1.07)</td>
<td>0.965</td>
<td>0.65</td>
<td>1,775.37</td>
</tr>
<tr>
<td>SBP(^2)</td>
<td>4</td>
<td>69,372</td>
<td>1.23 (0.45 to 2.01)</td>
<td>0.002</td>
<td>0.51</td>
<td>1,415.63</td>
</tr>
<tr>
<td>DBP(^2)</td>
<td>4</td>
<td>69,368</td>
<td>0.70 (0.2x to 1.19)</td>
<td>0.006</td>
<td>0.68</td>
<td>1,415.71</td>
</tr>
<tr>
<td>Ischemic stroke (all types)</td>
<td>4</td>
<td>9,520</td>
<td>1.19 (0.93 to 1.53)</td>
<td>0.160</td>
<td>0.93</td>
<td>194.24</td>
</tr>
<tr>
<td>Ischemic stroke (cardioembolic)</td>
<td>4</td>
<td>6,762</td>
<td>1.02 (0.65 to 1.58)</td>
<td>0.940</td>
<td>0.96</td>
<td>137.96</td>
</tr>
<tr>
<td>Ischemic stroke (large vessel)</td>
<td>4</td>
<td>6,816</td>
<td>1.44 (0.93 to 2.21)</td>
<td>0.100</td>
<td>0.31</td>
<td>139.06</td>
</tr>
<tr>
<td>Ischemic stroke (small vessel)</td>
<td>4</td>
<td>6,552</td>
<td>1.18 (0.71 to 1.95)</td>
<td>0.520</td>
<td>0.36</td>
<td>133.06</td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index(^3)</td>
<td>4</td>
<td>123,864</td>
<td>-0.017 (−0.06 to 0.02)</td>
<td>0.410</td>
<td>0.50</td>
<td>2,527.82</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>4</td>
<td>22,570</td>
<td>1.11 (0.94 to 1.32)</td>
<td>0.230</td>
<td>0.50</td>
<td>460.57</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>4</td>
<td>74,354</td>
<td>1.04 (0.88 to 1.22)</td>
<td>0.670</td>
<td>0.90</td>
<td>1,517.39</td>
</tr>
<tr>
<td>eGFR(^4)</td>
<td>4</td>
<td>74,354</td>
<td>0.004 (−0.01 to 0.02)</td>
<td>0.400</td>
<td>0.88</td>
<td>1,517.39</td>
</tr>
<tr>
<td>Serum albumin level(^5)</td>
<td>4</td>
<td>53,189</td>
<td>-0.002 (−0.02 to 0.01)</td>
<td>0.770</td>
<td>0.88</td>
<td>1,085.45</td>
</tr>
<tr>
<td>Serum protein level(^5)</td>
<td>4</td>
<td>53,189</td>
<td>0.008 (−0.02 to 0.04)</td>
<td>0.640</td>
<td>0.12</td>
<td>521.12</td>
</tr>
<tr>
<td><strong>Neurodegenerative</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis</td>
<td>2</td>
<td>12,263</td>
<td>0.79 (0.60 to 1.04)</td>
<td>0.090</td>
<td>0.23</td>
<td>258.39</td>
</tr>
<tr>
<td>Alzheimer disease</td>
<td>2</td>
<td>13,020</td>
<td>1.26 (0.89 to 1.78)</td>
<td>0.200</td>
<td>0.11</td>
<td>265.67</td>
</tr>
<tr>
<td>Parkinson disease</td>
<td>3</td>
<td>17,352</td>
<td>1.00 (0.85 to 1.17)</td>
<td>0.960</td>
<td>0.33</td>
<td>354.08</td>
</tr>
<tr>
<td><strong>Psychiatric</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autism</td>
<td>3</td>
<td>1,566</td>
<td>1.02 (0.97 to 1.07)</td>
<td>0.380</td>
<td>0.69</td>
<td>31.92</td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>4</td>
<td>16,731</td>
<td>1.17 (0.97 to 1.42)</td>
<td>0.110</td>
<td>0.49</td>
<td>341.41</td>
</tr>
<tr>
<td>Major depressive disorder</td>
<td>3</td>
<td>18,759</td>
<td>0.98 (0.81 to 1.18)</td>
<td>0.810</td>
<td>0.86</td>
<td>382.80</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>3</td>
<td>79,845</td>
<td>0.90 (0.82 to 0.99)</td>
<td>0.030</td>
<td>0.79</td>
<td>1,629.45</td>
</tr>
</tbody>
</table>

\(^1\)Effect size (95% CI) per 1-mg/l increase in lnCRP. For risk of disease, effect size is given as an OR, otherwise given in the specific units in which the outcome was measured. Derived from the IV causal estimator \(\alpha\).

\(^2\)Effect size unit is millimeters of mercury per 1-mg/l increase in lnCRP.

\(^3\)Effect size unit is standard deviations per 1-mg/l increase in lnCRP (the body mass index results were inverse normal transformed to a distribution with \(\mu = 0\) and \(\sigma = 1\)).

\(^4\)Effect size unit is milliliters/minute/1.73 m\(^2\) per 1-mg/l increase in lnCRP.

\(^5\)Effect size unit is grams/deciliter per 1-mg/l increase in lnCRP.

eGFR\(_{cr}\), estimated glomerular filtration rate from serum creatinine; F-value, F-statistic value for the genetic instrument; M, number of markers used in the genetic instrument; N, number of samples in the disease/trait meta-analysis; p-het, p-value of heterogeneity of effect test.

doi:10.1371/journal.pmed.1001976.t002
Fig 1. Genetic risk score \( \text{GRS}_{\text{GWAS}} \) for schizophrenia. The x-axis shows the effect size for the 15 SNPs for which data were available in the PGC schizophrenia dataset comprising the \( \text{GRS}_{\text{GWAS}} \) influencing levels of CRP, with corresponding standard error bars. The y-axis shows the log OR of the \( \text{GRS}_{\text{GWAS}} \) SNPs for schizophrenia (SCZ) with corresponding standard error bars. The effect estimate of CRP level on disease risk is represented by the red solid line, with gradient \( \alpha \). The 95% CI of this \( \alpha \) estimate is represented by the grey dashed lines. The included SNPs are shown by Arabic numbering: #1, rs2847281 (gene: \text{PTPN2}; chromosome: 18; basepair position: 12811593); #2, rs340029 (\text{RORA}; 15; 58682257); #3, rs6901250 (\text{GPRC6A}; 6; 117220718); #4, rs10745954 (\text{ASCL1}; 12; 102007224); #5, rs4705952 (\text{IRF1}; 5; 131867517); #6, rs12037222 (\text{PABPC4}; 1; 39837548); #7, rs12239046 (\text{NLRP3}; 1; 245668218); #8, rs6734238 (\text{L1F10}; 2; 113557501); #9, rs13233571 (\text{BCL7B}; 7; 72609167); #11, rs1260326 (\text{GCKR}; 2; 27584444); #12, rs4129267 (\text{L6R}; 1; 15269288); #13, rs1800961 (\text{HNF4A}; 20; 42475778); #14, rs4420065 (\text{LEPR}; 1; 5934049); #15, rs10521222 (\text{SALL1}; 16; 49716211); 12; 119905190); #17, rs2794520 (CRP; 1; 157945440). The three SNPs of #10, rs9987289 (\text{PPP1R3B}; 8; 9220768); #16, rs1183910 (\text{HNF1A}); and #18, rs4420638 (\text{APOC1}; 19; 50114786) were not present in the data of the PGC.

doi:10.1371/journal.pmed.1001976.g001
Table 3. The effect of the CRP genetic risk score instrument of 18 SNPs associated with CRP (GRS\textsubscript{GWAS}) on somatic and neuropsychiatric outcomes.

<table>
<thead>
<tr>
<th>Disease or Trait</th>
<th>M</th>
<th>Effect Size (95% CI)(^1)</th>
<th>Goodness-of-Fit Test p-Value</th>
<th>p-Het</th>
<th>F-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autoimmune/inflammatory</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Celiac disease</td>
<td>18</td>
<td>0.99 (0.85 to 1.16)</td>
<td>0.930</td>
<td>7.2 x 10(^{-4})</td>
<td>804.26</td>
</tr>
<tr>
<td>IBD (all types)</td>
<td>15</td>
<td>0.85 (0.74 to 0.98)</td>
<td>0.030</td>
<td>1.4 x 10(^{-5})</td>
<td>2,515.37</td>
</tr>
<tr>
<td>Crohn disease</td>
<td>17</td>
<td>0.81 (0.70 to 0.94)</td>
<td>0.005</td>
<td>4.4 x 10(^{-7})</td>
<td>1,125.63</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>17</td>
<td>1.05 (0.91 to 1.21)</td>
<td>0.490</td>
<td>0.01</td>
<td>1,389.63</td>
</tr>
<tr>
<td>Psoriasis vulgaris</td>
<td>17</td>
<td>1.12 (0.90 to 1.40)</td>
<td>0.310</td>
<td>0.19</td>
<td>470.47</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>17</td>
<td>1.36 (1.00 to 1.84)</td>
<td>0.049</td>
<td>0.04</td>
<td>362.00</td>
</tr>
<tr>
<td>Cutaneous psoriasis</td>
<td>17</td>
<td>1.00 (0.72 to 1.39)</td>
<td>0.990</td>
<td>0.16</td>
<td>256.74</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>18</td>
<td>0.93 (0.80 to 1.08)</td>
<td>0.350</td>
<td>1.8 x 10(^{-6})</td>
<td>1,352.79</td>
</tr>
<tr>
<td>Systemic lupus erythematos</td>
<td>11</td>
<td>1.06 (0.71 to 1.58)</td>
<td>0.780</td>
<td>0.27</td>
<td>244.68</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>11</td>
<td>0.84 (0.62 to 1.14)</td>
<td>0.280</td>
<td>0.63</td>
<td>396.89</td>
</tr>
<tr>
<td>Type 1 diabetes</td>
<td>15</td>
<td>1.10 (0.92 to 1.31)</td>
<td>0.310</td>
<td>3.47 x 10(^{-3})</td>
<td>1,415.16</td>
</tr>
<tr>
<td>Knee osteoarthritis</td>
<td>18</td>
<td>1.17 (1.01 to 1.36)</td>
<td>0.040</td>
<td>0.10</td>
<td>1,276.74</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAD</td>
<td>18</td>
<td>0.88 (0.84 to 0.94)</td>
<td>2.4 x 10(^{-5})</td>
<td>7.5 x 10(^{-12})</td>
<td>9,403.21</td>
</tr>
<tr>
<td>SBP(^2)</td>
<td>18</td>
<td>0.72 (0.11 to 1.34)</td>
<td>0.020</td>
<td>0.14</td>
<td>3,650.84</td>
</tr>
<tr>
<td>DBP(^2)</td>
<td>18</td>
<td>0.45 (0.06 to 0.84)</td>
<td>0.020</td>
<td>0.02</td>
<td>3,651.05</td>
</tr>
<tr>
<td>Ischemic stroke (all types)</td>
<td>18</td>
<td>1.06 (0.87 to 1.29)</td>
<td>0.570</td>
<td>0.37</td>
<td>500.95</td>
</tr>
<tr>
<td>Ischemic stroke (cardioembolic)</td>
<td>18</td>
<td>0.98 (0.69 to 1.39)</td>
<td>0.920</td>
<td>0.35</td>
<td>355.79</td>
</tr>
<tr>
<td>Ischemic stroke (large vessel)</td>
<td>18</td>
<td>1.30 (0.92 to 1.82)</td>
<td>0.140</td>
<td>0.97</td>
<td>358.63</td>
</tr>
<tr>
<td>Ischemic stroke (small vessel)</td>
<td>18</td>
<td>0.85 (0.58 to 1.25)</td>
<td>0.420</td>
<td>0.76</td>
<td>343.16</td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index(^3)</td>
<td>18</td>
<td>−0.005 (−0.03 to 0.02)</td>
<td>0.740</td>
<td>0.11</td>
<td>6,519.11</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>18</td>
<td>1.090 (0.95 to 1.24)</td>
<td>0.210</td>
<td>1.8 x 10(^{-3})</td>
<td>1,187.79</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>18</td>
<td>0.960 (0.84 to 1.09)</td>
<td>0.500</td>
<td>0.07</td>
<td>3,913.26</td>
</tr>
<tr>
<td>eGFR(_{cr})(^4)</td>
<td>18</td>
<td>0.011 (0.003 to 0.02)</td>
<td>0.005</td>
<td>7.2 x 10(^{-9})</td>
<td>3,913.26</td>
</tr>
<tr>
<td>Serum albumin level(^5)</td>
<td>18</td>
<td>0.011 (0.0004 to 0.02)</td>
<td>0.041</td>
<td>2.3 x 10(^{-18})</td>
<td>2,799.32</td>
</tr>
<tr>
<td>Serum protein level(^5)</td>
<td>18</td>
<td>0.031 (0.008 to 0.05)</td>
<td>0.009</td>
<td>0.03</td>
<td>1,343.95</td>
</tr>
<tr>
<td><strong>Neurodegenerative</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis</td>
<td>8</td>
<td>1.01 (0.79 to 1.29)</td>
<td>0.960</td>
<td>0.56</td>
<td>666.37</td>
</tr>
<tr>
<td>Alzheimer disease</td>
<td>11</td>
<td>1.26 (0.99 to 1.61)</td>
<td>0.060</td>
<td>0.23</td>
<td>685.16</td>
</tr>
<tr>
<td>Parkinson disease</td>
<td>10</td>
<td>1.06 (0.90 to 1.25)</td>
<td>0.500</td>
<td>0.50</td>
<td>913.16</td>
</tr>
<tr>
<td><strong>Psychiatric</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autism</td>
<td>9</td>
<td>0.89 (0.70 to 1.13)</td>
<td>0.350</td>
<td>0.99</td>
<td>82.32</td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td>18</td>
<td>1.21 (1.05 to 1.40)</td>
<td>0.007</td>
<td>0.15</td>
<td>880.47</td>
</tr>
<tr>
<td>Major depressive disorder</td>
<td>15</td>
<td>1.14 (0.96 to 1.36)</td>
<td>0.140</td>
<td>0.84</td>
<td>987.21</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>15</td>
<td>0.86 (0.79 to 0.94)</td>
<td>0.001</td>
<td>0.66</td>
<td>4,202.26</td>
</tr>
</tbody>
</table>

\(^1\)Effect size (95% CI) per 1-mg/l increase in lnCRP. For risk of disease, effect size is given as an OR, otherwise given in the specific units in which the outcome was measured. Derived from the IV causal estimator \(\alpha\).

\(^2\)Effect size unit is millimeters of mercury per 1-mg/l increase in lnCRP.

\(^3\)Effect size unit is standard deviations per 1-mg/l increase in lnCRP (the body mass index results were inverse normal transformed to a distribution with \(\mu = 0\) and \(\sigma = 1\)).

\(^4\)Effect size unit is milliliters/minute/1.73 m\(^2\) per 1-mg/l increase in lnCRP.

\(^5\)Effect size unit is grams/deciliter per 1-mg/l increase in lnCRP.

eGFR\(_{cr}\), estimated glomerular filtration rate from serum creatinine; F-value, F-statistic value for the genetic instrument; M, number of markers used in the genetic instrument; p-het, p-value of heterogeneity of effect test.
Fig 2. Polygenic risk scores for elevated CRP level and protective effect on schizophrenia, using individual-level genetic data.
doi:10.1371/journal.pmed.1001976.g002

Fig 3. Polygenic risk scores for elevated CRP level and explained variance of schizophrenia using individual-level genetic data.
doi:10.1371/journal.pmed.1001976.g003
for CAD (0.88 [0.84–0.94]; \(p < 2.4 \times 10^{-5}\)) (Table 3; Figs 4 and S1). GRS\textsubscript{GWAS} revealed a nominally significant effect of lnCRP on blood pressure: an increase of 0.72 (95% CI 0.11–1.34; \(p < 0.02\)) and 0.45 (0.06–0.84; \(p < 0.02\)) mm Hg in SBP and DBP, respectively (Table 3; S1 Fig).

Likewise, a genetically determined 10-s% increase in CRP level was nominally associated with a genetic predisposition to IBD, Crohn disease, CAD, DBP, eGFR\textsubscript{cr}, serum albumin, and serum protein. These heterogeneities in the effects of GRS\textsubscript{GWAS} may be attributable to pleiotropic effects of the SNPs used to build the GRS\textsubscript{GWAS}. We subsequently performed a stepwise removal of SNPs from GRS\textsubscript{GWAS} until no significant heterogeneity remained (Table 4). This adjustment in the GRS\textsubscript{GWAS} resulted in the removal of three SNPs from the GRS\textsubscript{GWAS} for IBD (in GCKR, IRF1, and PTPN2), five SNPs from the GRS\textsubscript{GWAS} for Crohn disease (in GCKR, IL6R, IRF1, PABPC4, and PTPN2), one SNP from the GRS\textsubscript{GWAS} for psoriatic arthritis (in IRF1), three SNPs for CAD (in APOC1, HNF1A, and IL6R), one SNP from the GRS\textsubscript{GWAS} for DBP (in PABPC4), two SNPs from the GRS\textsubscript{GWAS} for eGFR\textsubscript{cr} (in LEPR and GCKR), six SNPs from the GRS\textsubscript{GWAS} for serum albumin level (in APOC1, BCL7B, GCKR, PPPIR3B, PTPN2, and IRF1), and one SNP from the GRS\textsubscript{GWAS} for serum protein level (in GCKR). After removal of these variants from the GRS\textsubscript{GWAS}, we found no statistically significant (at \(p < 0.0016\)) association between genetically increased lnCRP level and any of these outcomes (Table 4). However, the effect estimate of CRP on DBP, serum albumin, and psoriatic arthritis showed nominal association at \(p < 0.05\). For example, for DBP, 17 SNPs remained in the GRS\textsubscript{GWAS} and yielded a slightly lower causal estimate (compared to the values before adjustment) of 0.39 (95% CI –0.01 to 0.78) mm Hg increase in DBP per 10-s% increase in lnCRP level, with a nominal significance of \(p < 0.05\).

Likewise, we hypothesized that the fact that GRS\textsubscript{GWAS} was not statistically significant for celiac disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes, and type 2 diabetes can be to some extent explained by the significant heterogeneity observed for these outcomes (Table 3). The stepwise adjustment in the GRS\textsubscript{GWAS} resulted in the removal of two SNPs from the GRS\textsubscript{GWAS} for celiac disease (in PABPC4 and PTPN2), one SNP from the GRS\textsubscript{GWAS} for ulcerative colitis (in GCKR), five SNPs from the GRS\textsubscript{GWAS} for rheumatoid arthritis (in HNF4A, IL6R, SALL1, NLRP3, and PTPN2), one SNP from the GRS\textsubscript{GWAS} for type 1 diabetes (in PTPN2), and one SNP from the GRS\textsubscript{GWAS} for type 2 diabetes (in APOC1). After adjusting for heterogeneity, the association of GRS\textsubscript{GWAS} with these outcomes remained statistically nonsignificant (Table 4).

**Discussion**

In this large-scale cross-consortium MR study of 32 complex outcomes, we found evidence for a potential protective causal relationship between elevated CRP level and schizophrenia in both genetic IVs (i.e., GRS\textsubscript{GRS} and GRS\textsubscript{GWAS}) and confirmed this protective relationship in follow-up analyses using individual-level genotype data from the schizophrenia GWAS. We also found a statistically significant association of CRP level with CAD, and nominally significant evidence for a predisposing causal association of CRP level with IBD, Crohn disease, psoriatic...
Fig 4. Genetic risk score GRS\textsubscript{GWAS} for bipolar disorder. The x-axis shows the effect size for the 18 SNPs comprising the GRS\textsubscript{GWAS} influencing levels of CRP, with corresponding standard error bars. The y-axis shows the log OR of the GRS\textsubscript{GWAS} SNPs for bipolar disorder (BIP) with corresponding standard error bars. The effect estimate of CRP level on disease risk is represented by the red solid line, with gradient $\alpha$. The 95% CI of this $\alpha$ estimate is represented by the grey dashed lines. The included SNPs are shown by Arabic numbering: #1, rs2847281 (gene: PTPN2; chromosome: 18; basepair position: 12811593); #2, rs340029 (RORA; 15; 58682257); #3, rs6901250 (GPRI6A; 6; 117220718); #4, rs10745954 (ASCL1; 12; 102007224); #5, rs4705952 (IRF1; 5; 131867517); #6, rs12037222 (PABPC4; 1; 39837548); #7, rs12239046 (NLPR3; 1; 245668218); #8, rs6734238 (IL1F10; 2; 113557501); #9, rs13233571 (HNF1A; 12; 119905190); #10, rs2794520 (CRP; 1; 157945440); #11, rs10521222 (SALL1; 16; 49716211); #16, rs1183910 (HNF1A; 12; 119905190); #17, rs2794520 (CRP; 1; 157945440); #18, rs4420638 (APOC1; 19; 50114786).
arthritis, knee osteoarthritis, SBP, DBP, eGFR, serum albumin level, serum protein level, and bipolar disorder, using GRS
GWAS as an IV. However, after adjustment for heterogeneity, neither GRS showed a significant effect (at
\( p < 0.0016 \)) of CRP level on any of these outcomes, including CAD, nor on the 20 other common somatic and psychiatric outcomes we investigated, including celiac disease, ulcerative colitis, psoriasis (all types), rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, type 1 and 2 diabetes, stroke (all types), body mass index, chronic kidney disease, amyotrophic lateral sclerosis, Alzheimer disease, Parkinson disease, autism, and major depressive disorder.

### CRP Protection against Schizophrenia

Strikingly, as opposed to the current literature and previous inconclusive small-scale studies [66–68], our findings suggest that genetically elevated levels of CRP are not predisposing but in fact protective for schizophrenia. The significant causal protective role of CRP for schizophrenia was consistent in both IVs using summary statistics, i.e., GRS\textsubscript{CRP} and GRS\textsubscript{GWAS}. When incorporating 18 genome-wide CRP-associated SNPs using individual-level data, we confirmed a modest, but significant, protective effect of CRP level for schizophrenia. This signal persisted when we included all SNPs meeting a less stringent \( p \)-value threshold of \( 1 \times 10^{-4} \). Notably, the leave-one-out sensitivity analysis revealed that the genetic overlap between CRP level and schizophrenia we observed at genome-wide and \( 1 \times 10^{-4} \) significance thresholds was not driven by a few major SNPs. In contrast, others have previously shown that CRP levels are significantly elevated in patients with schizophrenia [69,70], with a recent meta-analysis concluding

<table>
<thead>
<tr>
<th>Disease or Trait</th>
<th>M</th>
<th>Effect Size (95% CI)</th>
<th>Goodness-of-Fit Test ( p )-Value</th>
<th>( p )-Het</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autoimmune/inflammatory</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Celiac disease</td>
<td>16</td>
<td>1.05 (0.90 to 1.23)</td>
<td>0.56</td>
<td>0.10</td>
</tr>
<tr>
<td>IBD</td>
<td>12</td>
<td>0.92 (0.79 to 1.06)</td>
<td>0.24</td>
<td>0.14</td>
</tr>
<tr>
<td>Crohn disease</td>
<td>12</td>
<td>0.93 (0.79 to 1.08)</td>
<td>0.34</td>
<td>0.12</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>16</td>
<td>1.11 (0.96 to 1.28)</td>
<td>0.16</td>
<td>0.12</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>16</td>
<td>1.42 (1.05 to 1.94)</td>
<td>0.02</td>
<td>0.14</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>13</td>
<td>0.83 (0.71 to 0.97)</td>
<td>0.02</td>
<td>0.09</td>
</tr>
<tr>
<td>Type 1 diabetes</td>
<td>14</td>
<td>1.06 (0.89 to 1.27)</td>
<td>0.52</td>
<td>0.07</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAD</td>
<td>15</td>
<td>0.98 (0.91 to 1.06)</td>
<td>0.65</td>
<td>0.20</td>
</tr>
<tr>
<td>DBP\textsuperscript{2}</td>
<td>17</td>
<td>0.385 (0.008 to 0.78)</td>
<td>0.05</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>Metabolic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>17</td>
<td>0.95 (0.82 to 1.10)</td>
<td>0.52</td>
<td>0.09</td>
</tr>
<tr>
<td>eGFR\textsubscript{cr}\textsuperscript{3}</td>
<td>16</td>
<td>0.001 (−0.007 to 0.01)</td>
<td>0.74</td>
<td>0.11</td>
</tr>
<tr>
<td>Serum albumin level\textsuperscript{4}</td>
<td>12</td>
<td>−0.017 (−0.03 to −0.004)</td>
<td>0.01</td>
<td>0.07</td>
</tr>
<tr>
<td>Serum protein level\textsuperscript{4}</td>
<td>17</td>
<td>0.021 (−0.002 to 0.05)</td>
<td>0.07</td>
<td>0.31</td>
</tr>
</tbody>
</table>

\( ^{1} \text{Effect size (95\% CI) per 1-mg/l increase in lnCRP. For risk of disease, effect size is given as an OR, otherwise given in the specific units in which the outcome was measured. Derived from the IV causal estimator \( \alpha \).} \\
^{2} \text{Effect size unit is millimeters of mercury per 1-mg/l increase in lnCRP.} \\
^{3} \text{Effect size unit is milliliters/minute/1.73 m\textsuperscript{2} per 1-mg/l increase in lnCRP.} \\
^{4} \text{Effect size unit is grams/deciliter per 1-mg/l increase in lnCRP.} \\
M, number of markers used in the genetic instrument; \( p \)-het, \( p \)-value of heterogeneity of effect test.

doi:10.1371/journal.pmed.1001976.t004
that the association between elevated CRP and schizophrenia is indeed robust [71]. Given that clinical studies report elevated CRP levels in schizophrenia, one would expect to find that alleles for elevated CRP would confer an increased risk for schizophrenia. The fact that we found the completely opposite effect— in a cohort of over 25,000 cases and 30,000 controls— should give one pause when deriving clinical meaning from these results. Our observation that a genetically determined marginal increase in the level of CRP is likely to be protective for schizophrenia may fuel the debate about whether the observed CRP elevation in schizophrenia is a by-product of the pathogenesis of schizophrenia or directly contributing to clinical manifestations of the disorder [6]. Our finding may also point out potential biases in previous studies regarding the causes of elevated CRP levels in patients with schizophrenia, such as reverse causality and/or pleiotropic effects within chosen instruments.

The exact mechanism for how elevated CRP levels are linked to schizophrenia requires a well-defined experimental analysis. In addition to CRP variants, other recent studies have identified several inflammatory genetic variants associated with schizophrenia and bipolar disorder, which include variants in the major histocompatibility complex (MHC) region on Chromosome 6p21 [72]— harboring many cytokine genes [54,73–76]— and in the IL10 promoter [77], TNF promoter [78], IL1B [79], and C4 [80].

Biological Annotation
Following comments made by the reviewers, we explored the possible underlying pathways that may explain the potential protective causal association between CRP and schizophrenia. We performed a follow-up in silico functional pathway analysis using a previously reported approach [81] as summarized in S5 Methods and S4–S13 Tables. In brief, our results show that pathways associated with the interferon response are significantly enriched amongst genes harbored by CRP loci and their associated expression quantitative trait loci (eQTLs) and that there are differentially expressed genes between schizophrenia cases and controls. Previous studies showed that the induction of T cell IFN cytokine release stimulates microglia and astrocytes to facilitate glutamate clearance in neuronal cells without evoking inflammatory mediators [82,83]. One could speculate that CRP-interferon pathways may induce neuroprotection by contributing to glutamate clearance, leading to the protection of neurons against the oxidative stress associated with an excess of glutamate [84,85], and thereby offering a protective effect against schizophrenia.

CRP GRS\textsubscript{GWAS} Association with Bipolar Disorder
As for bipolar disorder, we found a nominal effect of a 1.21-fold increase in risk for bipolar disorder with a 10-s% increase in CRP level. Though this nominal predisposing effect needs to be confirmed, our finding corroborates epidemiological observations suggesting that elevated CRP is associated with the disease and supports a potential causal influence of general inflammation in bipolar disorder [86]. We note that, though it may be biologically sensible, this result failed to pass multiple testing correction. Confirmation by replication in independent cohorts, functional follow-up analyses, or the use of a stronger CRP GRS\textsubscript{GWAS} in upcoming studies is required to draw a definitive conclusion.

CRP GRS\textsubscript{GWAS} Association with Blood Pressure and Hypertension
We found nominally significant evidence for an up to ~0.70-mm Hg increase in blood pressure with a 10-s% increase in CRP level and no evidence of heterogeneity for SBP. Additionally, there was nominally borderline significance for a causal association between CRP and DBP after adjustment for heterogeneity. These nominally significant findings, on the one hand, are
in line with numerous epidemiological studies that have highlighted an association between elevated CRP and an increased risk of hypertension. For instance, one study found an association between CRP loci and hypertension in Asian individuals [87]. An additional line of support for a possible causal association of CRP and blood pressure comes from an experimental study in which an increase in CRP gene expression in mice, and subsequently CRP protein levels, led to a rise in SBP particularly [88]. Moreover, an ex vivo study by Zhou et al. showed that combining IL6 treatment and mechanical strain leads to a consistent increase in CRP expression at the protein and mRNA levels in smooth muscle cells [89]. Both inflammatory factors and local mechanical strains are abundant in blood vessels and are well-known risk factors for high blood pressure. Our finding did not reach a statistically significant level after correction for multiple testing; thus, it may echo previous MR studies that have failed to find a causal relationship between CRP level and blood pressure or hypertension in Europeans [90,91]. However, our systematic literature review showed that previous studies had some limitations (S1 Table). For instance, no study used a refined GWAS set of 18 CRP-associated SNPs; instead, they tested single or a limited set of CRP SNPs. Using such instruments might have led to biased estimates as their corresponding effects on CRP levels have been found to be small [30,57]. A combination of weak instruments and small sample sizes might have led to type II error [28,57] and hence to a conclusion of no causal association between CRP and blood pressure traits in previous studies. When all of the evidence is taken together, a direct link between CRP and blood pressure remains to be elucidated, though our nominal associations between GRS<sub>CRP</sub> and GRS<sub>GWAS</sub> and blood pressure do add to a line of findings from experimental studies suggesting a potential causal relationship between CRP and blood pressure.

**CRP GRS<sub>GWAS</sub> Association with Osteoarthritis**

Our nominally significant finding that CRP might be a potential causal factor for knee osteoarthritis (using GRS<sub>GWAS</sub>) should be interpreted with caution. In line with our findings, we have previously shown that levels of CRP were higher in women with early radiological knee osteoarthritis (i.e., Kellgren-Lawrence grade 2+) and in women whose disease progressed [92]. Additionally, another study showed that genetically elevated CRP levels contribute to osteoarthritis severity [93]. However, other studies have found contrasting results [71,72,94]. One systematic review provided evidence that the relationship between CRP and osteoarthritis does exist but is dependent on body mass index [95]. It remains to be further investigated whether weight gain over the lifetime mediates the potential causal association between genetically elevated CRP and knee osteoarthritis.

**CRP GRS<sub>GWAS</sub> Shows No Association with Other Remaining Outcomes**

The present study was able to calculate nominal causal estimates for IBD, Crohn disease, psoriatic arthritis, CAD, eGFR<sub>cr</sub>, serum albumin level, and serum protein level using CRP GRS<sub>GWAS</sub>, but the estimates were altered by removal of SNPs from GRS<sub>GWAS</sub> based on heterogeneity tests, resulting in nominal or nonsignificant associations. These outcomes appeared therefore to have heterogeneity in the causal estimates, suggesting that these observed estimates were biased, likely due to pleiotropic effects of CRP loci. These results corroborate negative findings of previous studies (S1 Table), suggesting that a causal role of CRP in these traits and diseases is unlikely.

**Methodological Concerns and Advantages**

Pleiotropic biases in Mendelian randomization analyses using CRP GRS<sub>GWAS</sub>. A detailed evaluation of pleiotropic SNPs in our study showed that the method applied to identify
heterogeneity sources was able to indicate and exclude several already known pleiotropic loci from the GRS$_{GWAS}$ IV. For instance, the use of a SNP in $IL6R$ (rs4129267), amongst others, resulted in heterogeneity of effects on CAD risk. The same variant contributed to heterogeneity of effects for Crohn disease in our study, and it has been shown that this SNP is associated with levels of biomarkers other than CRP [56]. Further, a MR study found that $IL6R$ SNPs, specifically the nonsynonymous SNP rs8192284, are associated with CAD risk and CRP levels [96]. Our selected $IL6R$ SNPs, namely rs4537545 and rs4129267, are in extremely high linkage disequilibrium with rs8192284 ($r^2 > 0.96$ for both SNPs in HapMap data, CEU population). Carriers of the risk allele of rs8192284 have higher CRP, IL6, and fibrinogen levels [96]. Fibrinogen is also a well-known risk factor for CAD. Therefore, it is unclear so far which biomarker(s) mediates the effect of $IL6R$ SNPs on CAD. Besides the $IL6$ locus, $APOC1$ and $PABPC4$ have been indicated as pleiotropic in three out of 32 our investigated outcomes, and $PTPN2$ and $GCKR$ in six. With this information taken together, we were able to disentangle at least part of the pleiotropy regarding the causal estimates of CRP for outcomes. Again, we found no significant association of CRP GRS$_{GWAS}$ with IBD, Crohn disease, psoriatic arthritis, CAD, eGFR$_{cr}$, serum albumin level, and serum protein level after adjustment for heterogeneity.

Using summary statistics of large-scale consortia. It is of utmost interest whether the observed effect of CRP as a risk predictor for human disease is causal, and thus whether reduction of CRP levels will lower the risk of disease. Here, we investigated the causality of CRP in 32 phenotypes by leveraging very large sample sizes collected by GWAS consortia, an approach that was much better powered than most previous MR studies. We found that genetically elevated CRP levels approximated by powerful instruments did not appear to contribute directly to most of the studied somatic and psychiatric outcomes. Our findings are consistent with previous MR studies reporting null associations of genetically elevated CRP levels with inflammation-related outcomes including CAD [56,59,97], type 2 diabetes [98], high body mass index [99], Alzheimer disease, and depression [100]. All previous MR studies were substantially limited to a single or a few outcomes, used only SNPs in the $CRP$ gene, or had sample sizes much smaller than that of the present study (S1 Table). In addition to these studies, the current GWAS data do not corroborate epidemiological observations suggesting that elevated CRP levels are associated with amyotrophic lateral sclerosis [101], Alzheimer disease [102], Parkinson disease [103], and major depressive disorder [104]. Furthermore, patients with immunity-related disorders frequently have a very high CRP level (as high as 100 mg/l) due to their disease status. Our findings may therefore more favorably indicate reverse causality. Taken together, these results show that CRP is highly unlikely to contribute causally to most of the major common somatic and neuropsychiatric outcomes that were investigated in the present study, with the possible exception of schizophrenia.

Strength of instrumental variables. The results presented in Table 2 show that our GRS$_{CRP}$ is not a weak instrument, as indicated by its high $F$-values owing to the large sample sizes of available outcomes from GWASs for the phenotypes under study. The strength of our instrument increased considerably in all disease classes when we used variants of multiple loci associated with CRP in GWASs. However, the variants comprising the CRP GRS$_{GWAS}$ explain on average only a moderate ~5% of the total variance in baseline CRP levels [30]. Moreover, the possibility of effect modification by nongenetic CRP-related factors on the outcomes remains to be investigated. We may be able to create even stronger instruments based on ongoing efforts to identify additional variation influencing CRP levels. Even if larger sample sizes and stronger instruments can be realized, the overwhelming lack of causal effects observed for most outcomes in our study implies that therapies targeted at lowering CRP will not directly result in decreased risk of the investigated outcomes, or in better symptom management [105,106].
Using summary statistics instead of individual-level data. Here we used summary association statistics obtained from previously conducted meta-GWASs in order to maximize our study power. One may argue this may induce bias compared to when one uses individual-level data. Nevertheless, previous studies showed high agreement in results from MR methods using GWAS summary data and individual-level data [60,107]; Furthermore, our analyses of individual-level data for schizophrenia led to the same conclusion as our analyses using summary statistics data, confirming the robustness of our methodological approach.

Other potential sources of bias. An important rationale for MR is that the gene variants do not change over time and are inherited randomly. Thus, the genetic variants are considered free from confounding and reverse causation [108]. However, one cannot completely control for the possibility of confounding of genotype–intermediate phenotype–disease associations. For instance, there could be a confounding effect by ethnic/racial group (i.e., population stratification), but this is unlikely to be a major problem in most situations [108]. In the present study, we included summary statistics data from highly credible results of meta-GWASs. All the original meta-GWASs corrected for population stratification in cohort-level analyses and at meta-GWAS level.

Another caveat of MR is that developmental compensation might occur, through a genotype being expressed during fetal development that in turn buffers the effects of either environmental or genetic factors, a process called canalization [108,109]. Therefore, buffering mechanisms could hamper the associations between genetic variants and the outcome of interest. As opposed to this, a lifetime exposure to a risk factor may enhance its effects on the disease [109]. However, it is not clear to what extent genetically determined small changes in any given exposure would be sufficient to induce compensation [108].

All 32 of the meta-GWASs from which instrument summary estimates were taken were performed in individuals of European descent in Europe and the US and included thousands of samples for each outcome (S1 Table), which was also the case for our previous CRP meta-GWAS from which we chose the CRP-associated SNPs to calculate GRS\textsubscript{GWAS}. Therefore, the results of this MR study are applicable to individuals of European descent and are not necessarily generalizable to other ethnic groups.

Conclusion
We showed that elevated CRP levels driven by genetic factors are causally associated with protection against schizophrenia, suggesting that CRP may be one important puzzle piece that leads to an improved understanding of the pathogenesis of schizophrenia. We observed nominal evidence that genetically elevated CRP is causally associated with SBP, DBP, knee osteoarthritis, and bipolar disorder. Based on current GWAS data, we cannot verify any causal effect of CRP on the other 27 common somatic and neuropsychiatric outcomes investigated in the present study. Therefore, disease-associated rise in CRP levels may be a response to the disease process rather than a cause for these 27 outcomes. This implies that interventions to lower CRP levels are unlikely to result in decreased risk for the majority of common complex outcomes.

Supporting Information

S1 Consortia. Consortia coauthors and collaborators.
(DOCX)

S1 Data. Individual association summary statistics of CRP lead SNPs and/or proxies with traits and diseases.
(XLSX)
S1 Fig. GRS_{CRP} and GRS_{GWAS} for each studied outcome. (DOCX)

S1 Financial Disclosure. Authors’ funding information. (PDF)

S1 Methods. Linkage disequilibrium of the four GRS_{CRP} SNPs. (DOCX)

S2 Methods. CRP GRS_{GWAS} for Alzheimer disease and body mass index. (DOCX)

S3 Methods. Web links. (DOCX)

S4 Methods. CRP polygenic risk score (CRP_{PRS}) for schizophrenia. (DOCX)

S5 Methods. In silico (gene) pathway analyses highlight the role of interferon in the causal pathway between CRP and schizophrenia. (DOCX)

S1 Table. Previous Mendelian randomization analyses using CRP variants as instruments. (XLSX)

S2 Table. CRP lead variants used in the genetic risk scores as instrumental variables. (XLSX)

S3 Table. Proxy SNPs of CRP lead variants used in the genetic risk scores as instrumental variables. (XLSX)

S4 Table. Biologically prioritized candidate gene set associated with CRP used as the input query to the gene set enrichment analysis. (XLSX)

S5 Table. Pathway enrichment results for the biologically prioritized candidate gene set associated with CRP used as the input query to the gene set enrichment analysis. (XLSX)

S6 Table. Genes (n = 144) that were significantly differentially expressed between schizophrenia and unaffected controls in the hippocampus. (XLSX)

S7 Table. Pathway enrichment results for 144 genes that were significantly differentially expressed between schizophrenia and unaffected controls in the hippocampus. (XLSX)

S8 Table. Biologically prioritized candidate gene set of CRP from Vaez et al. [81] (from S5 Table, “CRP genes,” in blue) and differentially expressed genes in schizophrenia cases versus controls from Hwang et al. [110] (from S7 Table, “SCZ expr genes,” in red) used as the input query to the pathway analysis. (XLSX)

S9 Table. Pathway enrichment results for the combined set of the biologically prioritized candidate gene set of CRP from Vaez et al. [81] and differentially expressed genes in...
schizophrenia cases versus controls from Hwang et al. 2013.

(S10) Table. List of genes at 108 genome-wide significant loci associated with schizophrenia.

(S11) Table. Brain and blood eQTL for credible sets of SNPs of the 108 schizophrenia loci.

(S12) Table. List of genes at 108 genome-wide significant loci associated with schizophrenia (yellow), brain eQTL (red), and blood eQTL (blue).

(S13) Table. Pathway enrichment results for the list of genes at 108 genome-wide significant loci associated with schizophrenia (yellow) and those associated with brain eQTL (red) and blood eQTL (blue).

Acknowledgments

We thank for Dan Arking for providing the genome-wide summary statistics data on CRP polymorphisms for the autism GWAS. We would also like to acknowledge the rheumatoid arthritis and systemic lupus erythematosus consortia, the Genetic Investigation of Anthropometric Traits (GIANT) consortium, and the PGC for making publicly available the data from which we extracted summary association statistics for CRP SNPs. The PAGE Consortium is grateful to Alex Tsoi for adding the consortium information and membership list.

The Type 1 Diabetes Genetics Consortium would like to thank all participants and their families, and also thank Smari Kristinsson, Larus Arni Hermannsson, and Asbjörn Krisbjörns-son of Raförnin for their extensive software design and contribution. We would like to thank the people with motor neuron disease and their families for their participation in this project. We acknowledge sample management undertaken by Biobanking Solutions funded by the Medical Research Council at the Centre for Integrated Genomic Medical Research, University of Manchester.

Consortia Coauthors

Please refer to S1 Consortia for the full names and affiliations of coauthors from the following five consortia: the Schizophrenia Working Group of the Psychiatric Genomics Consortium, the Autism Spectrum Disorder Working Group of the Psychiatric Genomics Consortium, the GERAD1 Consortium, the International Consortium for Blood Pressure Genome-Wide Association Studies, and the PAGE Consortium.

Author Contributions

Conceived and designed the experiments: BPP AA HS BZA CVD. Performed the experiments: NF JGA VM PES JPB AMV JB AS. Analyzed the data: BPP AA AV AM IN NF JGA VM PES JPB AMV JB AS AD BH SR SB MDM LT EE RPN SG CP TR DVH MD JN NW DA AAC BK HH HM JE TS CVD JM APM RW JP CW PM JGP YJ HS BZA JK. Contributed reagents/materials/analysis tools: CL AAC AD JK CVD. Wrote the first draft of the manuscript: BPP AA BZA. Contributed to the writing of the manuscript: BPP AA AV AW JGA VM PES AMV DEA BK TS JM RW JP JGP YJ HS BZA JK. Agree with the manuscript’s results and conclusions: BZA BPP AA AW AV IN NF PES JGA VM JPB AMV JB AS CL BH SR SB MDM LT EE RPN
SG CP TR DVH MD NW AAC AD HH HM JE JK DA TS BK CVD JM APM RW CW PM JP JGP YJ HS. All authors have read, and confirm that they meet, ICMJE criteria for authorship.

References


27. Danesh J, Pepys MB. C-reactive protein and coronary disease: is there a causal link? Circulation. 2002; 106:3038–3040. doi: 10.1161/01.CIR.0000028972.24962.3B PMID: 12022481


Editors' Summary

Background

Inflammation is an important part of the human immune response, the network of cells and molecules that protects the body from attack by pathogens (infectious organisms) and from harmful substances and foreign particles (for example, splinters). When human cells are attacked by pathogens or injured by trauma or chemicals, molecules called inflammatory mediators induce fluid leakage from the blood vessels into the damaged tissue and attract "phagocytes" (a type of immune cell) to the site of infection or injury to "eat" the germs and dead or damaged cells. The end result is inflammation, which is characterized by swelling, redness, heat, and pain. The inflammatory response, although unpleasant, limits the damage caused by foreign invaders or chemicals by preventing further contact with body tissues. Sometimes, however, inflammation can be harmful. Persistent dysregulation of the inflammatory response is implicated in numerous somatic disorders (diseases that affect the body, such as cardiovascular disease) and neuropsychiatric disorders (mental disorders attributable to diseases of the nervous system, such as schizophrenia).

Why Was This Study Done?

Observational studies suggest that increased blood levels of C-reactive protein (CRP, an inflammatory protein) are associated with certain somatic and neuropsychiatric disorders. But observational studies cannot prove that changes in CRP levels actually cause any of these disorders. It could be that the individuals who develop a specific disease and who have a high CRP level also share another unknown characteristic that is actually responsible for disease development (confounding). Alternatively, it could be that the disease itself increases CRP levels (reverse causation). It is important to know whether CRP is causally involved in the development of specific diseases because it might then be possible to prevent or treat these diseases using drugs that control CRP levels. Here, the researchers undertake a Mendelian randomization study to determine whether CRP has a causal relationship with 32 common complex somatic and neuropsychiatric outcomes. Because gene variants are inherited randomly, they are not prone to confounding and are free from reverse causation. So, if CRP levels actually cause a specific somatic or neuropsychiatric disease, genetic variants that affect CRP levels should be associated with an altered risk for that disease.

What Did the Researchers Do and Find?

The researchers used data collected by several consortia involved in large genome-wide association studies (studies that ask whether specific genetic changes across the whole human genome, or blueprint, are associated with specific diseases) to look for associations between 32 somatic and neuropsychiatric outcomes and two genetic risk scores (GRSs) for CRP level. GRS\textsubscript{CRP} consisted of four single nucleotide polymorphisms (SNPs; a type of genetic variant) in the gene encoding CRP; GRS\textsubscript{GWAS} consisted of 18 SNPs that were associated with CRP level in a genome-wide association study. The researchers report that a genetically increased CRP level was significantly associated with a reduced risk of schizophrenia (a significant association is one unlikely to have arisen by chance). In addition, they found a nominally significant association (an association that needs to be confirmed) between genetically increased CRP levels and an increased risk of knee osteoarthritis,
raised diastolic and systolic blood pressure, and bipolar disorder. Notably, there was no evidence for an effect of genetically increased CRP levels on any of the other 27 outcomes studied.

**What Do These Findings Mean?**
These findings suggest that genetically raised levels of CRP are causally associated with protection against schizophrenia, an unexpected finding given other recent studies that suggest that raised CRP levels and brain inflammation predispose individuals to schizophrenia. The findings also provide preliminary evidence that genetically raised levels of CRP may be causally associated with an increased risk of raised blood pressure, knee arthritis, and bipolar disorder. The lack of any association between genetically raised levels of CRP and the other outcomes studied suggests, however, that many previously identified disease-associated rises in CRP levels might be a response to the disease process rather than a cause of these diseases. Like all Mendelian randomization studies, the reliability of these findings depends on the validity of several assumptions made by the researchers and on the ability of the GRSs used in the study to explain variations in CRP level. Importantly, however, these findings suggest that interventions designed to lower CRP level are unlikely to decrease the risk of people developing the majority of common complex somatic and neuropsychiatric outcomes.

**Additional Information**
This list of resources contains links that can be accessed when viewing the PDF on a device or via the online version of the article at [http://dx.doi.org/10.1371/journal.pmed.1001976](http://dx.doi.org/10.1371/journal.pmed.1001976).

- Wikipedia has pages on inflammation, C-reactive protein, and Mendelian randomization (note: Wikipedia is a free online encyclopedia that anyone can edit; available in several languages)
- The MedlinePlus encyclopedia has a page on C-reactive protein (in English and Spanish)
- The American Heart Association provides a short article on inflammation and heart disease
- A UK National Health Service “Behind the Headlines” article explains a recent study that found an association between immune activity in the brain and schizophrenia
RESEARCH ARTICLE

Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients

Minghua Wu1*, Shervin Assassi1, Gloria A. Salazar1, Claudia Pedroza2, Olga Y. Gorlova3, Wei V. Chen3, Julio Charles1, Miranda L. Taing1, Kelley Liao1, Fredrick M. Wigley4, Laura K. Hummers4, Ami A. Shah4, Monique Hinchcliff5, Dinesh Khanna6, Elena Schiopu6, Kristine Phillips6, Daniel E. Furst7, Virginia Steen8, Murray Baron9, Marie Hudson9, Xiaodong Zhou1, Janet Pope10, Niall Jones11, Peter Docherty12, Nader A. Khalidi13, David Robinson14, Robert W. Simms15, Richard M. Silver16, Tracy M. Frech17, Barri J. Fessler18, Marvin J. Fritzler19, Jerry A. Molitor20, Barbara M. Segal20, Malahat Movahedian1, Javier Martín21, John Varga2 and Maureen D. Mayes1

Abstract

Background: Systemic sclerosis (SSc)-related interstitial lung disease (ILD) has phenotypic similarities to lung involvement in idiopathic interstitial pneumonia (IIP). We aimed to assess whether genetic susceptibility loci recently identified in the large IIP genome-wide association studies (GWASs) were also risk loci for SSc overall or severity of ILD in SSc.

Methods: A total of 2571 SSc patients and 4500 healthy controls were investigated from the US discovery GWAS and additional US replication cohorts. Thirteen IIP-related selected single nucleotide polymorphisms (SNPs) were genotyped and analyzed for their association with SSc.

Results: We found an association of SSc with the SNP rs6793295 in the LRRC34 gene (OR = 1.14, CI 95% 1.03 to 1.25, p value = 0.009) and rs11191865 in the OBFC1 gene (OR = 1.09, CI 95% 1.00 to 1.19, p value = 0.043) in the discovery cohort. Additionally, rs7934606 in MUC2 (OR = 1.24, CI 95% 1.01 to 1.52, p value = 0.037) was associated with SSc-ILD defined by imaging. However, these associations failed to replicate in the validation cohort. Furthermore, SNPs rs2076295 in DSP (β = -2.29, CI 95% -3.85 to -0.74, p value = 0.004) rs17690703 in SPPL2C (β = 2.04, CI 95% 0.21 to 3.88, p value = 0.029) and rs1981997 in MAPT (β = 2.26, CI 95% 0.35 to 4.17, p value = 0.02) were associated with percent predicted forced vital capacity (FVC%) even after adjusting for the anti-topoisomerase (ATA)-positive subset. However, these associations also did not replicate in the validation cohort.

Conclusions: Our results add new evidence that SSc and SSc-related ILD are genetically distinct from IIP, although they share phenotypic similarities.

Keywords: Idiopathic interstitial pneumonia (IIP), SSc-ILD, Genetic susceptibility

* Correspondence: Minghua.wu@uth.tmc.edu
1 Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA
Full list of author information is available at the end of the article

© 2016 Wu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Systemic sclerosis or scleroderma (SSc) is a complex autoimmune disease characterized by vasculopathy, autoantibody production and fibrosis in the skin and internal organs. The etiology of SSc remains unknown; effective treatments that target the underlying pathophysiology of SSc are unavailable and the disease-related mortality remains high [1]. Specifically, pulmonary fibrosis and pulmonary arterial hypertension (PAH) account for the majority of disease-related deaths in SSc [2]. SSc-associated interstitial lung disease (SSc-ILD) is usually characterized by a histologic pattern of nonspecific interstitial pneumonia (NSIP) or, less frequently, usual interstitial pneumonia (UIP). SSc-ILD has clinical and radiologic similarities to idiopathic interstitial pneumonia (IIP). A polymorphism in the MUC5B promoter region was strongly associated with familial and idiopathic pulmonary fibrosis (IPF; the most common IIP type) [3], but it has not been found to be a susceptibility locus for SSc or SSc-associated interstitial lung disease (SSc-ILD) [4–6].

Recently, large genome-wide association studies (GWASs) in fibrotic IIP (n = 1616 patients) and IPF (n = 542 patients and two validation cohorts n = 544 and n = 324) identified/confirmed susceptibility single nucleotide polymorphisms (SNPs) in TERT, AZGP1, MUC2, IVD, DSP, MAPT, DPP9, LRRC34, FAM13A, OBFC1, CSMD1, ATP11A [7] and TOLLIP, MDGA2, SPP2L2C [8]. Given the clinical and radiologic similarities between SSc-ILD and IIP, we examined the association of the 13 SNPs among the listed genes, identified in the above IIP and IPF GWASs [7, 8] (TOLLIP and MDGA2 genes were excluded because the related SNPs were not present on the Illumina BeadChip utilized in SSc GWAS) with SSc as a single disease entity, with SSc-ILD by imaging, or SSc-ILD severity (as determined by percent predicted forced vital capacity (FVC%)) in two large SSc patient samples.

Methods
Study population
Two non-Hispanic white populations (discovery and replication cohorts) were investigated. For the discovery cohort, we utilized data from our previously published SSc GWAS study consisting of 1486 SSc cases (patients from the US) and 3477 unaffected race- and ethnicity-matched controls [9]. Selected polymorphisms were genotyped in an independent replication cohort consisting of 1085 additional SSc cases (patients from the US and Canada) and 1023 additional unaffected controls. Patients were recruited at the University of Texas – Houston and from the following sites: the participating Canadian Scleroderma Research Group (CSRG) sites, University of California Los Angeles, University of Michigan, Georgetown University, Boston University, Medical University of South Carolina, Johns Hopkins University, University of Utah, Northwestern University, University of Alabama at Birmingham and University of Minnesota. All patients were enrolled in the National Scleroderma Family Registry and DNA Repository. All patients with SSc fulfilled the 1980 American College of Rheumatology classification criteria for SSc or had at least three of the five CREST (Calcinosis, Raynaud’s phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasias) features (Table 1).

The genotypes of unaffected controls for the discovery cohort were obtained from the Cancer Genetic Markers of Susceptibility (CGEMS; non-cancer healthy controls) studies and Illumina iControlDB database (www.illumina.com/iControlDB). Illumina, San Diego, CA, USA. The unaffected controls for the replication cohort were recruited through a nationwide effort by the Scleroderma Family Registry and DNA Repository.

Collection of blood samples and clinical information from case and control subjects was undertaken with fully informed consent and relevant ethical review board approval from each contributing center in accordance with the tenets of the Declaration of Helsinki.

SNP selection and genotyping assay
In the discovery cohort, genotyping was performed using the Illumina Bead-Array GWAS platform. Specifically, patients were genotyped using Illumina Human 610-Quad BeadChip and controls were genotyped on Illumina Hap550K-BeadChip [9]. The 13 single nucleotide polymorphisms (SNPs) identified/confirmed to be associated with IIP [7], rs2736100 (TERT), rs2076295 (DSP), rs4727443 (AZGP1), rs7934606 (MUC2), rs2034650 (IVD), rs1981997 (MAPT), rs12610495 (DPP9), rs6793295 (LRRC34), rs2609255 (FAM13A), rs11191865 (OBFC1), rs1278769 (ATP11A), rs1379326 (CSMD1) and an additional SNP rs17690703 (SPP2L2C) [8], were investigated in the discovery cohort. We also investigated association of 13 SNPs with anti-topoisomerase 1 antibody (ATA) and anti-centromere antibodies.

Table 1  Demographic and clinical features of SSc patients in the discovery and replication cohorts

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Discovery (n = 1486)</th>
<th>Replication (n = 1085)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>1307 (88.0 %)</td>
<td>934 (86.1 %)</td>
</tr>
<tr>
<td>Mean age ± years</td>
<td>54.5 ± 12.9 y</td>
<td>56.1 ± 12.8 y</td>
</tr>
<tr>
<td>Diffuse SSc</td>
<td>505 (34.0 %)</td>
<td>403 (37.1 %)</td>
</tr>
<tr>
<td>Disease duration</td>
<td>10.1 ± 8.7 y</td>
<td>10.9 ± 9.6 y</td>
</tr>
<tr>
<td>ACA</td>
<td>425 (28.6 %)</td>
<td>340 (31.3 %)</td>
</tr>
<tr>
<td>ATA</td>
<td>238 (16.0 %)</td>
<td>180 (16.6 %)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SSc-ILD</th>
<th>Yes</th>
<th>185 (65.6 %)</th>
<th>313 (61.9 %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>97 (34.4 %)</td>
<td>193 (38.1 %)</td>
<td></td>
</tr>
</tbody>
</table>
antibody (ACA) positive subgroup patients. The SNPs reaching a nominal level of significance \((p < 0.05)\) in the discovery cohort (rs6793295 and rs11191865) were genotyped in the replication cohort using TaqMan allele discrimination assays in a 7900HT fast real-time PCR system (Applied Biosystems, Foster City, CA, USA).

**SSc-ILD and severity of SSc-ILD**

We also investigated the association of the above SNPs with SSc-ILD by imaging. We compared the frequency of the above SNPs in patients with SSc-ILD to unaffected controls. SSc-ILD was defined by chest high-resolution computed tomography (HRCT)/chest X-ray images. SSC patients (total = 498; \(n = 185\) in the discovery cohort and \(n = 313\) in the replication cohort) were considered to have interstitial lung disease (ILD) by imaging if they had: (1) ground glass opacity or increased reticular marking on chest HRCT; or (2) increased basal reticular marking on chest X-ray (in total, 498 patients, 185 in the discovery cohort and 313 in the replication cohort had ILD). The number of patients with imaging-proven ILD is low because HRCT imaging results were available only \(n = 212\) in the discovery cohort and \(n = 347\) in the replication cohort patients. The case-case comparison in regard to presence of ILD was compared to controls by low number of patients with available HRCT imaging in the discovery cohort.

Furthermore, an association with severity of ILD was investigated. Percent predicted forced vital capacity (FVC\%) (measured in a total of 1954 patients; \(n = 1072\) in the discovery cohort and \(n = 882\) in the replication cohort) as a continuous variable was used as a surrogate for severity of SSc-ILD as this has been demonstrated to be a validated outcome measure for severity of ILD in randomized controlled studies of patients with SSC [10]. SNPs reaching the nominal significance level \((p < 0.05)\) in these two analyses were also genotyped in the replication cohort (rs7934606, rs2076295, rs17690703 and rs1981997).

**Statistical analysis**

We followed the same genetic inheritance modes for each specific SNP that was utilized in the IIP GWAS [7]. Specifically, all SNPs except for rs1379326 (CSMD1) were investigated in an additive model. Similar to the IIP GWAS [7], rs1379326 (CSMD1) was investigated in a recessive model. The additive model corresponds to the risk or protective effect conferred by the rarer (minor) allele (0, 1 or 2 copies) as a predictor of phenotypic status; and the recessive model corresponds to the effect conferred by only homozygous status for the rarer allele. Genotype data quality was verified for each SNP by testing for Hardy-Weinberg equilibrium (HWE). Hardy-Weinberg equilibrium was assessed by an \(x^2\) test or Fisher’s exact test. None of the included cohorts showed significant deviation from HWE for all the genotyped SNPs. Logistic regression that included both patients and controls was utilized to examine the association of the above SNPs with SSC overall and SSc-ILD. A linear regression model was used to investigate the association of these genetic variants with FVC\% predicted (data was normally distributed) as a continuous variable, among patients only. FVC\% predicted was investigated as a continuous rather than a dichotomous variable to increase our power to detect a difference in FVC levels conditional on the genotype. Anti-topoisomerase 1 antibody (ATA) status was included as a potential confounder in the multivariable regression model. The combined analysis of the discovery and the replication cohorts was performed via a random-effects meta-analysis model.

**Results**

**Discovery cohort**

We first investigated whether the 13 IIP-associated polymorphisms were associated with risk of SSC overall or with SSc-ILD. Several SNPs showed nominally significant associations with SSC in the discovery cohort (Table 2). Specifically, LRR34 rs6793295 \((\text{OR} = 1.14, \text{CI} 95\% 1.03\text{ to } 1.25, \text{ } p \text{ value } = 0.009)\) and OBFC1 rs11191865 \((\text{OR} = 1.09, \text{CI} 95\% 1.00\text{ to } 1.19, \text{ } p \text{ value } = 0.043)\) were associated with SSC compared to controls (Table 2). There were no significant associations observed when the SNP frequencies in SSC antibody subgroups (ATA- or ACA-positive patients) were compared to controls (Table 3).

Next, we investigated the association in the discovery cohort between the above polymorphisms and SSc-ILD by imaging or FVC\% predicted in order to investigate the relationship with SSc-ILD presence or severity. We also performed case-case comparison by presence of ILD with no ILD in SSC. Interestingly, rs7934606 in MUC2 \((\text{OR} = 1.24, \text{CI} 95\% 1.01\text{ to } 1.52, \text{ } p \text{ value } = 0.037)\) was associated with SSc-ILD by imaging when compared to controls (Table 4). Furthermore, three polymorphisms of DSP rs2076295 \((\beta = -2.29, \text{CI} 95\% -3.85\text{ to } -0.74, \text{ } p \text{ value } = 0.004)\), SPPL2C rs17690703 \((\beta = 2.04, \text{CI} 95\% 0.21\text{ to } 3.88, \text{ } p \text{ value } = 0.029)\) and MAPT rs1981997 \((\beta = 2.26, \text{CI} 95\% 0.35\text{ to } 4.17, \text{ } p \text{ value } = 0.02)\) were associated with FVC\% predicted (Table 5). Of note, the minor allele (A) of MAPT rs1981997 and (T) of SPPL2C rs17690703 were associated with higher FVC\% predicted, which is consistent with the IIP GWAS results with the minor allele being protective in that study \((\text{OR} < 1)\) [7]. Even after adjustment for ATA status, the above three polymorphisms showed nominally significant associations with ILD severity in SSC patients (Table 5). SPPL2C rs17690703 was associated ILD-SSc compared to SSC with no ILD as determined by imaging in the discovery cohort (Table S1 in Additional file 1).
Replication cohort and combined analysis

We genotyped the samples from the validation set for the above six SNPs, which either showed nominally significant associations \((p < 0.05)\) with risk of SSc overall (\(LRRC34\) rs6793295 and \(OBFC1\) rs11191865) or with SSc-ILD (\(MUC2\) rs7934606) and FVC\% predicted (\(DSP\) rs2076295, \(SPPL2C\) rs17690703 and \(MAPT\) rs1981997). However, these associations were not found in the replication cohort (Table 4 and upper part of Table 6). Contrary to the discovery cohort, \(MAPT\)...

<table>
<thead>
<tr>
<th>SNP</th>
<th>Gene</th>
<th>Minor allele</th>
<th>MAF (case)**</th>
<th>OR (95 % CI)</th>
<th>(p) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs2736100</td>
<td>TERT</td>
<td>T</td>
<td>0.50</td>
<td>1.04 (0.95; 1.13)</td>
<td>0.393</td>
</tr>
<tr>
<td>rs2076295</td>
<td>DSP</td>
<td>G</td>
<td>0.44</td>
<td>0.96 (0.88; 1.05)</td>
<td>0.387</td>
</tr>
<tr>
<td>rs4727443</td>
<td>AZGP1</td>
<td>A</td>
<td>0.41</td>
<td>1.03 (0.95; 1.13)</td>
<td>0.487</td>
</tr>
<tr>
<td>rs7934606</td>
<td>MUC2</td>
<td>A</td>
<td>0.41</td>
<td>1.08 (0.99; 1.18)</td>
<td>0.084</td>
</tr>
<tr>
<td>rs2034650</td>
<td>IVD</td>
<td>G</td>
<td>0.49</td>
<td>1.03 (0.95; 1.13)</td>
<td>0.458</td>
</tr>
<tr>
<td>rs1981997</td>
<td>MAPT</td>
<td>A</td>
<td>0.22</td>
<td>0.97 (0.88; 1.08)</td>
<td>0.636</td>
</tr>
<tr>
<td>rs12610495</td>
<td>DPP9</td>
<td>G</td>
<td>0.28</td>
<td>1.00 (0.91; 1.10)</td>
<td>0.967</td>
</tr>
<tr>
<td>rs6793295</td>
<td>LRRC34</td>
<td>C</td>
<td>0.29</td>
<td>1.14 (1.03; 1.25)</td>
<td>0.009</td>
</tr>
<tr>
<td>rs2609255</td>
<td>FAM13A</td>
<td>G</td>
<td>0.22</td>
<td>1.01 (0.91; 1.12)</td>
<td>0.851</td>
</tr>
<tr>
<td>rs11191865</td>
<td>OBFC1</td>
<td>G</td>
<td>0.52</td>
<td>1.09 (1.00; 1.19)</td>
<td>0.043</td>
</tr>
<tr>
<td>rs1278769</td>
<td>ATP11A</td>
<td>A</td>
<td>0.24</td>
<td>0.95 (0.86; 1.06)</td>
<td>0.365</td>
</tr>
<tr>
<td>rs1379326</td>
<td>CSMD1</td>
<td>G</td>
<td>0.26</td>
<td>0.86 (0.69; 1.08)</td>
<td>0.199</td>
</tr>
<tr>
<td>rs17690703</td>
<td>SPPL2C</td>
<td>T</td>
<td>0.26</td>
<td>1.03 (0.95; 1.11)</td>
<td>0.546</td>
</tr>
</tbody>
</table>

Gene names: TERT: telomerase reverse transcriptase; DSP: desmoplakin; AZGP1: alpha-2-glycoprotein 1, zinc-binding; MUC2: mucin 2; IVD: isoaveryl-CoA dehydrogenase; MAPT: microtubule-associated protein tau; DPP9: dipeptidyl-peptidase 9; LRRC34: leucine-rich repeat-containing 34; FAM13A: family with sequence similarity 13, member A; OBFC1: oligonucleotide/oligosaccharide-binding fold containing 1; ATP11A: ATPase, class VI, type 11A; CSMD1: CUB and Sushi multiple domains 1; SPPL2C: signal peptide peptidase-like 2C

SSc systemic sclerosis, SNP single nucleotide polymorphism, MAF minor allele frequency

*The minor allele is defined as the minor allele in the combined case and control group; **MAF is defined as the minor allele frequency in cases and controls; †Odds ratio for the minor allele in the additive model; ‡Odds ratio based on the recessive model

Table 3 Association studies of investigated genotypes in comparison of ATA- or ACA-positive SSc patients to controls in the discovery cohort

<table>
<thead>
<tr>
<th>SNP</th>
<th>Gene</th>
<th>ATA (+)</th>
<th>OR (95 % CI)</th>
<th>(p) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs2736100</td>
<td>TERT</td>
<td>1.01</td>
<td>0.84 (1.22)</td>
<td>0.881</td>
</tr>
<tr>
<td>rs2076295</td>
<td>DSP</td>
<td>1.01</td>
<td>0.83 (1.21)</td>
<td>0.945</td>
</tr>
<tr>
<td>rs4727443</td>
<td>AZGP1</td>
<td>1.12</td>
<td>0.93 (1.36)</td>
<td>0.226</td>
</tr>
<tr>
<td>rs7934606</td>
<td>MUC2</td>
<td>1.00</td>
<td>0.83 (1.20)</td>
<td>0.992</td>
</tr>
<tr>
<td>rs2034650</td>
<td>IVD</td>
<td>0.99</td>
<td>0.82 (1.19)</td>
<td>0.915</td>
</tr>
<tr>
<td>rs1981997</td>
<td>MAPT</td>
<td>0.92</td>
<td>0.73 (1.16)</td>
<td>0.495</td>
</tr>
<tr>
<td>rs12610495</td>
<td>DPP9</td>
<td>0.98</td>
<td>0.80 (1.20)</td>
<td>0.847</td>
</tr>
<tr>
<td>rs6793295</td>
<td>LRRC34</td>
<td>1.15</td>
<td>0.94 (1.42)</td>
<td>0.172</td>
</tr>
<tr>
<td>rs2609255</td>
<td>FAM13A</td>
<td>1.04</td>
<td>0.83 (1.30)</td>
<td>0.736</td>
</tr>
<tr>
<td>rs11191865</td>
<td>OBFC1</td>
<td>1.21</td>
<td>1.00 (1.45)</td>
<td>0.048</td>
</tr>
<tr>
<td>rs1278769</td>
<td>ATP11A</td>
<td>1.09</td>
<td>0.89 (1.35)</td>
<td>0.394</td>
</tr>
<tr>
<td>rs1379326</td>
<td>CSMD1</td>
<td>0.78</td>
<td>0.46 (1.31)</td>
<td>0.340</td>
</tr>
<tr>
<td>rs17690703</td>
<td>SPPL2C</td>
<td>0.97</td>
<td>0.76 (1.26)</td>
<td>0.870</td>
</tr>
</tbody>
</table>

Gene names: TERT: telomerase reverse transcriptase; DSP: desmoplakin; AZGP1: alpha-2-glycoprotein 1, zinc-binding; MUC2: mucin 2; IVD: isoaveryl-CoA dehydrogenase; MAPT: microtubule-associated protein tau; DPP9: dipeptidyl-peptidase 9; LRRC34: leucine-rich repeat-containing 34; FAM13A: family with sequence similarity 13, member A; OBFC1: oligonucleotide/oligosaccharide-binding fold containing 1; ATP11A: ATPase, class VI, type 11A; CSMD1: CUB and Sushi multiple domains 1; SPPL2C: signal peptide peptidase-like 2C

ATA anti-topoisomerase 1 antibody, ACA anti-centromere antibody, SSc systemic sclerosis, SNP single nucleotide polymorphism

*Additive model; †Recessive model
rs1981997 (OR = 0.79; CI 95% 0.68 to 0.91; p value = 0.002) and SPPL2C rs17690703 (OR = 0.64; CI 95% 0.49 to 0.83; p value = 0.001) were associated with SSc susceptibility but not with ILD severity in the replication cohort (Table 6). Furthermore, SPPL2C rs17690703 was not associated with SSc-ILD when compared to SSc without ILD by imaging in the validation cohort (Table S1 in Additional file 1).

In the combined discovery and replication cohorts (lower part of Table 6), only the LRRC34 rs6793295 was

Table 4 Association between the investigated genotypes in SSc-ILD (by imaging) patients compared to controls in the discovery and replication cohort

<table>
<thead>
<tr>
<th>SNP (coded allele)</th>
<th>Gene</th>
<th>SSc-ILD vs control (discovery cohort)</th>
<th>p value</th>
<th>OR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs2736100 (T)</td>
<td>TERT</td>
<td>1.14 (0.93; 1.40)</td>
<td>0.199</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2076295 (G)</td>
<td>DSP</td>
<td>1.13 (0.92; 1.39)</td>
<td>0.243</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs4727443 (A)</td>
<td>AZGP1</td>
<td>0.89 (0.71; 1.10)</td>
<td>0.270</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs7934606 (A)</td>
<td>MUC2</td>
<td>1.24 (1.01; 1.52)</td>
<td>0.037</td>
<td>1.14 (0.81; 1.63)</td>
<td>0.444</td>
</tr>
<tr>
<td>rs2034650 (G)</td>
<td>IVD</td>
<td>0.86 (0.70; 1.06)</td>
<td>0.152</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1981997 (A)</td>
<td>MAPT</td>
<td>0.81 (0.62; 1.06)</td>
<td>0.123</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs12610495 (G)</td>
<td>DPP9</td>
<td>1.17 (0.93; 1.46)</td>
<td>0.179</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs6793295 (G)</td>
<td>LRR3C4</td>
<td>1.02 (0.80; 1.30)</td>
<td>0.863</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2609255 (G)</td>
<td>FAM3A</td>
<td>0.99 (0.77; 1.27)</td>
<td>0.919</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs11191865 (G)</td>
<td>OBFC1</td>
<td>1.08 (0.87; 1.32)</td>
<td>0.496</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1278769 (A)</td>
<td>ATP11A</td>
<td>1.00 (0.79; 1.28)</td>
<td>0.987</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1379326 (G)</td>
<td>CSMD1</td>
<td>0.68 (0.51; 1.27)</td>
<td>0.224</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs17690703 (T)</td>
<td>SPPL2C</td>
<td>1.23 (0.87; 1.72)</td>
<td>0.238</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Gene names: TERT: telomerase reverse transcriptase; DSP: desmoplakin; AZGP1: alpha-2-glycoprotein 1, zinc-binding; MUC2: mucin 2; IVD: isovaleryl-CoA dehydrogenase; MAPT: microtubule-associated protein tau; DPP9: dipeptidyl-peptidase 9; LRR3C4: leucine-rich repeat-containing 34; FAM3A: family with sequence similarity 13, member A; OBFC1: oligonucleotide/oligosaccharide-binding fold containing 1; ATP11A: ATPase, class VI, type 11A; CSMD1: CUB and Sushi multiple domains 1; SPPL2C: signal peptide peptidase-like 2C

SSc systemic sclerosis, ILD interstitial lung disease, SNP single nucleotide polymorphism

*Additive model; †Recessive model

rs1981997 (OR = 0.79; CI 95% 0.68 to 0.91; p value = 0.002) and SPPL2C rs17690703 (OR = 0.64; CI 95% 0.49 to 0.83; p value = 0.001) were associated with SSc susceptibility but not with ILD severity in the replication cohort (Table 6). Furthermore, SPPL2C rs17690703 was not associated with SSc-ILD when compared to SSc without ILD by imaging in the validation cohort (Table S1 in Additional file 1).

In the combined discovery and replication cohorts (lower part of Table 6), only the LRRC34 rs6793295 was

Table 5 Association between the investigated genotypes and FVC% predicted in SSc patients in the discovery cohort

<table>
<thead>
<tr>
<th>SNP (Coded allele)</th>
<th>Gene</th>
<th>FVC%</th>
<th>p value</th>
<th>FVC% (adjusted for ATA status)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs2736100 (T)</td>
<td>TERT</td>
<td>0.51 (-1.04; 2.05)</td>
<td>0.521</td>
<td>0.76 (-0.83; 2.34)</td>
</tr>
<tr>
<td>rs2076295 (G)</td>
<td>DSP</td>
<td>-2.29 (-3.85; -0.74)</td>
<td>0.004</td>
<td>-2.52 (-4.09; -0.95)</td>
</tr>
<tr>
<td>rs4727443 (A)</td>
<td>AZGP1</td>
<td>-0.27 (-1.85; 1.32)</td>
<td>0.742</td>
<td>0.08 (-1.53; 1.70)</td>
</tr>
<tr>
<td>rs7934606 (A)</td>
<td>MUC2</td>
<td>-0.55 (-2.16; 1.05)</td>
<td>0.499</td>
<td>-0.75 (-2.37; 0.86)</td>
</tr>
<tr>
<td>rs2034650 (G)</td>
<td>IVD</td>
<td>0.67 (-0.90; 2.25)</td>
<td>0.402</td>
<td>0.37 (-1.22; 1.97)</td>
</tr>
<tr>
<td>rs1981997 (A)</td>
<td>MAPT</td>
<td>2.26 (0.35; 4.17)</td>
<td>0.020</td>
<td>3.19 (1.23; 5.14)</td>
</tr>
<tr>
<td>rs12610495 (G)</td>
<td>DPP9</td>
<td>0.57 (-1.18; 2.32)</td>
<td>0.523</td>
<td>1.05 (-0.72; 2.82)</td>
</tr>
<tr>
<td>rs6793295 (G)</td>
<td>LRR3C4</td>
<td>-0.46 (-2.19;1.27)</td>
<td>0.599</td>
<td>-1.05 (-2.82; 0.71)</td>
</tr>
<tr>
<td>rs2609255 (G)</td>
<td>FAM3A</td>
<td>1.72 (0.010; 3.55)</td>
<td>0.064</td>
<td>1.61 (-0.18; 3.41)</td>
</tr>
<tr>
<td>rs11191865 (G)</td>
<td>OBFC1</td>
<td>-0.73 (-2.27; 0.82)</td>
<td>0.356</td>
<td>0.02 (-1.55; 1.60)</td>
</tr>
<tr>
<td>rs1278769 (A)</td>
<td>ATP11A</td>
<td>-0.62 (-2.45; 1.20)</td>
<td>0.503</td>
<td>-0.74 (-2.60; 1.11)</td>
</tr>
<tr>
<td>rs1379326 (G)</td>
<td>CSMD1</td>
<td>3.35 (-0.84; 7.54)</td>
<td>0.117</td>
<td>3.12 (-1.08; 7.31)</td>
</tr>
<tr>
<td>rs17690703 (T)</td>
<td>SPPL2C</td>
<td>2.04 (0.21; 3.88)</td>
<td>0.029</td>
<td>2.11 (0.30; 3.91)</td>
</tr>
</tbody>
</table>

Gene names: TERT: telomerase reverse transcriptase; DSP: desmoplakin; AZGP1: alpha-2-glycoprotein 1, zinc-binding; MUC2: mucin 2; IVD: isovaleryl-CoA dehydrogenase; MAPT: microtubule-associated protein tau; DPP9: dipeptidyl-peptidase 9; LRR3C4: leucine-rich repeat-containing 34; FAM3A: family with sequence similarity 13, member A; OBFC1: oligonucleotide/oligosaccharide-binding fold containing 1; ATP11A: ATPase, class VI, type 11A; CSMD1: CUB and Sushi multiple domains 1; SPPL2C: signal peptide peptidase-like 2C

FVC% percent predicted forced vital capacity, SSc systemic sclerosis, ATA anti-topoisomerase 1 antibody, SNP single nucleotide polymorphism

*Additive model; †Recessive model
Table 6: Association analysis of investigated genotypes in SSc versus control comparison as well as FVC% in the replication and combined cohorts

<table>
<thead>
<tr>
<th>SNPs</th>
<th>Gene</th>
<th>Allele frequency</th>
<th>FVC%</th>
<th>FVC%-adjusted for ATA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>OR (95 % CI)</td>
<td>p value</td>
<td>p value</td>
</tr>
<tr>
<td>Replication</td>
<td>rs2076295 (G)</td>
<td>0.93 (0.82; 1.05)</td>
<td>0.252</td>
<td>0.32 (1.49; 2.13)</td>
</tr>
<tr>
<td></td>
<td>rs1981997 (A)</td>
<td>0.79 (0.68; 0.91)</td>
<td>0.002</td>
<td>0.15 (-2.05; 2.35)</td>
</tr>
<tr>
<td></td>
<td>rs6793295 (G)</td>
<td>1.06 (0.92; 1.21)</td>
<td>0.435</td>
<td>-0.54 (-2.53;1.45)</td>
</tr>
<tr>
<td></td>
<td>rs11191865 (G)</td>
<td>0.90 (0.80; 1.01)</td>
<td>0.093</td>
<td>-0.34 (-2.11; 1.44)</td>
</tr>
<tr>
<td></td>
<td>rs17690703 (T)</td>
<td>0.64 (0.49; 0.83)</td>
<td>0.001</td>
<td>2.20 (-1.38; 5.78)</td>
</tr>
<tr>
<td>Combined</td>
<td>rs2076295 (G)</td>
<td>0.95 (0.89; 1.02)</td>
<td>0.171</td>
<td>-1.02 (-3.58; 1.54)</td>
</tr>
<tr>
<td></td>
<td>rs1981997 (A)</td>
<td>0.89 (0.78; 1.02)</td>
<td>0.091</td>
<td>1.26 (-0.81; 3.32)</td>
</tr>
<tr>
<td></td>
<td>rs6793295 (C)</td>
<td>1.11 (1.03; 1.20)</td>
<td>0.010</td>
<td>-0.50 (-1.80; 0.81)</td>
</tr>
<tr>
<td></td>
<td>rs11191865 (G)</td>
<td>1.01 (0.90; 1.13)</td>
<td>0.912</td>
<td>-0.55 (-1.72; 0.61)</td>
</tr>
<tr>
<td></td>
<td>rs17690703 (T)</td>
<td>1.04 (0.97; 1.13)</td>
<td>0.221</td>
<td>2.32 (0.68; 3.96)</td>
</tr>
</tbody>
</table>

Gene names: TERT: telomerase reverse transcriptase; DSP: desmoplakin; AZGP1: alpha-2-glycoprotein 1, zinc-binding; MUC2: mucin 2; IVD: isovaleryl-CoA dehydrogenase; MAPT: microtubule-associated protein tau; DPP9: dipeptidyl-peptidase 9; LRRC34: leucine-rich repeat-containing 34; FAM13A: family with sequence similarity 13, member A; OBFC1: oligonucleotide/oligosaccharide-binding fold containing 1; ATP11A: ATPase, class VI, type 11A; CSMD1: CUB and Sushi multiple domains 1; SPPL2C: signal peptide peptidase-like 2C.

SSc systemic sclerosis, FVC % percent predicted forced vital capacity, ATA anti-topoisomerase 1 antibody, SNP single nucleotide polymorphism

†Additive model

associated with risk of SSc overall (OR = 1.11; CI 95 % 1.03 to 1.2; p value = 0.01). However, the observed significance level was not stronger in the combined cohort than in the discovery cohort and this association did not withstand correction for multiple comparisons. Specifically, the p value = 0.13 in the combined cohort after Bonferroni correction for multiple comparisons. Furthermore, LRRC34 rs6793295 was not associated with FVC% predicted in the combined cohort. SPPL2C rs17690703 was associated with FVC% predicted in the combined cohort but not after ATA adjustment or with overall SSc risk (Table 6). The observed association of SPPL2C rs17690703 with FVC% did not withstand correction for multiple comparison (p corr = 0.078).

Discussion

The aim of this study was to assess genetic components of SSc and SSc-related ILD, specifically to determine if SSc-ILD and IIP share common genetic risk factors. We analyzed 13 SNPs which showed robust association with IIP in a previous GWAS report [7, 8]. However, we failed to replicate these associations with SSc or SSc-related ILD in a large North American cohort.

Interstitial lung disease (ILD) is the most common pulmonary manifestation in patients with SSc [11] and is the most frequent cause of SSc disease-related death [12]. ILD occurs with greater frequency and increased severity in patients with diffuse cutaneous SSc (dc-SSc) and in ATA-positive patients. In SSc-ILD, loss of lung function and extent of fibrosis are the most important prognostic factors. It is known that genetic factors contribute not only to SSc susceptibility, but also to predisposition to SSc clinical phenotypes including disease type (limited versus diffuse cutaneous disease) and autoantibody status [13]. Recently, several lines of evidence have suggested that, even though SSc-ILD has phenotypic similarities to IIP, the genetic risk factors for these two conditions are quite different. For example the MUCSB promoter region polymorphism (rs868903), which was strongly associated with familial and idiopathic pulmonary fibrosis [3, 7], was not identified as a susceptibility locus for SSc or SSc–associated interstitial lung disease [4–6]. In addition, the two large SSc GWAS reports (each with independent discovery and validation cohorts) identified the major histocompatibility complex (MHC) class II region as being the most strongly associated region with SSc [9, 14], whereas MHC loci were not found to be risk factors in the IIP GWAS [7].

The present study has some limitations. In our study, only a subgroup of SSc patients had undergone HRCT. We performed a case-case comparison in regard to presence of SSc-ILD versus no SSc-ILD in the low number of patients because HRCT results were not available in the remainder of patients. The genotype results for TOL-LIP and MDGA2 genes were not available on our GWAS platform and could not be investigated. Furthermore, this is a cross-sectional study, thus, we cannot examine whether the investigated genetic loci have predictive significance for ILD progression. However, mean disease duration of this study was more than 10 years and most of the SSc-ILD cases had been already established. Therefore, we believe the cross-sectional FVC% is a reasonable surrogate for severity of ILD.
Conclusions
In this study, we confirm that genetic susceptibility loci for IIP are not risk loci for SSC or severity of SSc-ILD in two validation SSC cohorts of non-Hispanic white ethnic background. Our findings and those of previous genetic susceptibility studies in SSC [15] implicate pathways in innate and adaptive immunity, whereas susceptibility loci for IIP relate to epithelial cell injury/dysfunction and abnormal wound healing [16]. Future challenges will be to identify the functional relevance of these variants for the final common pathway that results in the phenotype of fibrotic lung disease. This study represents an important step forward toward a better understanding of the complex genetic association of SSC particularly with lung involvement. We add new evidence that SSCs and SSC-ILD are genetically distinct from IIP.

Additional file

Additional file 1: Table S1. Association between the investigated genotypes in SSC-ILD (by imaging) patients compared to SSC-no ILD (by imaging) in the discovery and replication cohort. (DOCX 19 kb)

Abbreviations
ACA: Anti-centromere antibody; ATA: Anti-topoisomerase 1 antibody; CGEMS: Cancer Genetic Markers of Susceptibility; CREST: Calcinosis, Raynaud’s phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasias; dCSSc: Diffuse cutaneous SSC; FVC%: Percent predicted forced vital capacity; GWAS: Genome-wide association study; HRCT: High-resolution computed tomography; HWE: Hardy-Weinberg equilibrium; IIP: Idiopathic interstitial pneumonia; ILD: Interstitial lung disease; IPP: Idiopathic pulmonary fibrosis; MHC: Major histocompatibility complex; NSIP: Nonspecific interstitial pneumonia; PAH: Pulmonary arterial hypertension; SNP: Single nucleotide polymorphisms; SSC: Systemic sclerosis; SSC-ILD: SSC-associated interstitial lung disease; UIP: Usual interstitial pneumonia.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MW, SA, JV, and MDM contributed to study conception and design, MW, SA, GAS, JC, MLT, KL, FMW, LHk, AAS, MH, DK, ES, KP, DEF, VS, MB, MH, XZ, JP, NJ, PD, NAK, DR, RWS, RMs, TMF, BJF, MIF, JAM, BMS, MM, JM, JV, and MDM contributed to acquisition of data. MW, SA, GAS, CP, DYG, WVC, JC, MLT, KL, FMW, LHk, AAS, MH, DK, ES, KP, DEF, VS, MB, MH, XZ, JP, NJ, PD, NAK, DR, RWS, RMs, TMF, BJF, MIF, JAM, BMS, MM, JM, JV, and MDM contributed to analysis and interpretation of data. MW had full access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. All authors were involved in drafting the manuscript or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication.

Acknowledgements
The authors thank Marilyn Perry and Yuixia Du for their work as Registry coordinators and we are grateful for the generous participation of our subjects. This work was supported by the Scleroderma Foundation New Investigator Award to Dr. Wu, and by the National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Centers of Research Translation (CORT) grant P50AR054144 to Dr. Mayes, NIH grant K23AR061436 to Dr. Assassi, NIH/NIAMS Scleroderma Family Registry and DNA Repository grant N01-AR022251 to Dr. Mayes, NIH/NIAMS grant AR055258 to Dr. Mayes, NIH National Center for Clinical and Translational Sciences grant 5UL1TR002414, Department of Defense Congressionally Directed Medical Research Program W81XWH-13-1-0452, Proposal number PR120687 to Dr. Mayes.

Author details
1Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA. 2Department of Pediatrics, The University of Texas McGovern Medical School at Houston, 6431 Fannin Street, Houston, TX 77030, USA. 3Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth, 1 Rope Ferry Road, Hanover, NH 03755, USA. 4Division of Rheumatology, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview circle, Baltimore, MD 21224, USA. 5Division of Rheumatology, Northwestern University Feinberg School of Medicine, 240 East Huron Street, Chicago, IL 60611, USA. 6Department of Internal Medicine, Division of Rheumatology, University of Michigan Health Center, 300 North Ingalls Street, Ann Arbor, MI 48109, USA. 7Division of Rheumatology, University of California Los Angeles, 1000 Veterans Avenue, Los Angeles, CA 90024, USA. 8Division of Rheumatology, Georgetown University Medical Center, 3800 Reservoir Road, Washington, MD 20007, USA. 9Division of Rheumatology, McGill University, 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada. 10Division of Rheumatology, St. Joseph’s Health Care, University of Western Ontario, 268 Grosvenor Street, London, ON, Canada. 11Division of Rheumatology, University of Alberta, 11405-87 Avenue, Edmonton, AB T6G 1C9, Canada. 12Division of Rheumatology, Moncton Hospital, 135 MacBeath Avenue, Moncton, NB E1C 6Z8, Canada. 13Division of Rheumatology, McMaster University at Hamilton, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada. 14Division of Rheumatology, University of Manitoba, 820 Sherbrook Street, Winnipeg, MB R3A 1R9, Canada. 15Division of Rheumatology, Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA. 16Division of Rheumatology, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425, USA. 17Division of Rheumatology, University of Utah, 30 North 1900 East, Salt Lake City, UT 84132, USA. 18Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1825 University Boulevard, Birmingham, AB 35294, USA. 19Division of Rheumatology, University of Calgary Cumming School of Medicine, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada. 20Division of Rheumatology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA. 21Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas, C/Ventanilla 11, 18001 Granada, Spain.

Received: 8 July 2015 Accepted: 6 January 2016
Published online: 20 January 2016

References
Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis

Shervin Assassi,1 William R. Swindell,2 Minghua Wu,1 Filemon D. Tan,1 Dinesh Khanna,2 Daniel E. Furst,3 Donald P. Tashkin,3 Richard R. Jahan-Tigh,1 Maureen D. Mayes,1 Johann E. Gudjonsson,2 and Jeffrey T. Chang1

Objective. To examine the heterogeneity of global transcriptome patterns in systemic sclerosis (SSc) skin in a large sample of patients with SSc and control subjects.

Methods. Skin biopsy specimens obtained from 61 patients enrolled in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS) cohort and 36 unaffected control subjects with a similar demographic background were examined by Illumina HumanHT-12 bead arrays. Followup experiments using quantitative polymerase chain reaction and immunohistochemical analysis were also performed.

Results. We identified 2,754 differentially expressed transcripts in SSc patients compared with controls. Clustering analysis revealed 2 prominent transcriptomes in SSc patients: the keratin and fibroinflammatory signatures. Higher keratin transcript scores were associated with shorter disease duration and interstitial lung disease, while higher fibroinflammatory scores were associated with diffuse cutaneous involvement, a higher skin score at the biopsy site, and a higher modified Rodnan skin thickness score. A subgroup of patients with significantly longer disease duration had a normal-like transcript pattern. Analysis of cell type–specific signature scores revealed remarkable heterogeneity across patients. Significantly higher scores were calculated for fibroblasts (72% of patients), microvascular cells (61%), macrophages (54%), and dendritic cells (DCs) (49%). The majority of samples with significantly higher fibroblast scores (35 of 44 [80%]) had significantly increased macrophage and/or DC scores. Further analysis and immunohistochemical staining indicated that the keratin signature was not a general marker of keratinocyte activation but was in fact associated with an activation pattern in hair and adnexal structures.

Conclusion. Prominent fibroinflammatory and keratin signatures are present in SSc skin. Expression profiles of SSc skin show significant heterogeneity, and this finding might be useful for stratifying patients for targeted therapies or predicting the response to immunosuppression.

Systemic sclerosis (SSc; scleroderma) is a multisystem autoimmune disease associated with high morbidity and mortality (1). Global gene expression profiling with microarrays allows an unbiased genome-wide analysis revealed 2 prominent transcriptomes in SSc patients: the keratin and fibroinflammatory signatures. Higher keratin transcript scores were associated with shorter disease duration and interstitial lung disease, while higher fibroinflammatory scores were associated with diffuse cutaneous involvement, a higher skin score at the biopsy site, and a higher modified Rodnan skin thickness score. A subgroup of patients with significantly longer disease duration had a normal-like transcript pattern. Analysis of cell type–specific signature scores revealed remarkable heterogeneity across patients. Significantly higher scores were calculated for fibroblasts (72% of patients), microvascular cells (61%), macrophages (54%), and dendritic cells (DCs) (49%). The majority of samples with significantly higher fibroblast scores (35 of 44 [80%]) had significantly increased macrophage and/or DC scores. Further analysis and immunohistochemical staining indicated that the keratin signature was not a general marker of keratinocyte activation but was in fact associated with an activation pattern in hair and adnexal structures.

Conclusion. Prominent fibroinflammatory and keratin signatures are present in SSc skin. Expression profiles of SSc skin show significant heterogeneity, and this finding might be useful for stratifying patients for targeted therapies or predicting the response to immunosuppression.

Supported by the NIH (grants KL2-RR-024149 and K23-AR-061436 to Dr. Assassi, K08-AR-060802 to Dr. Gudjonsson, and UL1-TR-000371), the Scleroderma Foundation (SCORE Grant to Dr. Assassi), the A. Alfred Taubman Medical Research Institute (Kenneth and Frances Eisenberg Emerging Scholar Award to Dr. Gudjonsson), the Doris Duke Foundation (grant 2013106 to Dr. Gudjonsson), and the US Department of Defense (contract W81XWH-13-1-0452 to Dr. Mayes).

1Shervin Assassi, MD, MS, Minghua Wu, MD, PhD, Filemon D. Tan, MD, PhD, Richard R. Jahan-Tigh, MD, Maureen D. Mayes, MD, MPH, Jeffrey T. Chang, PhD: University of Texas Health Science Center at Houston; 2William R. Swindell, PhD, MS, Dinesh Khanna, MD, MS, Johann E. Gudjonsson, MD, PhD: University of Michigan, Ann Arbor; 3Daniel E. Furst, MD, Donald P. Tashkin, MD: University of California, Los Angeles.

Dr. Khanna has received consulting fees from Actelion, Bayer, Bristol-Myers Squibb, Cytori, Roche/Genentech, InterMune, Lycera, Merck, and Seattle Genetics (less than $10,000 each). Dr. Furst has received consulting fees, speaking fees, and/or honoraria from AbbVie, Actelion, Bristol-Myers Squibb, Amgen, Gilead, GlaxoSmithKline, Novartis, Pfizer, Roche/Genentech, UCB, Cytori, and Janssen (less than $10,000 each). Dr. Mayes has received consulting fees, speaking fees, and/or honoraria from Practice Point Communications, Medtelligence, Boehringer-Ingelheim, and Cytori (less than $10,000 each), receives royalties from Oxford University Press for The Scleroderma Book, from Harry Stewart Talks for a video of a prerecorded lecture on scleroderma, and from the British Medical Journal for a monograph on scleroderma, and has served as a paid consultant to the Gerson-Lehrman Group and to Leerink Partners, investment analysis companies, regarding systemic sclerosis unmet needs. Dr. Gudjonsson has received consulting fees, speaking fees, and/or honoraria from Novartis and AnaptysBio (less than $10,000 each) and owns stock or stock options in NuMedii.

Address correspondence to Shervin Assassi, MD, MS, Division of Rheumatology, University of Texas Health Science Center at Houston, 6431 Fannin Street, MSB 5.266, Houston, TX 77030. E-mail: shervin.assassi@uth.tmc.edu.

Submitted for publication June 15, 2014; accepted in revised form July 14, 2015.
wide assessment of the transcript dysregulation in a given tissue. This technology is now increasingly used to fingerprint pathologic processes, stratify diseases at the molecular level, and predict disease outcome (2–6). Development of effective treatment options in SSc has been hampered by a lack of sufficient understanding of its pathophysiology. Global gene expression studies in SSc at the end-organ level (7–10) or in peripheral blood cells (11–15) have indicated the presence of distinct transcript patterns in the majority of patients.

Skin is a prominently affected and easily accessible end-organ in SSc. Previous global gene expression studies have shown that SSc skin has a distinct gene expression profile, with inflammatory as well as fibrotic signatures (7,10). In a larger study involving 24 patients with SSc, the subgroup of patients with diffuse cutaneous SSc (dcSSc) could be divided into 3 distinct groups and the patients with limited cutaneous SSc (lcSSc) into 2 groups based on the intrinsic gene expression profiles observed in their skin biopsy specimens. A subgroup of patients including those with dcSSc and those with lcSSc showed an inflammatory pattern. Another subgroup of SSc patients with diffuse skin involvement showed a proliferative gene expression profile. A third subgroup of patients had a “normal-like” gene expression signature (9). Two other studies by the same group of investigators confirmed the presence of these 3 intrinsic subsets in independent samples (inflammatory, proliferative, and normal-like) (16,17).

In the present study, we investigated the heterogeneity of SSc transcript profiles in a large, well-characterized sample using a comprehensive gene expression profiling platform. First, we examined the impact of skin status (affected versus unaffected) on the SSc gene expression profile. Second, we identified 2 gene expression signatures in our large data set and examined the relationship between these signatures and SSc clinical features and previously described intrinsic transcript signatures (9). Last, we investigated the specific contribution of different cell types present in the skin (e.g., fibroblasts or macrophages) to the observed transcript heterogeneity in SSc skin.

**PATIENTS AND METHODS**

**Patients and control subjects.** Sixty-one patients were recruited from the Genetics versus Environment in Scleroderma Outcome Study (GENISOS) (18) or at the baseline visit in an investigator-initiated, open-label phase I/IIa study of imatinib (19). In addition to samples obtained at baseline, follow-up samples were also obtained from 5 of the 61 patients enrolled in the GENISOS cohort. All patients fulfilled the American College of Rheumatology/European League Against Rheuma-tism classification criteria for SSc (20). We also investigated 36 control subjects who had a similar demographic background. The study protocol was approved by the institutional review boards of the participating institutions, and all participants provided fully informed, voluntary consent.

Disease type was defined based on the extent of skin involvement (21). Patients who had diffuse skin involvement at any time during their disease course were categorized as having dcSSc. The modified Rodnan skin thickness score (MRSS) (22) was used to assess skin involvement, and the skin score at the biopsy site was also recorded (0–3 scale, where 0 = not involved and 3 = severe thickening). The presence of moderate to severe interstitial lung disease (ILD) was defined as a forced vital capacity of <70% predicted and findings indicative of pulmonary fibrosis on high-resolution computed tomography of the chest. Patients were considered as being treated with immunosuppressive agents if they had received immunosuppressive medication within 4 weeks of skin biopsy (with the exception of prednisone at a dose of <5 mg or hydroxychloroquine).

**Skin biopsy and quantitative reverse transcription–polymerase chain reaction (qRT-PCR) analysis.** Three-millimeter punch biopsy samples of skin were obtained from the arms of the study subjects and were immediately immersed in RNA-later solution (Qiagen) and stored at −80°C. RNA was extracted using RNeasy Fibrous Tissue kits (Qiagen). Global gene expression was assessed using Illumina HumanHT-12 bead arrays. All microarray experiments were performed in a single batch (see Supplementary Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract). Microarray data from this study are available from NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/) using accession no. GSE58095. There is overlap with accession no. GSE47162, but the previous data set does not include any control samples.

Quantitative RT-PCR was also performed for 2 prominently overexpressed keratin transcripts, keratin 25 (type I keratin) and keratin 85 (type II keratin) to confirm the microarray results. In these experiments, the expression values were normalized to those of GAPDH. Relative quantification was performed using the C ΔCt method, where ΔCt values were calculated based on GAPDH and transcript levels in controls.

**Immunohistochemical analysis.** Immunohistochemical analysis for 2 general markers of epidermis activation (keratin 6 and keratin 16) and keratin 85 (which was prominently overexpressed in our samples) was performed in skin biopsy samples obtained from 5 SSc patients with the keratin transcript signature and from unaffected control subjects (matched for age, sex, and ethnicity), as well as in a biopsy sample from pso-riatic skin (positive control) (see Supplementary Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract).

**Microarray data analysis.** Raw data were analyzed with BRB ArrayTools (http://linus.nci.nih.gov/BRB-ArrayTools.html). Data were normalized according to the quantile method. Genes whose log intensity variance was in the bottom 75th percentile were filtered out, and 11,819 transcripts met this criterion. Differentially expressed genes were detected using Significance Analysis of Microarrays (SAM), at a false discovery rate of <5% (23). The sets of differentially expressed genes were also modeled using Ingenuity Pathways Analysis (IPA) software, and upstream regulators were identified. The goal of Upstream Regulator Analysis in IPA is to identify upstream
regulators and predict whether they are activated or inhibited, given the observed gene expression changes in the experimental data set. IPA uses a Z score algorithm to make predictions. The Z score algorithm is designed to reduce the chance that random data will generate significant predictions. Upstream Regulator Analysis is based on expected causal effects between upstream regulators and targets; the expected causal effects are derived from the literature compiled in Ingenuity Knowledge Base.

Comprehensive transcript scores for the keratin and fibroinflammatory signatures were also calculated. For this purpose, we normalized each transcript included in the profiles to mean = 0 and variance = 1. To derive the composite score, we averaged the expression values of the positively correlated genes with the inverse values of the negatively correlated genes. We also calculated a composite score for predicted activation of the Wnt/β-catenin pathway based on a previously published data set, using the above algorithm (24). The statistical methods used to examine the relationship between these transcript composite scores and clinical outcomes depended on the distribution of composite scores (dependent variable). The distribution of the keratin scores was right skewed. Therefore, nonparametric methods were used for analysis of the keratin scores. Specifically, Spearman’s rho was used if the independent variable was continuous, and Wilcoxon’s rank sum test was used if the independent variable was categorical. Parametric tests were used for analysis of the composite fibroinflammatory scores (Pearson’s correlation and linear regression).

**Analysis of cell type-specific expression.** Skin consists of a complex set of cell types, each of which contributes to the aggregate expression data generated from a given biopsy. We performed cell type-specific expression analysis according to the approach previously described by our group (25), to investigate the potential contribution of these cell types to the SSc skin transcript profile (see Supplementary Methods, available on the *Arthritis & Rheumatology* web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract).

**RESULTS**

Sixty-one patients with SSc and 36 control subjects were assessed in this study. The demographic and clinical characteristics of the study population are shown in Supplementary Table 1, available on the *Arthritis & Rheumatology* web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract.

**Skin thickening at the biopsy site is a prominent source of heterogeneity.** The transcriptome of the majority of SSc patients differed from that of control subjects. There were 2,754 differentially expressed genes in SSc patients compared with controls (see Additional Tables 1 and 2, available on the *Arthritis & Rheumatology* web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract). IPA revealed that the top 3 represented canonical pathways belonged to hepatic fibrosis, agranulocyte adhesion/diapedesis, and granulocyte adhesion/diapedesis. The top significantly activated upstream transcription regulators were interferon (IFN) regulatory factor 7 (IRF-7), NF-κβ, IRF-1, STAT-1, and tumor protein 53, while the top upstream activated cytokines/growth factors were transforming growth factor β1 (TGFβ1), IFNα, oncostatin M, IFNα2, and IFNγ (see also Supplementary Figure 1 and Additional Table, available on the *Arthritis & Rheumatology* web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract). Next, we examined the SSc gene profile based on the status of skin involvement at the biopsy site (Figure 1); a complete list of differentially expressed transcripts in all comparison groups is shown in Additional Table 1 (available on the *Arthritis & Rheumatology* web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract).

A comparison of patients with clinically affected skin at the biopsy site and control subjects revealed 4,184 differentially expressed transcripts belonging to hepatic fibrosis, agranulocyte adhesion/diapedesis, and dendritic cell (DC) maturation, while a comparison of SSc patients with clinically unaffected skin at the biopsy site and controls resulted in only 24 differentially expressed genes (the small number of differentially expressed transcripts in this comparison precluded a meaningful pathway analysis). Furthermore, we detected prominent gene expression differences between SSc

![Table 1. Clinical correlates of keratin, fibroinflammatory, and normal-like signatures*](https://example.com/table1.png)

<table>
<thead>
<tr>
<th>Clinical variable</th>
<th>Keratin score</th>
<th>Fibroinflammatory score</th>
<th>Clustering with controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>rs</td>
<td>P†</td>
<td>r</td>
</tr>
<tr>
<td>Male sex</td>
<td>NA</td>
<td>0.658</td>
<td>NA</td>
</tr>
<tr>
<td>Diffuse cutaneous involvement</td>
<td>NA</td>
<td>0.179</td>
<td>NA</td>
</tr>
<tr>
<td>Immunosuppressive agents</td>
<td>NA</td>
<td>0.902</td>
<td>NA</td>
</tr>
<tr>
<td>Interstitial lung disease</td>
<td>NA</td>
<td>0.017</td>
<td>NA</td>
</tr>
<tr>
<td>Affected skin at biopsy site</td>
<td>NA</td>
<td>0.658</td>
<td>NA</td>
</tr>
<tr>
<td>Disease duration</td>
<td>–0.32</td>
<td>0.02</td>
<td>–0.19</td>
</tr>
<tr>
<td>Concurrent MRSS</td>
<td>0.03</td>
<td>0.85</td>
<td>0.66</td>
</tr>
<tr>
<td>Skin score at biopsy site</td>
<td>0.01</td>
<td>0.98</td>
<td>0.55</td>
</tr>
</tbody>
</table>

* 95% CI = 95% confidence interval; NA = not applicable; MRSS = modified Rodnan skin thickness score.
† Odds ratio (OR).
patients with clinically affected skin at the biopsy site and those with unaffected skin at the biopsy site. This comparison resulted in 142 differentially expressed transcripts belonging to the top 3 overrepresented canonical pathways.

We also performed a parallel analysis in order to investigate whether the heterogeneity based on the status of skin at the biopsy site is driven by disease type. In a comparison between patients with dcSSc and controls, there were 3,983 differentially expressed transcripts belonging to hepatic fibrosis, DC maturation, and graft-versus-host signaling, while 71 differentially expressed transcripts were detected in a comparison between patients with lcSSc and controls, with overrepresentation of the hepatic fibrosis pathway. Of note, there were no differentially expressed transcripts when patients with dcSSc were compared with those with lcSSc, indicating that the status of skin at the biopsy site is a more prominent source of heterogeneity than disease type. Of note, a pairwise comparison between affected and unaffected skin within the same individual SSc patients, as previously performed (9,10,16,17), could not be conducted in our study, because biopsy samples obtained from other typically uninvolved anatomic areas such as the buttock area were not performed.

**Differentially expressed gene expression profiles in SSc patients.** Figure 2 shows the unsupervised hierarchical clustering of 2,754 differentially expressed genes identified in the comparison between SSc samples and controls (for additional information see Supplementary Figure 2, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract). Two partially overlapping gene clusters were overexpressed in SSc patients (Figure 2). The first gene cluster was highly enriched with keratins and keratin-associated proteins (mainly hair and adnexal structure keratins), with 77 of 93 transcripts (82.8%) being keratin-related (see Additional Table, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract). Thirty-four patients (57.6%), including those with clinically affected skin and those with unaffected skin (see Supplementary Figure 3, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract), as well as both patients with lcSSc and patients with dcSSc, clustered in the group with overexpression of the keratin signature (data not shown). The keratin signature was significantly less common among control subjects (present in only 8 controls [22.2%]; P = 0.002).

We also investigated levels of 2 representative keratin transcripts, keratin 25 and keratin 85, by qRT-PCR. As shown in Supplementary Figure 4 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract), levels of both keratin 25 (type I keratin) and keratin 85 (type II keratin) were significantly higher in patients compared with controls (median fold changes 21.1 [P = 0.015] and 15.7 [P = 0.003], respectively).

The second overexpressed cluster was enriched with genes involving inflammatory (including IFN-inducible genes) and fibrotic pathways, such as THY1, COL1A1, COMP, OAS1, and CCL2 (Figure 2; see also Additional Table, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract). As shown in Supplementary Figure 5 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract), this fibroinflammatory signature was present in 44 patients (74.6%), while only 5 control subjects had this signature (P < 0.001). IPA of this cluster
revealed that the top 3 overrepresented canonical pathways were hepatic fibrosis, agranulocyte adhesion/diapedesis, and DC maturation. In this cluster, genes belonging to inflammatory and fibrotic pathways were coexpressed. As shown in Figure 2, this gene cluster partially overlapped with the keratin signature. Similar to previously published data (9), 14 SSc samples (23.7%) clustered with control samples (Figure 2; see also Supplementary Figure 2, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract).

Cross comparison with the inflammatory and proliferative intrinsic subsets. We mapped the inflammatory intrinsic subset (60 genes corresponding to 93 probes) and the proliferative intrinsic subset (56 genes corresponding to 86 probes) previously described by Milano et al (9) to probes present on Illumina HumanHT-12 arrays. As shown in Supplementary Figure 6 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract), some patient samples showed increased coexpression of transcripts in the inflammatory intrinsic subset, but we did not observe homogeneous overexpression of proliferative intrinsic genes among patient samples (see Supplementary Figure 7, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract). We also investigated the overlap between the above-mentioned fibroinflammatory cluster and these 2 intrinsic gene subsets. Twenty inflammatory intrinsic genes (23 probes) were also present in our fibroinflammatory cluster, whereas only 5 genes were in common between the proliferative intrinsic gene subset and our fibroinflammatory gene cluster.

We also performed a hierarchical clustering analysis using unbiased selection of genes that deviated at least 2-fold from the mean in at least 5 samples in order to parallel the analytic approach described in previous SSc skin gene expression studies (9,10). Following this approach, 1,870 genes were identified. As shown in Supplementary Figure 8 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract), unsupervised hierarchical clustering using this gene list demonstrated that a subgroup of SSc samples (especially those from patients with affected skin) clustered together. Furthermore, there were clusters of genes that corresponded to the samples with an intrinsic inflammatory signature (9) and the above-described keratin signature, but samples with a prominent intrinsic proliferative signature (9) and their corresponding genes could not be detected. Furthermore, 13 of 58 genes in the inflammatory intrinsic signature overlapped with our list of 1,870 transcripts (P < 0.001, odds ratio [OR] 3.48, 95% confidence interval [95% CI] 1.89–6.41), while only 1 of 55 genes in the proliferative intrinsic signature overlapped with this
gene list ($P = 0.127$, OR 0.32, 95% CI 0.06–1.61). This indicates that the previously described inflammatory intrinsic signature (9) had significant overlap with our list of 1,870 genes, while the proliferative intrinsic genes did not show a significant overlap with the genes that have highly varying levels in our data set.

Correlates of keratin and fibroinflammatory signatures. Next, we calculated composite scores for the keratin and fibroinflammatory clusters. As shown in Supplementary Figure 9 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract), both clusters showed higher composite scores in patients compared with controls ($P < 0.001$ for the keratin cluster and $P < 0.001$ for the fibroinflammatory clusters).

Table 1 shows clinical correlates of these 2 composite transcript scores. A higher composite keratin score was associated with shorter disease duration and the presence of ILD, while a higher composite fibroinflammatory score was associated with a higher MRSS, local skin score, and diffuse cutaneous involvement. Composite scores were not associated with SSc-related antibodies (data not shown) or treatment with immunosuppressive agents.

Examination of clinical correlates in the 14 SSc patients with a “normal-like signature” revealed that they had a significantly longer disease duration. In addition, a composite score for predicted activation of the Wnt/β-catenin pathway in our data set based on a previously published gene list (24) was calculated. Both the keratin and fibroinflammatory composite scores were significantly correlated with the Wnt/β-catenin composite scores ($r_s = 0.29$ [$P = 0.004$] and $r = 0.56$ [$P < 0.001$], respectively).

Analysis of cell type signature scores. As shown in Figure 3, the 1,604 overexpressed transcripts in SSc skin were enriched in genes specifically expressed in fibroblasts, macrophages, microvascular tissue, and DCs. Similarly, the 1,150 underexpressed transcripts were enriched in genes specifically expressed in lymphocytes (NK cells, CD4+ and CD8+ T cells, and B cells), and epidermis-related cell types (melanocytes, keratinocytes, and hair outer root sheath [ORS] cells). Again, calculation of cell type signature scores revealed significant heterogeneity across patients.

At the individual patient level (Figure 4), significantly higher scores were more frequently calculated for fibroblasts (72% of patients), indicating that genes specifically expressed in fibroblasts were increased in most of the biopsy specimens from patients with SSc (for additional information, see Supplementary Figure 10, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract). Similarly, in the majority of patients, we calculated significantly higher signature scores for microvascular and macrophage-related transcripts. Consistent with coexpression of fibrotic and inflammatory transcripts in our
unsupervised hierarchical clustering experiments, the majority of samples with significantly higher fibroblast scores (35 of 44 [80%]) had significant macrophage and/or DC scores. Furthermore, the top cell-based profiles correlating with the fibroinflammatory signature in the initial clustering (Figure 2) were macrophage genes ($r = 0.75$, $P < 0.005$) and fibroblast genes ($r = 0.68$, $P < 0.001$). There was also a subgroup of patients with elevated expression of hair ORS–specific genes; the top cell-based profiles correlating with the keratin signature in the initial clustering (Figure 2) were hair ORS genes ($r_s = 0.44$, $P < 0.001$) and keratinocyte genes ($r_s = 0.38$, $P < 0.001$).

Longitudinal progression of the keratin signature. In an exploratory investigation, we examined the longitudinal progression of the above-mentioned signatures (Figure 2) in 5 patients. The keratin signature increased numerically over time in the 2 patients with early disease (disease duration <2 years), while it declined numerically in the remainder of the patients (see Supplementary Figure 11, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract). The fibroinflammatory score showed less variation over time, although a downward trend over time was observed in the majority of samples (see Supplementary Figure 11). None of the observed changes reached statistical significance, which might be attributable to the small sample size ($n = 5$).

Immunohistochemical studies of the keratin signature. As shown in Figure 5, keratin 6 and keratin 16 staining in SSc skin samples (5 with a keratin signature) and matched controls was confined to hair follicles...
and eccrine sweat glands, whereas there was diffuse staining of the epidermis in a sample of psoriatic skin (positive controls). The keratin 85 staining was confined to hair matrix/precortex and hair cuticle in all 3 sample types (SSc, psoriasis, and controls) and was not present in the epidermis.

**DISCUSSION**

In the present study, we investigated the global gene expression profile in a large sample of patients with SSc and control subjects, using a comprehensive microarray platform to dissect the heterogeneity of transcriptome patterns in affected SSc skin. SSc skin samples showed prominent fibroinflammatory and keratin transcript profiles that correlated with certain disease features. Furthermore, we performed a cell-based modular analysis that showed substantial heterogeneity in the inflammatory profile of SSc skin. These findings may have important implications for identification of therapeutic targets and development of biomarkers.

A prominent fibroinflammatory signature correlating with the MRSS and the local skin score was present in the majority of SSc skin samples. Hierarchical clustering and cell type–specific signature scores indicated that inflammatory and fibrotic signatures coexist in most patients. As expected, the majority of patients in the current study (72%) displayed significant up-regulation of the fibroblast cell-type signature, while the overall inflammatory profile of SSc patients showed significant heterogeneity. This heterogeneity might provide important information for stratifying patients for targeted therapies and/or responses to general immunosuppression. The DC/macrophage modules were the most commonly up-regulated inflammatory modules (>50%), whereas NK cell, CD4, and CD8 T cell modules were up-regulated in only 10%, 18%, and 21% of cases, respectively. A similar analysis in psoriatic plaques revealed a more inflammatory and less fibrotic profile. In patients with psoriasis, the majority of samples displayed heightened macrophage, DC, NK cell, and CD8 T cell signatures, while only 9% of samples showed up-regulation of the fibroblast signature (25). This finding is also clinically plausible, because psoriatic plaques are more responsive to immunosuppression than is SSc skin.

Full-thickness skin biopsy specimens consist of a heterogeneous collection of cell types, each of which contributes to the aggregate expression measurement for any individual gene. However, few previous global gene expression studies in SSc skin have included analyses to relate the observed transcript heterogeneity to cell-specific signatures. Whitfield et al (10) measured gene expression in 11 different cell lines grown in culture that represent cell types likely to be present in skin. A comparison of the transcript profile of these cell lines with skin samples revealed that SSc skin had prominent dysregulation of fibroblast- and endothelial-related genes. Gardner et al (7) examined the gene expression profile of SSc skin and concomitantly collected explanted passage 4 fibroblasts. A comparison of skin and fibroblast transcriptomes showed that a subgroup of differentially expressed transcripts are likely to be of fibroblast origin, while other cell types were also required for full expression of the SSc phenotype. Composite scores for the cell-specific signatures were not calculated in either of those studies.

Pendergrass et al (17) also performed a cell type–specific analysis based on 2 previously published data sets (26,27). Similar to our analysis, a composite score was calculated for cell-based gene signatures. However, we have here calculated a rank-based signature score statistic while using a novel and large collection of data samples to identify signature genes for each cell type (25,28,29). Pendergrass et al also observed significant heterogeneity in the SSc skin inflammatory profile. However, a cross-comparison between their specific cell type signatures and our results is difficult, because the cell types were defined differently. Similar to our results, a prominent fibroblast signature in patient samples was observed. The most prominent inflammatory cell signature in the Pendergrass study was the granulocyte signature, while the macrophage signature was the most prominent inflammatory signature in our study. Those investigators also reported a combined signature for myeloid cells that was present in the majority of patients.

We also investigated the presence of previously described intrinsic inflammatory and fibrotic signatures (9,16,17) in our data set. A subset of SSc samples showed an increased coexpression pattern for the intrinsic inflammatory transcripts, but this was not observed for the intrinsic proliferative transcripts. In the present study, we not only included a larger number of patients but also investigated a substantially higher number of control subjects with a similar demographic background (36 control subjects in the present study versus 6–10 in previous studies [9,16,17]). This larger number increased the power to detect differentially expressed transcripts and better reflects the heterogeneity within each study population (patients and controls) during the clustering analysis. Furthermore, we used a platform that includes 54% more genes (30,500 versus 19,800), allowing us to perform a more comprehensive investigation of SSc skin. For example, only 55.1% of keratin signature genes were...
present in the previously used platform (16,17). Based on our results, it seems prudent to continue broader molecular profiling of SSc skin to characterize the transcript dysregulations most relevant for understanding disease mechanisms, creating subsets, identifying therapeutic targets, and developing biomarkers.

We observed a prominent keratin signature in SSc skin, which is a novel finding. Previous research mainly focused on molecular dysregulations in the dermal layer of SSc skin, although phenotypic changes in the skin such as hypopigmentation or hyperpigmentation also imply involvement of the epidermis (30). Previous studies have also indicated overexpression of the key cytokines TGFβ (31), monocyte chemotactic protein 1 (32), vascular endothelial growth factor (33), and interleukin-2 receptor (34) in SSc epidermis. A proteomic analysis of lesional scleroderma skin showed prominent dysregulation of proteins specific to epidermal differentiation in addition to those involved in extracellular matrix production and myofibroblast contractility (35). In a followup study, epidermal keratinocyte maturation was delayed, and an activation pattern with upregulation of keratin 6 and keratin 16 was observed in both clinically involved and uninvolved skin of patients with early dcSSc. Furthermore, coculture of epidermis from SSc patients and normal human fibroblasts promoted fibroblast contractility to the extent observed with TGFβ, while epidermis from healthy controls did not have a similar effect (36).

Similar to the above-mentioned study (36), the keratin transcript signature was present in involved and uninvolved skin in the present study. However, our immunohistochemical staining results did not indicate that the keratin signature that we observed was a marker of general activation of keratinocytes, as seen in psoriatic skin (25). Specifically, keratin 6 and keratin 16, both of which are usually expressed only in hair and eccrine sweat glands but show broad epidermal staining in diseases with general activation of keratinocytes (e.g., psoriasis), did not show a broad epidermal staining pattern in SSc patients with the keratin signature. The keratin signature consisted mainly of upregulation of hair- and adnexal structure–related keratins. Consistent with this notion, keratin 85 staining was confined to hair follicles and eccrine sweat glands. Of note, we do not believe that the observed keratin signature is due to the higher number of hair follicles in SSc patients, because the same anatomic site was biopsied in patients and controls. Furthermore, there was no association between the keratin signature and male sex.

The observed association between the keratin signature and shorter disease duration supports the notion that this transcript profile is a time-dependent occurrence. The observed keratin signature might be a response of the hair follicle to the molecular changes in SSc skin. Hair follicle morphogenesis and growth are regulated through complex and reciprocal epithelial mesenchymal interactions. The dermal papilla is essential for follicle formation in the embryo and for initiating the next period of hair growth in adults (37). Activation of Wnt/β-catenin signaling is an important stimulator of new hair growth and differentiation (38–40). In our data set, the keratin signature correlated with the predicted activation of the Wnt/β-catenin pathway, supporting the notion that the up-regulation of this pathway in SSc (41) might contribute to the observed keratin signature. The observed association of the keratin signature with ILD might also stem from common upstream regulators for ILD and this transcript signature. Further studies are needed to investigate the potential role of this signature in the pathogenesis of SSc. In general, our results provide further evidence for the presence of molecular dysregulation in several skin compartments (not only dermis) in SSc.

Similar to what was observed in previous studies, a subset of patients showed normal-like gene expression profiles (7,9,16,17). These patients had a significantly longer disease duration, and a trend for association of a normal-like signature with longer disease duration was observed in a previous SSc skin data set (17). This finding is also supported by the decreasing composite fibroinflammatory scores observed in our pilot longitudinal study (see Supplementary Figure 11, available on the Arthritis & Rheumatology web site at http://online library.wiley.com/doi/10.1002/art.39289/abstract). Patients with a normal-like transcript profile also tended to have milder disease (lower MRSS and lower skin score at the biopsy site), although these findings did not reach statistical significance.

Patients in whom skin at the biopsy site was affected were more likely to have a distinct gene expression profile and a higher composite fibroinflammatory score. However, we were unable to compare the gene expression profile of skin biopsy specimens obtained from 1 affected area (e.g., the arm) and 1 unaffected area (usually the buttock or back) in the same individual, because biopsies of the buttocks area were not performed in our study. Furthermore, the number of differentially expressed genes in clinically affected versus unaffected SSc skin was substantially lower than the number of transcripts in affected SSc skin versus control skin, indicating substantial heterogeneity in the group with unaffected SSc skin. It is likely that a subgroup of
SSc patients with clinically unaffected skin have histologic changes characteristic of SSc.

In conclusion, this large global SSc skin gene expression study indicated the presence of prominent fibroinflammatory and keratin profiles. A subset of patients with a longer disease duration had a normal-like gene expression profile. Furthermore, analysis of cell type–specific signature scores revealed significant heterogeneity in the inflammatory profile of SSc skin, which might provide important information for stratifying patients to enable targeted therapies and to predict the response to immunosuppression.

ACKNOWLEDGMENTS

We thank Dr. Samuel Theodore for his assistance with the data collection and Julio Charles for performing the laboratory experiments. We are also grateful to Professor Lutz Langbein (University of Heidelberg, Germany) for providing the KRT85 antibodies.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Assassi had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Assassi, Tan, Forst, Mayes, Gudjonsson, Chang.

Acquisition of data. Assassi, Tan, Khamma, Forst, Tashkin, Mayes.


REFERENCES

15. Swindell WR, Johnston A, Voorhees JJ, Elder JT, Gudjonsson JE. Dissecting the psoriasis transcriptome: inflammatory- and


38. Lo CC, Prowse DM, Watt FM. Transient activation of β-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours. Development 2004;131:1787–99.


Antinuclear Antibody Negative Systemic Sclerosis

GA Salazar\textsuperscript{a}, S Assassi\textsuperscript{a}, F Wigley\textsuperscript{b}, L Hummers\textsuperscript{b}, J Varga\textsuperscript{c}, M Hinchcliff\textsuperscript{c}, D Khanna\textsuperscript{d}, E Schiopu\textsuperscript{d}, K Phillips\textsuperscript{d}, DE Furst\textsuperscript{e}, V Steen\textsuperscript{f}, M Baron\textsuperscript{g}, M Hudson\textsuperscript{g}, SS Taillefer\textsuperscript{g}, J Pope\textsuperscript{h}, N Jones\textsuperscript{i}, P Docherty\textsuperscript{j}, NA Khalidi\textsuperscript{k}, D Robinson\textsuperscript{l}, R Simms\textsuperscript{m}, R Silver\textsuperscript{m}, TM Frech\textsuperscript{m}, B Fessler\textsuperscript{o}, J Molitor\textsuperscript{q}, M Fritzier\textsuperscript{q}, B Segal\textsuperscript{q}, F Al-Kassab\textsuperscript{a}, M Perry\textsuperscript{a}, J Yang\textsuperscript{a}, S Zamanian\textsuperscript{a}, JD Reveille\textsuperscript{a}, FC Arnett\textsuperscript{b}, C Pedroza\textsuperscript{a}, and MD Mayes\textsuperscript{a}

\textsuperscript{a}University of Texas Medical School at Houston, Division of Rheumatology. 6431 Fannin St. MSB 5.270, Houston TX 77030, USA

\textsuperscript{b}Johns Hopkins University. 5501 Hopkins Bayview Circle. Asthma and Allergy Center. Baltimore, MD 21224, USA

\textsuperscript{c}Feinberg School of Medicine. Northwestern University. Dept. of Medicine. 251 E Huron St Galter Suite 3–150. Chicago, IL 60611. USA

\textsuperscript{d}University of Michigan. Division of Rheumatology. Taubman Center Floor 3 Reception A. 1500 E Medical Center Dr SPC 5370. Ann Arbor, MI 48109. USA

\textsuperscript{e}University of California Los Angeles. Division of Rheumatology. Box 951670, 32–59. Rehab. Los Angeles, CA 90095-1670. USA

\textsuperscript{f}Georgetown University Medical Center. Division of Rheumatology. 4000 Reservoir Road NW, Washington, DC 20007, USA

\textsuperscript{g}McGill University, Division of Rheumatology. Jewish General Hospital. Suite A 725 3755 Cote St, Catherine Rd Montreal QC H3T 1E2. Canada


\textsuperscript{i}University of Alberta, Canada. Rheumatology 10839 124\textsuperscript{th} St. NW Edmonton AB T5M 0H4. Canada

\textsuperscript{j}The Moncton Hospital. South East Regional Health Authority. 135 Macbeath Avenue. Moncton NB E1C 6Z8. Canada

\textsuperscript{k}McMaster University. Internal Medicine/Rheumatology. 25 Charlton Ave East, Suite 708. Hamilton ON L8N 1Y2. Canada
Abstract

Objective—To examine the demographic and clinical characteristics of systemic sclerosis (SSc) patients without antinuclear antibodies (ANA) compared to ANA positive patients.

Methods—SSc patients enrolled in the Scleroderma Family Registry and DNA Repository were included. Relevant demographic and clinical data were entered by participating sites or obtained by chart review. ANA and SSc related antibodies were determined in all investigated patients using commercially available kits at our laboratories.

Results—This study included 3249 patients, of whom 208 (6.4%) were ANA negative. The proportion of male patients was higher in the ANA negative group (OR 1.65; p=0.008). ANA negative patients experienced less vasculopathic manifestations of SSc. The percent predicted diffusing capacity of carbon monoxide (DLco) was higher in ANA negative patients (p=0.03). Pulmonary arterial hypertension (PAH) per right heart catheterization was less common in the ANA negative group (OR= 0.28; p=0.03). Furthermore, patients with negative ANA had a lower prevalence of telangiectasias and digital ulcers/pits (OR= 0.59; p=0.03 and OR=0.38; p=0.01, respectively). Although diffuse cutaneous involvement was more common, the modified Rodnan Skin Score (mRSS) was lower in the ANA negative group (2.4 points lower, p=0.05). Furthermore, they experienced more malabsorption (p=0.05). There was no difference in the frequency of pulmonary fibrosis or scleroderma renal crisis. All-cause mortality was not different between the two groups (p=0.28).

Conclusions—In conclusion, the results of this study suggest that SSc patients who are ANA negative constitute a distinct subset of SSc with less vasculopathy (less PAH, digital ulcers and fewer telangiectasias), a greater proportion of males and possibly, more frequent lower gastrointestinal involvement.
1. Introduction

Systemic Sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin and internal organs, as well as vasculopathy and immune dysregulation. SSc is a clinically heterogeneous disease that can range from limited skin involvement and minimal internal organ disease to rapidly progressive organ involvement and skin fibrosis resulting in premature death.

Autoantibody formation is one of the hallmarks of SSc. Several studies have shown that the autoantibodies found in patients with SSc carry considerable value in diagnosis and in predicting various clinical outcomes [1–4]. Although SSc related autoantibodies are associated with specific genotypes as well as characteristic clinical manifestations, the role of ANA antibodies and its subsets in the pathogenesis of SSc is unclear. While the great majority of patients with SSc have circulating antinuclear antibodies (ANA) (90–95%), a small percentage of patients are ANA negative (5–10%) [1, 2]. Although the typical clinical presentations of the different subsets of ANA positive patients have been extensively examined, the detailed demographic and clinical characteristics of patients without detectable ANA have not been clearly explored.

The purpose of this study was exploratory and to describe the clinical manifestations of this SSc subgroup by determining their clinical and demographic differences compared to ANA positive patients. Our hypothesis was that ANA negative patients are a subgroup of SSc with a distinct clinical presentation.

2. Patients and Methods

2.1 Study population

Patient information was obtained from the Scleroderma Family Registry and DNA Repository [5] database. Patients were recruited at the University of Texas – Houston and from the following participating sites including: the participating Canadian Scleroderma Research Group (CSRG) sites, University of California Los Angeles, University of Michigan, Georgetown University, Boston University, Medical University of South Carolina, Johns Hopkins University, University of Utah, Northwestern University, University of Alabama Birmingham and University of Minnesota. All patients that agreed to be enrolled in the National Scleroderma Family Registry and DNA Repository at the participating sites were included in the current study. Of note, 390 of the Canadian patients included in our study were also investigated in a recently published study that investigated the frequency of autoantibody negative SSc patients constituting a small overlap of 12% in the study population between these two studies [6].

All study patients fulfilled the 1983 American College of Rheumatology preliminary criteria for SSc [7] or had ≥3 of the 5 clinical features of the CREST syndrome (Calcinosis, Raynaud’s phenomenon, Esophageal dysfunction, Sclerodactyly or Telangiectasias) with sclerodactyly being mandatory [8].
2.2 Autoantibodies

Presence of antinuclear antibodies (ANA) was investigated in all patients at the time of enrollment using indirect immunofluorescence on HEp-2 cells as the antigen substrate in the Rheumatology laboratory of the University of Texas Health Science Center at Houston. A titer of >1:80 was considered positive. All ANA titers and patterns were determined by the same investigator (FCA). Anticentromere antibodies (ACA) were determined by the pattern of immunofluorescence staining on HEp-2 cells. Antitopoisoamerase antibodies (anti-topo), anti-U1-RNP (RNP), anti-SSA (anti-Ro60) and anti-SSB (anti-La) were determined by passive immunodiffusion against calf thymus extract with commercial kits (Inova Diagnostics, San Diego, CA, USA). Anti-RNA polymerase III (RNA Pol-III) antibodies were determined by enzyme-linked immunosorbent assay (MBL, Co. Ltd, Nagoya, Japan). To be considered ANA negative both the ANA and all other autoantibodies listed above had to be negative. The comparison group was defined as patients with a positive ANA.

A repeat ANA testing was performed in a subgroup of ANA negative patients from whom a follow-up serum sample was available (n=19). Only one patient became positive after repeat testing, this patient was excluded from the analysis.

2.3 Clinical manifestations

Cross-sectional demographic and clinical data were entered directly or captured from medical records utilizing a standard abstract form. Clinical manifestations were entered based on the findings of latest clinic visit.

Age, sex, disease type, disease duration (calculated from the onset of both Raynaud’s and the first non-Raynaud’s phenomenon symptom attributable to SSc), and modified Rodnan skin score (mRSS) at the time of study entry, were recorded. Disease type (limited cutaneous versus diffuse cutaneous SSc) was defined based on the extent of skin involvement as assessed by the physician upon enrollment.

Malabsorption was defined as diarrhea associated with >10% loss of body weight. Scleroderma renal crisis was defined as accelerated hypertension, rapidly progressive renal insufficiency and/or microangiopathic hemolysis. Electrocardiography and 2-dimensional echocardiography findings were recorded and were used to determine the presence of pericarditis or clinically significant pericardial effusion.

Interstitial lung disease (ILD) was defined as imaging changes consistent with scleroderma-related fibrosis including honeycombing, increased interstitial markings or ground glass opacity on chest radiograph, chest computed tomography (CT) or high resolution CT (HRCT) of the chest and restrictive lung disease indicative of ILD was determined when the forced vital capacity (FVC) predicted value was <70%. Only 35 patients or 3% of the 1098 that were classified as having ILD by these means had an FEV1 (forced expiratory volume) to FVC ratio below 0.7 indicative of a possible obstructive process. These patients were excluded from the ILD analyses to prevent misclassification.

Pulmonary arterial hypertension (PAH) was defined by mean pulmonary artery pressure ≥25 mm Hg on right heart catheterization (RHC) with pulmonary wedge pressure <15.
Pulmonary Hypertension (PH) was defined as a right ventricular systolic pressure (RVSP) ≥ 50 mm Hg on 2-dimensional echocardiography when RHC was not available; this cut-off value was chosen because previous studies have shown RVSP >50 corresponds most reliably to pulmonary hypertension on RHC [10, 11].

Not all enrolled patients underwent all diagnostic studies reflecting the practice pattern of participating sites and individual physicians. Specifically, pulmonary function test results were available for analysis in 2624 cases, whereas echocardiogram was available for 1356 patients. When more than one echocardiogram was available the highest measurement was recorded. Chest imaging (chest X-ray, chest CT, or HRCT) was available in 756, 400 and 754 patients respectively. Right heart catheterization (RHC) was performed when clinically indicated in 415 patients, 381 were ANA positive and 31 were ANA negative.

2.4 Vital Status

A vital status search was performed only in patients that were enrolled at the University of Texas - Houston for whom personal identifiers were available. The vital status of these 1475 patients was determined by the National Death Index (NDI), at Centers for Disease Control and Prevention (CDCP) and the online Social Security Death Index (SSDI). The ascertainment of vital status was complete based on the available information in the above mentioned data bases. The censoring date was January 30th 2013.

All study subjects provided written informed consent and the study was approved by all participating sites.

3. Data Analysis

Analysis was carried out using STATA 12 (Statacorp LP, College Station, TX, USA) statistical package. Clinical manifestations were considered the outcome (dependent) variables and ANA status was the independent variable. Initial comparisons were conducted by chi-square or t-test depending on whether the outcome being analyzed was categorical or continuous, respectively.

Multivariable analysis adjusting for potential confounders, specifically age at enrollment, disease duration, disease type (limited or diffuse cutaneous disease) and gender was performed. The same confounding variables were used for all multivariable analysis. Linear regression was used for continuous variables while logistic regression was used for the categorical. The results were adjusted for multiple comparisons using the False Discovery Rate (FDR) or Benjamini-Hochberg <5% adjustment method. The FDR method was used because several independent variables such as markers of pulmonary hypertension were not independent from each other.

All-cause mortality analysis with disease onset as the starting point was performed by Cox proportional-hazards regression and was graphically depicted by Kaplan-Meier survival curve.
4. Results

4.1 Demographic characteristics

A total of 3249 patients were included in this study, of whom 208 (6.4%) were ANA negative. Table 1 shows the demographic and basic clinical characteristics of patients with and without ANA antibodies. There was no difference for mean age at disease onset which was 44 years for both groups. When considering the onset of Raynaud’s phenomenon as the starting point for disease onset there was still no significant difference for mean age at disease onset. There were more males in the ANA negative group. No differences were observed in the ethnic composition between the two groups.

4.2 Clinical Characteristics

The mean disease duration from non-Raynaud’s phenomenon onset to diagnosis was 1.9 years for ANA negative and 2.2 years for ANA positives patients. The mean disease duration from Raynaud’s phenomenon onset to diagnosis and the average disease duration from SSC onset (non-Raynaud’s phenomenon) to study entry were not different between the two groups (Table 1). Similar findings for this analysis were observed if the disease duration was measured from Raynaud’s phenomenon onset (12 years for ANA positive and 13 for ANA negative, \( p=0.20 \)). ANA negative patients had a higher proportion of diffuse skin involvement than their ANA positive counterparts (Table 1). The severity of skin involvement as evaluated by the modified Rodnan skin score (mRSS) was not different in the initial comparison (Table 2). Although ANA negatives had a higher percentage of patients with diffuse skin involvement, the multivariable analysis adjusting for potential confounders including disease type (plus age at enrollment, disease duration, and gender) showed that the fibrosis severity as measured by mRSS was lower in the in the ANA negative group (Table 3).

The FVC % predicted was lower in ANA negative patients; however, the multivariable analysis adjusting for the above mentioned confounders failed to show a significant difference (Table 3). The DLco % predicted was higher in the ANA negative patients (Table 2). Pulmonary arterial hypertension (PAH) verified by right heart catheterization (RHC) was significantly less common in the ANA negative group (Table 2). Only 7 ANA negative patients had PAH compared to 213 ANA positive patients.

When patients who had PAH diagnosed per RHC and patients that did not have a RHC but had an RVSP>50 mmHg per echocardiogram were included in the analysis, a total of 2040 patients were analyzed (1907 were ANA positive and 133 were ANA negative). In this analysis, we again observed a statistically significant difference between the two groups for pulmonary hypertension (PH) (Table 2).

After adjusting for potential confounders (disease type, age at enrollment, disease duration, and gender), the difference in prevalence of PAH by RHC between the two groups remained statistically significant (Table 3). When centromere antibody status was added to the model, the relationship was still significant (\( p=0.009 \)). PH (per RHC or RVSP>50) was also statistically significant in the multivariable model but the level of significance was not sustained after adjusting for multiple comparisons (Table 3). ANA negative patients were
found to have a lower prevalence of telangiectasias and digital ulcers/pits (Table 2). As shown in Table 3, these differences remained significant in the multivariable model.

ANA negative patients experienced more malabsorption (Table 2). This finding remained significant in the multivariable analysis (Table 3).

There was no difference in creatine kinase (CK) levels, fibrotic changes per chest imaging or ejection fraction by echocardiogram (LVEF<50%) between the two groups. Also no difference was observed for the presence of Raynaud’s phenomenon, GERD or calcinosis. Of note, there were no cases of primary biliary cirrhosis (PBC) in the ANA negative group and 12 in the ANA positive group but this finding did not reach statistical significance.

Ten patients had scleroderma renal crisis (SRC) in the ANA negative group. While the ANA status (negative versus positive) was not associated with higher occurrence of SRC in the overall cohort, ANA negative patients were more likely to develop SRC than patients with anti-topo or ACA (OR= 3.83, CI 1.49–9.84, p=0.005 and OR= 11.86, CI 3.68–38.22, p<0.001, respectively). Only RNA-polymerase III, which is a well-known risk for SRC, was associated with a higher risk compared to the ANA negative group (OR 4.87; CI=3.19–7.44; p<0.001) after adjusting for confounders).

### 4.3 Survival Analysis

Among 1475 patients in whom a death search could be performed, 300 had died. The ANA status was not associated with overall mortality either in the univariable or the multivariable analysis. The univariable analysis showed a hazard ratio (HR) 0.96 (CI 0.62–1.49, p=0.87). Multivariable analysis correcting for potential confounders resulted in a HR=0.83 (CI 0.53–1.30, p=0.42). Kaplan-Meier survivor function is shown in figure 1.

### 4.4 ANA follow up

Nineteen ANA negative patients in our database had a follow-up serum sample. The repeat ANA was performed at a mean of 4.5 years after the initial determination (SD 4.3 years). Out of these, only one patient who was initially ANA negative seroconverted to ANA positive upon follow-up testing. The pattern was atypical (few bright speckles).

### 5. Discussion

This study is the first to specifically focus on the demographic and clinical features of ANA negative SSc in a large and diverse sample of patients. Our study was of sufficient size for statistical analysis and our survival cohort was also larger than published cohorts to date. We observed that ANA negative patients represent a distinct subset of patients who have the fibrotic features of SSc but are less likely to have the vasculopathic features of the disease.

We observed that PAH and clinical markers of vasculopathy such as digital ulcerations and telangiectasias were less common in ANA negative patients.

Our findings show that, although SSc is relatively uncommon in males, ANA negative patients in our study were more commonly male. The ANA negative patients might also have a higher frequency of malabsorption.
Only a few studies have previously described some of the clinical characteristics of ANA negative patients. Hamaguchi et al delineated the clinical manifestations of SSC patients based on antibody subsets and included 203 Japanese SSC patients, 10 of whom were ANA negative (5% of their sample) [12]. They reported lower severity of skin involvement, rare incidence of PAH, ILD and pitting scars (one patient each) in the ANA negative group.

The German network for SSC published a study focusing on the correlation of clinical features and the different antibody subsets [13]. Within their sample of 863 patients, 50 (5.8%) were ANA negative. In their study, ANA negative cases had significantly less frequent PAH, digital ulcers and Raynaud’s phenomenon.

More recently Hudson et al published their observations on autoantibody negative SSC in the CSRG cohort [6]. Their sample included 874 patients. They divided their patients into groups based on their ANA and/or ENA (Extractable Nuclear Antigens) status as positive (+) versus negative (−). ENA antibodies also included cytoplasmic antibodies. This resulted in 3 different study groups (group 1: ANA+/ENA+, group 2: ANA+/ENA− and group 3: ANA−/ENA−). Their sample included 15 patients (1.7%) who were autoantibody negative (group 3). Three hundred ninety of the patients examined in our study were also studied by Hudson et al, indicating a small overlap of 12% in the study population between our studies. Only univariable comparisons without correction for potential confounders were performed due to sample size limitations and were done between the ANA+/ENA− group and the remaining two groups separately. They reported lower prevalence of Raynaud’s phenomenon and telangiectasias in the autoantibody negative group. They did not observe any other clinical differences, possibly due to sample size limitations or differences in the study design.

Despite the small overlap with this last study (390 patients), thanks to our multi-institutional international effort our cohort was able to support a more in depth analysis and represents the largest sample of ANA negative SSC patients described in the literature to date. The data collected from this endeavor enabled us to conduct for the first time, robust clinical correlations given the significantly larger sample size, wider geographic catchment area and multi-ethnic population. Encouragingly the results of the above mentioned studies support several of our findings. Similar to our results, these studies indicate that ANA negative patients have less often vasculopathic features of disease.

The association of SSC vasculopathic features with ANA positivity might have pathophysiological implications. This relationship was still present after correcting for ACA which has been associated with susceptibility to PAH. Therefore any circulating ANA is potentially a risk for PAH compared to the absence of ANA. Our analysis showed a significant difference for overall markers of vasculopathy in ANA positive compared to ANA negative patients including PAH, telangiectasias and digital ulcers/pits. A correlation between PAH and telangiectasias was previously described by Shah et al which supports the notion that vasculopathic features tend to occur together and that there is a subgroup of patients who have more vasculopathy [14].
Several studies have described the relationship of specific antinuclear antibodies including ACA, RNP and Th/To to the presence of PAH. More recently, Nihtyanova et al also reported an association between PAH and RNA-polymerase III antibody positivity.\[15\] The relationship of ACA with digital ulcers, telangiectasias and microvascular damage per capillaroscopy has also been observed \[1–3, 16–18\]. However, the pathophysiologic role of these antibodies has not been determined (direct cause of vascular damage, or an epiphenomenon). It is also possible that ANA negative patients have other antibodies that are not currently detected by our traditional assays causing the observed clinical differences or that the ANAs are associated with other antibodies that are causing the vascular damage. Studies designed to understand the pathophysiology of this important manifestation of SSc are needed.

Several studies have linked autoantibody production with genetics in SSc. Multiple polymorphisms in the human leukocyte (HLA) regions have been linked to SSc and the association of some of the class II haplotypes with the different ANA subsets has been described \[19–21\]. Also familial SSc studies have shown a concordance of autoantibodies between family members \[22, 23\]. Although the relationship between ANA and the genetic background has been studied, the genetics of the ANA negative subgroup are not known. The discovery that these patients are more commonly male underlines the importance of exploring the genetics of this subset. If genetics do not play a role than other causes for the observed clinical differences such as hormonal changes or differentially expressed epigenetic mechanisms by gender should be considered.

ANA negative patients have a lower frequency of PAH which is a common cause of mortality for SSc patients; however their all-cause mortality was not different. This could be due to severe GI involvement or ILD. Dedicated longitudinal prospective studies are needed to analyze this finding in more detail. We considered the possibility of detection bias in our study given that ANA negative SSc is rare and can be easily missed unless clinically evident, but this would have biased toward female sex, longer disease duration before diagnosis and diffuse disease. We observed more diffuse disease in the ANA negative group. However, the severity of skin fibrosis as measured by mRSS was lower in the multivariable analysis that included adjustment for disease type. Interestingly, the ANA negative group did not have longer time to diagnosis as we expected, and had a higher proportion of males. It is also important to mention that although RHC was obtained for only a subgroup of patients which could arguably bias the results of our analysis, we observed that the proportion of ANA negative and positive patients was not statistically different between the patients that had a RHC versus the patients that did not have one (7% vs 6% in ANA negatives and 92% vs 93% in ANA positives, \(p=0.4\)).

Taken together, these data support the concept that ANA negative SSc patients are a subgroup of patients with distinct demographic and clinical manifestations. Further prospective clinical studies as well as genetic studies examining this subpopulation of patients are warranted. Also studies examining the pathophysiologic link between ANAs and vasculopathy in SSc should be considered.
The ANA negativity appears stable over time, as almost all patients in a follow-up subset of the original cohort that had an initial negative determination remained negative for up to 14 years when retested. Only one patient that was initially negative became positive upon follow up. The repeated ANA had an IIF pattern of few bright speckles also known as NSp-I or “multiple nuclear dots” (MND).\[24, 25\] Among a variety of potential MND targets, this pattern was seen in patients with sp100 antibodies, which are very specific for primary biliary cirrhosis (PBC) \[26, 27\]. However this particular patient has not developed PBC up until now. We acknowledge that longitudinal data were only available in a small subgroup of ANA negative patients. Nevertheless, we believe this limited longitudinal study provides important pilot data on stability of ANA negativity over time, which needs to be verified in larger follow-up studies.

The present study has some limitations. Reflecting the practice patterns of treating physicians, the data on clinical manifestations and diagnostic studies were not available in all patients. Furthermore, the diagnostic tests and basic laboratory studies were done at different centers. Although the data collection and patient inclusion for this study was performed before the 2013 ACR/EULAR classification criteria were published, we set out to determine how many of our patients fulfilled these criteria. Based on the available data, we were able to classify 97.5 percent of our sample. However our data does not include capillaroscopy information for all the participating sites therefore we cannot make assumptions on the 80 remaining patients which were not classified.

It is possible that some of the observed associations are false-positive findings; however, almost all the statistically significant differences observed remained significant after adjusting our analysis for multiple comparisons. Furthermore, we observed negative associations with several independent vasculopathic features supporting the notion that these associations are true biological findings rather than random spurious results.

As this is a cross-sectional study, the information on highest ever mRSS was not available. We could not investigate cause-specific mortality and prevalence of malignancy as this information was not captured in our data base. The paucity of data on chemical studies to clearly define malabsorption is also a limitation. Although we realize that our definition of malabsorption was relatively non-specific and did not include measures of bacterial overgrowth, stool fat measurements or laboratory tests for malabsorption such as carotene, we feel that clinically significant weight loss along with diarrhea is a reasonable surrogate. Moreover although the survival analysis was performed only on patients who were enrolled at UT Houston (due to lack of personal identifiers in our data base for those enrolled at other centers), we do not think this introduces a systemic bias as the percentage of ANA negative patients was not different between the patients who had mortality data available and the patients who did not (6.8% vs 5.9%, \(p=0.3\)). Finally, we cannot report on percentage of patients who were ANA positive at a lower titer (i.e. 1:40) because this was not examined in our laboratory.

The strengths of the current study are that the ANA testing was centrally performed and read by the same investigator and our large sample which is multi-ethnic and representative of
the SSc population across a wide geographic area in the United States and Canada. Finally, this sample includes the largest ANA negative SSc sample reported to date.

6. Conclusion

In conclusion, the results of this study suggest that SSc patients who are ANA negative constitute a distinct subset of SSc with less vasculopathy (less PAH, digital ulcers and fewer telangiectasias), a greater proportion of males and possibly, more frequent lower gastrointestinal involvement.

It is important to understand the clinical characteristics and genetics of ANA negative patients with SSc because this will allow further understanding the role of ANA in the pathophysiology of SSc.

Acknowledgments

We would like to thank Tony Mattar for his assistance in the database management, Julio Charles for performing the IIF laboratory studies and all the participating sites including: the Canadian Scleroderma Research Group, University of California Los Angeles, University of Michigan, Georgetown University, Boston University, Medical University of South Carolina, Johns Hopkins University, University of Utah, Northwestern University, University of Alabama Birmingham and University of Minnesota. We would also like to thank and acknowledge the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health and the Department of Defense for their support of our centers to accomplish this study. NIH/NIAMS K23 AR061436 (Assassi); NIH/NIAMS N01-AR-0-2251 (Mayes); NIH/NIAMS K24 AR063120-02 (Khanna); NIH/NIAMS-R01-AR055258; NIH/NIAMS P50-AR05414; U01AI09099-01 (Mayes) and the Department of Defense Congressionally Directed Medical Research Programs (W81XWH-07-01-0111-Mayes). Finally, we would like to extend a special acknowledgement to the late Dr. Janet Markland who contributed to this project. We would like to recognize her not only for her participation in this study but also for being a part of the effort to advance scleroderma research.

References


Figure 1.
Kaplan-Meier survivor function of ANA negative SSc patients compared to ANA positive patients

$\text{p}=0.87$

$\text{HR}=0.96 \ (CI \ 0.62-1.49)$
Table 1
Analysis of demographic and basic clinical parameters in systemic sclerosis (SSc) patients who are ANA negative compared with ANA positive patients.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>ANA negative (n=208)</th>
<th>ANA positive (n=3041)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at disease onset, mean +SD years</td>
<td>44.7+13.7</td>
<td>44.6+13.5</td>
<td>0.97</td>
</tr>
<tr>
<td>Disease duration to diagnosis, mean +SD</td>
<td>1.9+3.6</td>
<td>2.2+4.0</td>
<td>0.43</td>
</tr>
<tr>
<td>Disease duration to enrollment, median (IQR)</td>
<td>7.8(11.64)</td>
<td>6.9(10.99)</td>
<td>0.10</td>
</tr>
<tr>
<td>Gender (male),%</td>
<td>41(19.7)</td>
<td>402(13.2)</td>
<td>0.008</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian,%</td>
<td>182(88.3)</td>
<td>2516(83.7)</td>
<td>0.07</td>
</tr>
<tr>
<td>African American,%</td>
<td>12(5.8)</td>
<td>221(7.3)</td>
<td>0.41</td>
</tr>
<tr>
<td>Hispanic,%</td>
<td>10(4.8)</td>
<td>204(6.7)</td>
<td>0.28</td>
</tr>
<tr>
<td>Asian,%</td>
<td>1(0.4)</td>
<td>42(1.4)</td>
<td>0.27</td>
</tr>
<tr>
<td>American Indian,%</td>
<td>1(0.4)</td>
<td>23(0.7)</td>
<td>0.65</td>
</tr>
<tr>
<td>Unknown or mixed,%</td>
<td>2(0.09)</td>
<td>35 (1.2)</td>
<td>0.78</td>
</tr>
<tr>
<td>Disease type (diffuse),%</td>
<td>105(49.8)</td>
<td>1240(40.1)</td>
<td>0.007</td>
</tr>
</tbody>
</table>
Comparisons of clinical parameters in systemic sclerosis (SSc) patients who are ANA negative versus ANA positive.

<table>
<thead>
<tr>
<th></th>
<th>ANA negative (n=208)</th>
<th>ANA positive (n=3041)</th>
<th>OR $^a$</th>
<th>b coef $^a$</th>
<th>95% CI</th>
<th>$p$</th>
<th>Adjusted $P$*</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRSS, mean +SD</td>
<td>12 (10)</td>
<td>11 (10)</td>
<td>N/A</td>
<td>0.25</td>
<td>−2.25, 2.77</td>
<td>0.84</td>
<td>0.85</td>
</tr>
<tr>
<td>Telangiectasias,%</td>
<td>71/114 (62)</td>
<td>1505/2061 (73)</td>
<td>0.60</td>
<td>N/A</td>
<td>0.41, 0.91</td>
<td>0.01</td>
<td>0.03</td>
</tr>
<tr>
<td>Digital ulcers and pits,%</td>
<td>41/105 (39)</td>
<td>1088/1925 (56)</td>
<td>0.49</td>
<td>N/A</td>
<td>0.32, 0.73</td>
<td>0.001</td>
<td>0.008</td>
</tr>
<tr>
<td>Calcinosis,%</td>
<td>26/95 (27)</td>
<td>518/1791 (28)</td>
<td>0.92</td>
<td>N/A</td>
<td>0.58, 1.47</td>
<td>0.74</td>
<td>0.85</td>
</tr>
<tr>
<td>FVC%, mean +SD</td>
<td>80.6±21.7</td>
<td>84.1±19.4</td>
<td>N/A</td>
<td>−3.5</td>
<td>−6.69, −0.44</td>
<td>0.02</td>
<td>0.04</td>
</tr>
<tr>
<td>DLCO%, mean +SD</td>
<td>72±25</td>
<td>68±22</td>
<td>N/A</td>
<td>4.02</td>
<td>0.25, 7.8</td>
<td>0.03</td>
<td>0.05</td>
</tr>
<tr>
<td>Fibrosis per imaging,%</td>
<td>50/67 (74)</td>
<td>716/1102 (64)</td>
<td>1.66</td>
<td>N/A</td>
<td>0.93, 2.96</td>
<td>0.08</td>
<td>0.13</td>
</tr>
<tr>
<td>MPAP per RHC, mean +SD</td>
<td>23.4±18</td>
<td>29.4±13</td>
<td>N/A</td>
<td>−6.20</td>
<td>−11.30, −1.10</td>
<td>0.01</td>
<td>0.03</td>
</tr>
<tr>
<td>PAH per RHC,%</td>
<td>7/31 (22.5)</td>
<td>221/405 (55.4)</td>
<td>0.23</td>
<td>N/A</td>
<td>0.09, 0.55</td>
<td>&lt;0.001</td>
<td>0.008</td>
</tr>
<tr>
<td>PH (per RHC and/or RVSP&gt;50),%</td>
<td>13/133 (9.7)</td>
<td>332/1907 (17.4)</td>
<td>0.51</td>
<td>N/A</td>
<td>0.28, 0.92</td>
<td>0.02</td>
<td>0.04</td>
</tr>
<tr>
<td>GERD,%</td>
<td>116/130 (89)</td>
<td>1834/2144 (85)</td>
<td>1.40</td>
<td>N/A</td>
<td>0.79, 2.47</td>
<td>0.24</td>
<td>0.36</td>
</tr>
<tr>
<td>Malabsorption,%</td>
<td>48/94 (51)</td>
<td>576/1597 (36)</td>
<td>1.84</td>
<td>N/A</td>
<td>1.21, 2.80</td>
<td>0.004</td>
<td>0.02</td>
</tr>
<tr>
<td>CK, mean +SD</td>
<td>249 (309)</td>
<td>209 (704)</td>
<td>N/A</td>
<td>39.34</td>
<td>−380, 429</td>
<td>0.85</td>
<td>0.85</td>
</tr>
<tr>
<td>Renal crisis,%</td>
<td>10/208 (4.8)</td>
<td>103/3041 (3.3)</td>
<td>1.44</td>
<td>N/A</td>
<td>0.74, 2.8</td>
<td>0.28</td>
<td>0.38</td>
</tr>
<tr>
<td>Low LVEF(&lt;50), %</td>
<td>4/106 (3.7)</td>
<td>39/1614 (2.4)</td>
<td>1.58</td>
<td>N/A</td>
<td>0.55, 4.51</td>
<td>0.39</td>
<td>0.48</td>
</tr>
</tbody>
</table>

Abbreviations: ANA= antinuclear antibodies, mRSS= modified Rodnan skin score, FVC= Forced vital capacity, DLCO= diffusing capacity of carbon monoxide, PAH= Pulmonary arterial hypertension, PH= Pulmonary Hypertension, MPAP= Mean pulmonary artery pressure, RHC= Right heart catheterization, RVSP= Right ventricular systolic pressure, GERD= Gastroesophageal reflux disease, CK= creatine kinase, LVEF= Left ventricular ejection fraction. OR =odds ratio; b coef= b coefficient; 95% CI=95% confidence interval; SD= standard deviation.

$^a$Linear regression was used for continuous data; logistic regression was used for categorical data

*After False Discovery Rate (FDR) or Benjamini-Hochberg adjustment method for multiple comparisons.
**Table 3**

Multivariable analysis of clinical parameters in systemic sclerosis (SSc) patients who are ANA negative compared with ANA positive patients.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>Adjusted P</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRSS</td>
<td>N/A</td>
<td>−2.48</td>
<td>0.018</td>
</tr>
<tr>
<td>Telangiectasias</td>
<td>0.59 (0.38, 0.91)</td>
<td>0.01</td>
<td>0.03</td>
</tr>
<tr>
<td>Digital ulcers and pits</td>
<td>0.38 (0.24, 0.59)</td>
<td>&lt;0.001</td>
<td>0.01</td>
</tr>
<tr>
<td>Calcinosis</td>
<td>0.63 (1.08, 0.37)</td>
<td>0.09</td>
<td>0.15</td>
</tr>
<tr>
<td>FVC%</td>
<td>0.59 (5.33, 0.95)</td>
<td>0.17</td>
<td>0.25</td>
</tr>
<tr>
<td>DLCO%</td>
<td>5.16 (1.33, 8.99)</td>
<td>0.008</td>
<td>0.03</td>
</tr>
<tr>
<td>Fibrosis per imaging</td>
<td>1.46 (0.81, 2.64)</td>
<td>0.20</td>
<td>0.27</td>
</tr>
<tr>
<td>MPAP per RHC</td>
<td>N/A</td>
<td>−5.58</td>
<td>0.04</td>
</tr>
<tr>
<td>PAH per RHC</td>
<td>0.28 (0.11, 0.70)</td>
<td>0.006</td>
<td>0.03</td>
</tr>
<tr>
<td>PH (per RHC and/or RVSP&gt;50)</td>
<td>0.52 (0.28, 0.94)</td>
<td>0.03</td>
<td>0.06</td>
</tr>
<tr>
<td>GERD</td>
<td>1.32 (0.75, 2.35)</td>
<td>0.33</td>
<td>0.41</td>
</tr>
<tr>
<td>Malabsorption</td>
<td>1.66 (1.08, 2.56)</td>
<td>0.02</td>
<td>0.05</td>
</tr>
<tr>
<td>CK</td>
<td>N/A</td>
<td>26.64</td>
<td>−394, 447</td>
</tr>
<tr>
<td>Renal crisis</td>
<td>1.23 (0.62, 2.43)</td>
<td>0.53</td>
<td>0.61</td>
</tr>
<tr>
<td>Low LVEF (&lt;50)</td>
<td>1.31 (0.45, 3.83)</td>
<td>0.61</td>
<td>0.65</td>
</tr>
</tbody>
</table>

Abbreviations: ANA= antinuclear antibodies, mRSS= modified Rodnan skin score, FVC= Forced vital capacity, DLCO= diffusing capacity of carbon monoxide, PAH= Pulmonary arterial hypertension, PH= Pulmonary Hypertension, MPAP= Mean pulmonary artery pressure, RHC= Right heart catheterization, RVSP= Right ventricular systolic pressure, GERD= Gastroesophageal reflux disease, CK= creatine kinase, LVEF= Left ventricular ejection fraction, OR=odd ratio; b coef= b coefficient; 95% CI=95% confidence interval; SD= standard deviation.

*Linear regression was used for continuous data; logistic regression was used for categorical data. The multivariable analysis was adjusted for age, disease duration, gender and disease type.

*After False Discovery Rate (FDR) or Benjamini-Hochberg adjustment method for multiple comparisons.
Detection of anti-U3-RNP/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis

Lisa K. Peterson1 · Troy D. Jaskowski2 · Maureen D. Mayes3 · Anne E. Tebo1,2

Published online: 14 October 2015
© Springer Science+Business Media New York 2015

Abstract The aim of this study was to evaluate the performance and clinical relevance of a commercially available line immunoblot assay (LIA) for detecting anti-U3-RNP/fibrillarin (anti-U3-RNP), against immunoprecipitation (gold standard). This study involved a multi-ethnic cohort of 1000 American systemic sclerosis (SSc) patients and 50 healthy controls. Antinuclear antibodies and centromere antibodies were detected by indirect immunofluorescent antibody test, anti-topo I by immunodiffusion and anti-RNAP III by ELISA. The presence of anti-U3-RNP in select serum samples was detected by immunoprecipitation (IP) and LIA. By IP, U3-RNP antibody was detected in 75 (7.5 %) patients with SSc. Overall agreement between LIA and IP was very good (κ = 0.966). Analytic sensitivity and specificity of the U3-RNP LIA was 100 and 94.7 %, respectively. Clinical features associated with positivity for the anti-U3-RNP antibody include diffuse cutaneous SSc and increased prevalence of renal crisis, consistent with previous studies that used IP. Testing for U3-RNP antibodies is only performed by a small number of laboratories due to the complexity of both performance and interpretation of the IP. LIA is faster and less complex than IP. Excellent agreement between IP and LIA demonstrates that LIA is an acceptable and attractive alternative to IP for anti-U3-RNP detection.

Keywords Systemic sclerosis · Autoantibodies · Anti-fibrillarin · Anti-U3 small nucleolar ribonucleoprotein · Antinuclear antibodies

Introduction Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by fibrosis of the skin and internal organs, Raynaud’s phenomenon and the presence of antinuclear antibodies (ANA). Anti-centromere, anti-topoisomerase I (anti-topo-1 or anti-Scl-70) and anti-RNA polymerase III (anti-RNAP III) are the most common ANA-positive patients with SSc, but only account for the ANA in 45–90 % of patients [1–5]. An increasing number of SSc-specific autoantibodies and their corresponding autoantigens have been identified. Detection of these autoantibodies aids in diagnosis, prognosis and therapeutic decisions [1–3, 6–9].

Anti-fibrillarin was first described as a clumpy nucleolar pattern on ANA IFA using sera from patients with progressive SSc [10]. It was subsequently named anti-fibrillarin based on reactivity of SSc patient sera with fibrillar regions of nucleoli [11]. It recognizes a highly conserved 34 kDa protein that is a component of U3 ribonucleoprotein (U3-RNP) [12–16]. Antibodies against U3-RNP/fibrillarin (anti-U3-RNP) are considered to be a very specific marker for SSc and are associated with shorter mean disease duration at time of diagnosis, younger age of onset, severe diffuse cutaneous SSc (dcSSc) and internal organ involvement [9, 15, 17, 18]. Antibodies reactive with
U3-RNP are found in 5–8% of SSC patients [4, 12, 19]. U3-RNP antibodies are more prevalent in male SSC patients and among African American patients with SSC compared to patients from other ethnic groups [20–25]. Moreover, anti-U3-RNP is the second most common ANA in African American patients with SSC [21], and is found in 12–48% of ANoA-positive SSC patients [6, 10, 11, 26, 27]. Thus, although infrequent in the general population, U3-RNP antibodies are a marker for severe SSC, especially in male and African American patients.

Testing for U3-RNP antibodies is only performed by a small number of laboratories due to the complexity of both performance and interpretation of the immunoprecipitation (IP) [4, 19]. Autoantibodies to U3-RNP are not currently included in the classification criteria for SSC, but may be incorporated if testing became more widely available [28]. Recently, an LIA was developed for the detection of 12 SSC-associated antibodies including U3-RNP. Several studies have evaluated the performance of the LIA as a whole on unselected SSC patient populations, but this approach yielded minimal information about the performance for markers with low prevalence, such as U3-RNP [4, 29–32]. Thus, the concordance between LIA and IP for the detection of anti-U3-RNP is not known. In this study, we evaluated the performance of the more rapid and less complex LIA assay as an alternative to the gold standard IP approach yielded minimal information about the performance and interpretation of the immunoprecipitation (IP) [4, 19]. Autoantibodies to U3-RNP are not currently included in the classification criteria for SSC, but may be incorporated if testing became more widely available [28]. Recently, an LIA was developed for the detection of 12 SSC-associated antibodies including U3-RNP. Several studies have evaluated the performance of the LIA as a whole on unselected SSC patient populations, but this approach yielded minimal information about the performance for markers with low prevalence, such as U3-RNP [4, 29–32]. Thus, the concordance between LIA and IP for the detection of anti-U3-RNP is not known. In this study, we evaluated the performance of the more rapid and less complex LIA assay as an alternative to the gold standard IP method for the detection of anti-U3-RNP in a multi-ethnic cohort of American patients with the two main forms of SSC, dcSSc and limited cutaneous (lcSSc).

### Materials and methods

#### Serum samples

From a multi-racial cohort of 1000 SSC patients (Scleroderma Family Registry and DNA Repository, SFRDR), 98 sera [ANoA alone (n = 94) or ANoA and nuclear speckled patterns (n = 4)] negative for antibodies to Scl-70 by immunodiffusion, to RNA polymerase III (RNAP III) by ELISA and to centromere (ACA) by indirect fluorescent antibody were identified for autoantibody characterization by IP and U3-RNP LIA. Sera were tested by IP by Dr. Minoru Satoh at the University of Florida. The patients were characterized clinically based on extent of skin involvement, age at disease onset, disease duration at blood draw, gender and ethnicity. The study was approved by the Institutional Review Boards at the University of Utah School of Medicine, Salt Lake City, and the University of Texas Health Science Center at Houston. Written informed consents from all subjects according to the declaration of Helsinki were obtained at the University of Texas Health Science Center at Houston.

#### Detection of SSC-associated antibodies by immunoblot

Sera from 98 samples previously tested for anti-U3-RNP by IP and 50 “self-proclaimed” healthy adults were used in this study. Sera were tested for autoantibodies against U3-RNP using the Systemic Sclerosis (Nucleoli) Profile (IgG) Immunoblot (Euroimmun AG, Lübeck, Germany) according to the manufacturer’s instructions. The blot strips were digitized using a camera and band intensities determined using the USLine-Scan software (Euroimmun AG). Signal strengths of <6 Units (U) were considered negative, 6–10 Units (U) were considered borderline, and results >10 U were considered positive according to the manufacturer’s recommendations.

#### Statistical analysis

Agreement between the assays was quantified using Cohen’s κ statistics for pair-wise comparisons. Kappa coefficients >0.75 signify substantial agreement. Significance of associations between sets of categorical data was determined using the Chi-square test. Statistical analysis was performed using Prism 5.0 (GraphPad Software). Differences were considered statistically significant for p values <0.05.

#### Results

Anti-U3-RNP IP and LIA results concurred in 98.9% of patients, yielding a κ coefficient 0.966 (Fig. 1a). Two U3-RNP IP positive sera were borderline by LIA, one of which reacted with Ro-52 by LIA and the other did not react with any of the antigens on the LIA (data not shown). Both of these samples were from patients with dcSSc. One LIA U3-RNP positive sera was not detected by IP and another was borderline by IP. Interestingly, both of these samples reacted with Th/To by IP. The sample that was positive by LIA, but negative by IP was from a patient with lcSSc. The sample that was positive for U3-RNP by LIA but borderline by IP was from a patient with dcSSc. Four samples that were anti-U3-RNP negative by IP had borderline results by LIA, all from patients with dcSSc. Two additional samples had borderline results for U3-RNP by IP, one of which was negative by LIA and the other was also borderline by LIA. Both of these samples were from patients with dcSSc. Comparison of U3-RNP LIA results in patients with the two main forms of SSC, dcSSc and lcSSc, and healthy controls confirmed the diagnostic performance of the LIA assay (Fig. 1b). In addition, LIA demonstrated that the prevalence of anti-U3-RNP was significantly higher in the dcSSc group (80.6%) compared to the lcSSc group (55.2%);
Based on the semi-quantitative values generated by the LIA, patients with dcSSc also had significantly higher levels of antibodies to U3-RNP [mean of 35.3 U (95 % CI 30–40.6 U)] compared to those with lcSSc [mean of 17.1 U (95 % CI 11.3–22.9 U)] (p = 0.0005). The black dotted lines indicate the cutoff level for positivity according to the manufacturer’s recommendation. The gray dotted lines indicate the cutoff level for samples considered borderline according to the manufacturer’s recommendation. *p < 0.05, **p < 0.01, and ***p < 0.001.

Table 1 summarizes the demographic and clinical information for SSc patients with concordant results by LIA and IP. There was no difference between these methods for associations between anti-U3-RNP and demographic or clinical features. There was a trend toward a greater proportion of men (1:4.83 vs 1:9; p = 0.7255), a younger age at the time of diagnosis (mean age 35.9 vs 43.0 years; p = 0.651) and a higher prevalence of renal crisis (22.9 vs 12.5 %; p = 0.6130) in anti-U3-RNP positive patients, but these associations did not reach statistical significance. There was no difference in disease duration at

<table>
<thead>
<tr>
<th>Demographic features and disease classification</th>
<th>Anti-U3-RNP positive (n = 70)</th>
<th>Anti-U3-RNP negative (n = 18)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at onset (years)</td>
<td>35.9 ± 15.0</td>
<td>43.0 ± 11.2</td>
<td>ns</td>
</tr>
<tr>
<td>Age at onset (years, median)</td>
<td>35.7</td>
<td>43.0</td>
<td>ns</td>
</tr>
<tr>
<td>Disease duration (years, mean ± SD)</td>
<td>5.7 ± 6.0</td>
<td>5.9 ± 4.0</td>
<td>ns</td>
</tr>
<tr>
<td>Disease duration (years, median)</td>
<td>3.4</td>
<td>5.7</td>
<td>ns</td>
</tr>
<tr>
<td>Female (n = 74)</td>
<td>58 (82.9)</td>
<td>16 (88.9)</td>
<td>ns</td>
</tr>
<tr>
<td>Male (n = 14)</td>
<td>12 (17.1)</td>
<td>2 (11.1)</td>
<td>ns</td>
</tr>
<tr>
<td>Hispanic (n = 27)</td>
<td>16 (22.9)</td>
<td>11 (61.1)</td>
<td>0.003</td>
</tr>
<tr>
<td>Caucasian (n = 11)</td>
<td>8 (11.4)</td>
<td>3 (16.7)</td>
<td>ns</td>
</tr>
<tr>
<td>African American (n = 51)</td>
<td>47 (67.1)</td>
<td>4 (22.2)</td>
<td>0.001</td>
</tr>
<tr>
<td>Diffuse (n = 58)</td>
<td>54 (77.1)</td>
<td>4 (22.2)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Limited (n = 30)</td>
<td>16/58 (93.1)%</td>
<td>4/58 (6.9)%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Renal crisis (n = 5)</td>
<td>4/14 (28.6)</td>
<td>1/8 (12.5)</td>
<td>ns</td>
</tr>
</tbody>
</table>

ANoA anti-nucleolar antibody, SSc systemic sclerosis, U3-RNP U3 ribonucleoprotein, LIA line immunoblot assay, IP immunoprecipitation, ns no significant difference, SD standard deviation

* Comparison of anti-U3-RNP production in patients with diffuse cutaneous SSc

** Comparison of anti-U3-RNP production in patients with limited cutaneous SSc
the time of blood draw between patients that were positive vs negative for anti-U3-RNP. Anti-U3-RNP positivity was associated with a higher proportion of African American patients (67.1 vs 22.2 %; \( p = 0.001 \)) and a lower proportion of Hispanic patients (22.9 vs 61.1 %; \( p = 0.003 \)).

The U3-RNP LIA had a sensitivity of 100 %, specificity of 94.7 %, positive predictive value of 98.6 % and negative predictive value of 100 % compared to IP, with an AUC of 0.99 (Figs. 1a, 2a). ROC analysis comparing SSc patients with healthy controls demonstrated a sensitivity of 79.1 %, specificity of 100 %, positive predictive value of 100 % and negative predictive value of 70.8 %, with an AUC of 0.86 (Fig. 2b). DcSSc patients also demonstrated a significant (\( p < 0.0001 \)) AUC of 0.94 (95 % CI 0.90–0.99) when compared to healthy controls. In contrast, ROC analysis comparing lcSSc patients with healthy controls demonstrated an AUC of 0.6845 (95 % CI 0.55–0.82). Similarly, ROC analysis comparing deSSc patients to lcSSc patients demonstrated a significant AUC of 0.7848 (95 % CI 0.69–0.88). Thus, anti-U3-RNP measured by LIA is clinically useful for discriminating between SSc patients and healthy controls (Fig. 2), particularly for dcSSc.

### Discussion

The increased prevalence of anti-U3-RNP in African American patients with dcSSc compared to other ethnic groups has been recognized in a number of sero-epidemiological studies [9, 15, 17, 18, 20–25]. In addition, the presence of anti-U3-RNP antibodies is considered a specific marker for SSc and found in 5–8 % of these patients [4, 12, 19]. Despite the significance of this antibody in the diagnostic evaluation and management of SSc, its availability in routine clinical laboratories remains restricted due to methodologic limitations [4, 12, 19]. In this study, the diagnostic and clinical implications for testing U3-RNP antibodies in a multi-ethnic cohort of SSc patients by a conventional immunoassay (LIA) and the IP were comparable. The LIA is faster, less subjective and more cost-effective than IP enabling incorporation of anti-U3-RNP testing in a routine laboratory setting.

Of clinical significance, the presence of U3-RNP antibodies by LIA was associated with high prevalence in African Americans as well as dcSSc. Furthermore, the observation that anti-U3-RNP positive patients have a higher prevalence of renal crisis was supported by the trend toward a higher prevalence of renal crisis found in this study [9, 15, 17, 18], but data regarding kidney involvement was only available for 23.5 % of the cohort, which may explain why statistical significance was not achieved. However, of the patients with renal crisis included in this study, 80 % were positive for anti-U3-RNP. Previous studies have shown an association between anti-U3-RNP positivity and male gender and a younger age at disease onset [9, 15, 17–19]. This study demonstrated a similar trend, but failed to reach statistical significance likely due to the cross-sectional nature of the study, potential selection bias and the small number of men in the study. Of the men included in this study, 80 % were positive for anti-U3-RNP. Previous studies have shown an association between anti-U3-RNP positivity and male gender and a younger age at disease onset [9, 15, 17–19]. This study demonstrated a similar trend, but failed to reach statistical significance likely due to the cross-sectional nature of the study, potential selection bias and the small number of men in the study. Of the men included in this study, 80 % were positive for anti-U3-RNP. Anti-U3-RNP positivity is associated with a nucleolar pattern [10, 11]. In our study, all of the patients were ANoA positive, but 4 (4 %) patients had ANoA in...
combination with a nuclear speckled pattern. All four of these patients were negative for anti-U3-RNP by both IP and LIA (data not shown).

Detection of anti-U3-RNP using the EUROLINE LIA in samples that were negative for anti-U3-RNP by IP has previously been reported [18]. However, this reactivity was of low signal intensity and overlapped with that detected in controls. Similar results were observed in this study, but it remains to be determined whether this low-level reactivity is due to contaminants in the antigen preparation or the LIA being more sensitive than IP.

This study is not without limitations. Like most studies of this nature, this study is cross-sectional and limited by the paucity of clinical data for internal organ involvement. Secondly, the cohort is highly selected and does not represent routine patient population. Another potential setback in the study design is the limited ethnic diversity of the healthy control population which was comprised of predominantly Caucasian donors. Lastly, although a limited number of U3-RNP antibody negative SSc patients by IP were evaluated in the LIA, the analytical specificity in the context of other autoimmune diseases with a high incidence of myositis commonly associated with this antibody was not tested. This is particularly important as neither this study, nor others using EUROLINE systemic sclerosis LIA and IP have investigated the specificity of the assay for the detection of anti-U3-RNP with respect to other autoimmune diseases [4, 29–32].

Despite these limitations, the concordance between LIA and the IP assay considered the gold standard for detecting anti-U3-RNP antibodies represent a positive outlook for autoantibody testing in SSc. However, testing for anti-U3-RNP antibodies should only be considered in SSc patients who have positive ANA with a nucleolar staining pattern, particularly in African American patients, deSSc and/or renal crisis. Overall, this study shows excellent agreement between the Euroline LIA and IP for the detection of antibodies against U3-RNP, making it an acceptable and attractive alternative to IP.

Acknowledgments The authors thank Dr. Minoru Satoh for testing the samples by IP at the University of Florida. EUROLINE Systemic Sclerosis (Nucleoli) Profile (IgG) kits were provided by EURO-IMMUN US, which was not involved in the study design or the writing of this manuscript.

References


13. Baserga SJ, Yang XD, Steitz JA. An intact Box C sequence in the U3 snRNA is required for binding of fibrillarin, the protein common to the major family of nucleolar snRNPs. EMBO J. 1991;10(9):2645–51.


Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects

Michael Wodkowski, Marie Hudson, Susanna Proudman, Jennifer Walker, Wendy Stevens, Mandana Nikpour, Shervin Assassi, Maureen D. Mayes, Solène Tatibouet, Mianbo Wang, Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Interest Group (ASIG), Genetics versus Environment in Scleroderma Outcome Study (GENISOS), Murray Baron & Marvin J. Fritzler

To cite this article: Michael Wodkowski, Marie Hudson, Susanna Proudman, Jennifer Walker, Wendy Stevens, Mandana Nikpour, Shervin Assassi, Maureen D. Mayes, Solène Tatibouet, Mianbo Wang, Canadian Scleroderma Research Group (CSRG), Australian Scleroderma Interest Group (ASIG), Genetics versus Environment in Scleroderma Outcome Study (GENISOS), Murray Baron & Marvin J. Fritzler (2015) Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects, Autoimmunity, 48:8, 542-551, DOI: 10.3109/08916934.2015.1077231

To link to this article: http://dx.doi.org/10.3109/08916934.2015.1077231

Published online: 31 Aug 2015.

Article views: 272

View Crossmark data
Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects

Michael Wodkowski¹, Marie Hudson¹,²,³, Susanna Proudn¹,⁴,⃣ Jennifer Walker⁶, Wendy Stevens⁷, Mandana Nikpour⁷,⁸, Shervin Assassi⁹, Maureen D. Mayes⁹, Solène Tatibouet³, Mianbo Wang³, Canadian Scleroderma Research Group (CSRG) *, Australian Scleroderma Interest Group (ASIG)**, Genetics versus Environment in Scleroderma Outcome Study (GENISOS)***, Murray Baron¹,²,³, and Marvin J. Fritzler¹⁰

¹Department of Medicine, McGill University, Montréal, Quebec, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, Quebec, Canada, ³Lady Davis Institute, Jewish General Hospital, Montréal, Quebec, Canada, ⁴Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁵Discipline of Medicine, University of Adelaide, Bedford Park, Australia, ⁶Department of Allergy and Immunology, Flinders Medical Centre, Bedford Park, Australia, ⁷Department of Rheumatology, St. Vincent’s Hospital Melbourne, Fitzroy, Victoria, Australia, ⁸Department of Medicine, The University of Melbourne at St. Vincent’s Hospital, Melbourne, Victoria, Australia, ⁹Division of Rheumatology and Immunogenetics, University of Texas Health Science Centre at Houston, Houston, TX, USA, and ¹⁰Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

Abstract

Objective: Autoantibodies directed against the two principal antigens of the human exosome complex, PM75 and PM100, are present in systemic sclerosis (SSc) sera and have been associated with myositis and calcinosis. However, there is a paucity of data on the clinical correlates of these autoantibodies separately and in the absence of other SSc-specific antibodies. The aim of this study was to assess the clinical correlates of monospecific anti-PM75 and anti-PM100 in SSc.

Methods: A tri-nation cohort of 1574 SSc subjects was formed, clinical variables were harmonized and sera were tested for anti-PM75 and anti-PM100 antibodies using a line immunoassay.

Results: Forty-eight (3.0%) subjects had antibodies against PM75 and 18 (1.1%) against PM100. However, only 16 (1%) had monospecific anti-PM75 antibodies and 11 (0.7%) monospecific anti-PM100 antibodies (i.e. in isolation of each other and other SSc-specific antibodies). Monospecific profiles of each autoantibody included more calcinosis. An increased frequency of myositis was only seen in subjects positive for both anti-PM75 and anti-PM100 antibodies. Lung disease was only associated with anti-PM75 and subjects with anti-PM100 antibodies had better survival compared to other antibody subsets.

Conclusion: The prevalence of monospecific anti-PM75 and anti-PM100 antibodies in this large SSc cohort was low. Disease features associated with anti-PM/Scl antibodies may depend on particular and possibly multiple antigen specificities. However, due to the small samples, these results need to be interpreted with caution. International collaborations are key to understanding the clinical correlates of uncommon serological profiles in SSc.

Keywords

Autoantibodies, anti-PM/Scl antibodies, autoimmunity, observational cohort, systemic sclerosis

History

Received 7 January 2015
Revised 2 June 2015
Accepted 19 July 2015
Published online 31 August 2015
Introduction

The wide spectrum of serum autoantibodies in systemic sclerosis (SSc) has been extensively studied in the context of the diagnostic uncertainty, varying clinical phenotypes and unpredictable course of the disease [1]. SSc-specific antibodies, namely anti-topoisomerase I (ATA), anti-centromere (ACA) and anti-RNA polymerase III (ARNAP), and a number of SSc-associated antibodies (anti-Ro52/TRIM21, U1RNP and PM/Scl antibodies) are now understood to be biomarkers of diagnosis and prognosis and may contribute to disease pathogenesis [2,3].

Among these, autoantibodies against the human exosome complex were discovered as early as 1977 [4]. They were designated as anti-PM/Scl since they were commonly found in patients with polymyositis and scleroderma overlap syndrome (20–55%) in contrast to SSc alone (3–11%) [5]. To date, anti-PM/Scl antibodies have been associated with a variety of clinical profiles, of which the associations with inflammatory myositis and calcinosis have been the most consistently reported [6,7].

The PM/Scl complex consists of as many as 16 proteins that are located primarily in the nucleus and are involved in RNA processing and degradation. The major B cell targets of the PM/Scl complex have been identified as PM100 (and its major epitope called PM1-Alpha) and PM75, both named for their molecular masses [6]. Commercial assays to detect anti-PM100 and anti-PM75 antibodies are available and a few studies have reported distinct clinical associations with these autoantibodies [8,9]. However, to our knowledge, there have been no studies to date that have examined the clinical profiles of SSc patients with anti-PM75 and anti-PM100 antibodies present in isolation (i.e. monospecific) of each other and of other SSc-specific antibodies (ACA, ATA or ARNAP), possibly because of the paucity of subjects with these serological profiles. It is possible that clinical characteristics associated with other SSc autoantibodies may obscure the distinct phenotypes associated with anti-PM75 and anti-PM100 antibodies. The aim of this study was therefore to identify the demographic, clinical and serological characteristics of SSc subjects with monospecific anti-PM75 and anti-PM100 antibodies in a large international, multi-centered cohort.

Methods

Sources of data

The study subjects were SSc patients enrolled in the Canadian Scleroderma Research Group (CSRG), the Australian Scleroderma Interest Group (ASIG) or the American GENISOS cohorts. Briefly, patients in the CSRG are recruited from 15 sites across Canada, must have a diagnosis of SSc verified by an experienced rheumatologist, be >18 years of age and be fluent in English or French. Over 98% of the cohort meet the 2013 ACR/EULAR classification criteria for SSc [10]. Patients in the Australian Scleroderma Cohort Study (ASCs) are recruited by ASIG investigators from 12 Australian centers specializing in the care of patients with SSc, according to similar inclusion criteria. All patients fulfilled either the 1980 preliminary ACR criteria for classification of SSc, or the Medsger criteria for limited SSc [11]. The Genetics versus Environment in Scleroderma Outcome Study (GENISOS) cohort is a longitudinal cohort of patients with early SSc. Patients were enrolled within 5 years of disease onset as determined by the first non-Raynaud’s phenomenon symptom from three University of Texas institutions at Houston, San Antonio, and Galveston. All enrolled patients fulfill the 2013 ACR/EULAR classification criteria for SSc [10].

Ethics committee approval for this study was obtained at McGill University (Montreal, Canada) and at all participating CSRG, ASIG, and GENISOS study sites. All subjects provided informed written consent to participate in the data collection protocol. The CSRG subjects included in this study were those whose baseline visits were between September 2004 and February 2011, for ASIG between December 2007 and September 2011 and GENISOS between January 1998 and January 2013, and who had complete serological profiles for anti-PM75 and anti-PM100 antibodies as detected by the methods described below.

Clinical variables

Patients recruited into this study underwent standardized medical evaluation including medical histories, physical examinations and laboratory investigations. Demographic information regarding age, sex and ethnicity was collected by patient self-report. Disease duration was recorded by study physicians and defined as the interval between the onset of the first non-Raynaud disease manifestation and baseline study visit.

Skin involvement was assessed using the modified Rodnan skin score, a widely used clinical assessment where the examining rheumatologist records the degree of skin thickening ranging from 0 (no involvement) to 3 (severe thickening) in 17 areas (total score range 0–51). Limited cutaneous disease (lcSSc) was defined as skin involvement distal to the elbows and knees with or without facial involvement; diffuse cutaneous disease (dcSSc) was defined as skin involvement proximal to the elbows and knees, with or without truncal involvement. Those with a clinical diagnosis of SSc but no skin involvement were included with the lcSSc subset.

A history of inflammatory myositis, calcinosis, inflammatory arthritis and scleroderma renal crisis was recorded by a study physician. Creatine kinase (CK) was measured by local laboratories.

To assess gastrointestinal involvement, patients answered yes/no to six questions concerning gastroesophageal reflux disease, dysphagia, antibiotics for bacterial overgrowth, episodes of pseudo-obstruction, fecal incontinence and hyperalimentation.

The presence of interstitial lung disease (ILD) was determined using a clinical decision rule that was recently published [12]. Using this algorithm, ILD was considered present if a high resolution computed tomography (HRCT) scan of the lung was interpreted by an experienced radiologist as showing ILD or, in the case where no HRCT is available, if either a chest X-ray was reported as showing either increased interstitial markings (not thought to be due to congestive heart failure) or fibrosis, and/or if a study physician reported the presence of typical “velcro-like crackles” on physical examination.
Table 1. Baseline characteristics according to antibody status (N = 1574). Subjects in the anti-PM75, anti-PM100, ACA, ATA and ARNAP groups have monospecific antibodies, i.e. exclusive of each other.

<table>
<thead>
<tr>
<th></th>
<th>PM75 (N = 16)</th>
<th>PM100 (N = 11)</th>
<th>ACA (N = 487)</th>
<th>ATA (N = 251)</th>
<th>ARNAP (N = 206)</th>
<th>Others (N = 603)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sociodemographic variables</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>81.3% (13)</td>
<td>90.9% (10)</td>
<td>94.1% (458)</td>
<td>79.3% (199)</td>
<td>83.0% (171)</td>
<td>83.6% (504)</td>
</tr>
<tr>
<td>Age, years</td>
<td>56.6 ± 11.7</td>
<td>47.5 ± 13.3</td>
<td>59.4 ± 11.6</td>
<td>52.1 ± 13.0</td>
<td>53.6 ± 12.2</td>
<td>53.4 ± 13.0</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td>0</td>
<td>1</td>
<td>18</td>
<td></td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>93.8% (15)</td>
<td>100.0% (10)</td>
<td>88.7% (416)</td>
<td>76.8% (185)</td>
<td>84.4% (173)</td>
<td>76.6% (445)</td>
</tr>
<tr>
<td>Black</td>
<td>0.0% (0)</td>
<td>0.0% (0)</td>
<td>1.1% (5)</td>
<td>5.8% (14)</td>
<td>2.9% (6)</td>
<td>7.9% (46)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>0.0% (0)</td>
<td>0.0% (0)</td>
<td>3.6% (17)</td>
<td>5.8% (14)</td>
<td>4.4% (9)</td>
<td>8.6% (50)</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>10.9 ± 10.9</td>
<td>11.7 ± 9.8</td>
<td>11.6 ± 9.9</td>
<td>8.3 ± 8.6</td>
<td>7.2 ± 7.3</td>
<td>9.1 ± 9.1</td>
</tr>
<tr>
<td>Age at disease onset</td>
<td>45.7 ± 12.9</td>
<td>35.8 ± 14.1</td>
<td>47.8 ± 13.8</td>
<td>43.7 ± 13.8</td>
<td>46.4 ± 12.0</td>
<td>44.3 ± 13.8</td>
</tr>
</tbody>
</table>

**Disease subsets**

| Limited cutaneous disease | 75.0% (12) | 90.9% (10) | 87.3% (425) | 46.8% (117) | 20.1% (41) | 59.6% (358) |
| Diffuse cutaneous disease | 25.0% (4)  | 9.1% (1)   | 12.7% (62)  | 53.2% (133) | 79.9% (163) | 40.4% (243)  |

**Clinical variables**

| Modified Rodnan skin score | 10.8 ± 9.6 | 4.4 (3.3) | 7.3 ± 6.8 | 14.0 ± 10.0 | 20.3 ± 11.4 | 10.8 ± 10.1 |
| Inflammatory myositis      | 7.7% (1)   | 0.0% (0)  | 4.7% (20) | 10.0% (22)  | 9.8% (18)   | 12.4% (68)   |
| Calciosis                 | 37.5% (6)  | 36.4% (4) | 31.6% (151) | 22.3% (56) | 27.7% (56) | 22.1% (132) |
| Arthritis                 | 31.3% (5)  | 36.4% (4) | 22.6% (110) | 32.3% (81) | 34.8% (71) | 28.7% (172) |

**GI symptoms**

| GERD                     | 87.5% (14) | 54.6% (6) | 86.2% (418) | 81.2% (203) | 83.4% (171) | 77.5% (466) |
| Dysphagia                | 68.8% (11) | 45.5% (5) | 59.1% (282) | 46.4% (115) | 43.1% (88) | 51.9% (307) |
| Antibiotics for bacterial overgrowth | 14.3% (2) | 0.0% (0) | 7.7% (35) | 6.6% (15) | 7.1% (13) | 5.9% (29) |
| Episodes of pseudo-obstruction | 0.0% (0) | 0.0% (0) | 4.1% (20) | 2.0% (5) | 2.9% (6) | 1.8% (11) |
| Fecal incontinence       | 28.6% (4)  | 12.5% (1) | 26.8% (113) | 9.0% (18) | 16.2% (27) | 13.1% (54) |
| Hyperalimentation         | 0.0% (0)   | 0.0% (0)  | 1.5% (5)    | 3.5% (5)    | 4.0% (5)    | 2.7% (9)     |
| Number of GI symptoms (0–6) | 1.9 ± 0.9 | 1.1 ± 0.9 | 1.8 ± 1.0 | 1.4 ± 0.9 | 1.5 ± 1.0 | 1.5 ± 0.9 |
| Scleroderma renal crisis  | 0.0% (0)   | 0.0% (0)  | 0.0% (0)    | 0.0% (0)    | 2.0% (5)    | 3.0% (2)    |
| Intestinal ulcer disease  | 50.0% (8)  | 20.0% (2) | 17.8% (84) | 56.1% (139) | 37.3% (76) | 40.7% (239) |
| Pulmonary hypertension    | 21.4% (3)  | 2.0% (0)  | 16.2% (68) | 13.3% (25) | 13.4% (23) | 11.9% (53) |

**Laboratory tests**

| CK at baseline visit     | 90.5 ± 51.0 | 69.1 ± 27.5 | 88.0 ± 70.6 | 107.0 ± 80.5 | 107.2 ± 121.7 | 128.7 ± 241.3 |
| Percentage with CK > 3x normal at baseline | 0.0% (0) | 0.0% (0) | 0.8% (3) | 0.0% (0) | 1.9% (3) | 2.4% (12) |
| Number of CK during follow up                 | 134.3 ± 151.3 | 81.5 ± 39.3 | 121.4 ± 166.8 | 143.7 ± 124.9 | 140.9 ± 134.3 | 188.7 ± 611.3 |
| Percentage with CK > 3x normal during follow up | 0.0% (0) | 0.0% (0) | 2.0% (9) | 1.8% (4) | 2.7% (5) | 0.2% (16) |

**Serology**

| ANA positive            | 86.7% (13) | 100.0% (11) | 99.4% (484) | 98.0% (246) | 96.1% (197) | 88.4% (533) |

ACA: anti-centromere antibodies; ATA: anti-topoisomerase I antibodies; ARNAP: anti-RNA polymerase III antibodies; SD: standard deviation; NA: not available; GI: gastrointestinal; GERD: gastroesophageal reflux disease; HRCT: high resolution computed tomography scans of the lungs; CXR: chest X-ray; CK: creatinine kinase; ANA: anti-nuclear antibody.
Pulmonary hypertension was defined as an estimated systolic pulmonary artery pressure (sPAP) ≥45 mmHg measured using the Doppler flow measurement of the tricuspid regurgitant jet on cardiac echocardiography (an estimate that correlates strongly with right heart catheter studies) [13] for CSRG and GENISOS subjects, or mean pulmonary artery pressure (mPAP) ≥25 mmHg with a pulmonary capillary wedge pressure (PCWP) <15 mmHg on right heart catheterization for ASIG subjects.

Serology

Autoantibody analysis of the CSRG and GENISOS cohorts were performed in a central laboratory, Mitogen Advanced Diagnostics Laboratory, University of Calgary and the ASIG analyses were performed using an identical immunoassay kit and protocols. Serum aliquots were stored at −80°C until needed for diagnostic assays. Antinuclear antibodies were detected by indirect immunofluorescence (IIF) performed on HEp-2 cells (ImmunoConcepts, Sacramento, CA, USA). Anti-PM75 and anti-PM100, ACA (CENP A and CENP B), ATA and ARNAP (RP11 and RP155) antibodies were detected by Euroline systemic sclerosis profile line immunoassay (LIA) (Euroimmun, Luebeck, Germany) according to manufacturer’s instructions (http://www.euroimmun.com/index.php?id=anwendungen&L=1). With the intent of optimizing specificity, antibodies were reported as absent (negative, equivocal and low titres) and present (moderate and high titres).

Statistical analysis

Descriptive statistics were used to summarize the baseline demographic and clinical characteristics of the patients. Given the exploratory nature of the analysis and the small samples in the sub-groups, clinically relevant numerical differences between sub-groups were considered informative. Exploratory statistical analyses were also performed using Chi-square tests, Fisher’s exact tests and Mann–Whitney’s U tests, as indicated. Kaplan Meier analysis was used to compare survival between autoantibody subsets and log rank p values were reported. No correction for multiple testing was done and p<0.05 was considered statistically significant. All statistical analyses were performed with SAS v.9.2 (SAS Institute, Cary, NC).

Results

This study included 1574 SSc subjects who had complete serological profiles for anti-PM75 and anti-PM100 antibodies (Table 1). Of these, 48 (3.0%) had antibodies detected against PM75, 18 (1.1%) against PM100 and 26 (1.7%) against both PM75 and PM100 (Figure 1A). However, only 16 (1%) had monospecific anti-PM75 antibodies and 11 (0.7%) monospecific anti-PM100 antibodies (i.e. in isolation of each other and other SSc-specific antibodies; Figure 1B). In addition, there were 487 (30.9%) subjects with monospecific ACA, 251 (15.9%) monospecific ATA and 206 (13.1%) monospecific ARNAP. Considering the small sample number in the anti-PM75 and anti-PM100 groups, sociodemographic characteristics were generally similar between the various antibody groups, except for the fact that the anti-PM100 group had a younger age at disease onset (35.8 years) in comparison to anti-PM75 (45.7 years) and to the other antibody groups (43.7–47.8 years; Table 1 and Supplementary Table 1).

The majority of anti-PM75 and anti-PM100 patients had lcSSc (75.0% and 90.9%, respectively), which was similar to ACA patients (87.3%) but higher than those with ATA (46.8%) and ARNAP (20.1%) antibodies (Table 1 and Supplementary Table 1). The modified Rodnan skin score was 10.8 ± 9.6 and 4.4 ± 3.3 in the anti-PM75 and anti-PM100 groups, compared to 7.3 ± 6.8, 14.0 ± 10.0 and 20.3 ± 11.4 in the ACA, ATA and ARNAP groups, respectively (Table 1 and Supplementary Table 1).

The prevalence of inflammatory myositis was low in the patient groups with monospecific anti-PM/ScI antibodies (1/13 (7.7%) in the anti-PM75 group and 0/8 in the anti-PM100 group) and was lying in the same range as in those patients with

Figure 1. Venn diagrams showing overlap between anti-PM75 and anti-PM100 antibodies. (A) Subjects with non-exclusive PM75 and PM100 (i.e. possible overlap with ACA, ATA, ARNAP). (B) Subjects with monospecific PM75 and PM100 (i.e. no overlap with ACA, ATA, ARNAP). ACA: anticentromere antibodies; ATA: anti-topoisomerase I antibodies; ARNAP: anti-RNA polymerase III antibodies.
Table 2. Baseline characteristic all subjects with anti-PM75 and anti-PM100 antibodies, including those with antibodies overlapping with ACA, ATA and ARNAP.

<table>
<thead>
<tr>
<th></th>
<th>Anti-PM75 (N = 48)</th>
<th>Anti-PM100 (N = 18)</th>
<th>Anti-PM75 and anti-PM100 positive (N = 26)</th>
<th>Anti-PM75 and anti-PM100 Negative (N = 1482)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (N) or mean ± SD</td>
<td>% (N) or mean ± SD</td>
<td>% (N) or mean ± SD</td>
<td>% (N) or mean ± SD</td>
</tr>
<tr>
<td>Socio-demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>85.4% (41)</td>
<td>88.9% (16)</td>
<td>84.6% (22)</td>
<td>86.1% (1276)</td>
</tr>
<tr>
<td>Age, years</td>
<td>55.3 ± 12.8</td>
<td>48.2 ± 13.7</td>
<td>54.8 ± 12.3</td>
<td>55.2 ± 12.8</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>89.4% (42)</td>
<td>94.1% (16)</td>
<td>84.0% (21)</td>
<td>81.3% (1165)</td>
</tr>
<tr>
<td>Black</td>
<td>0.0% (0)</td>
<td>0.0% (0)</td>
<td>4.0% (1)</td>
<td>4.9% (70)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>2.1% (1)</td>
<td>0.0% (0)</td>
<td>8.0% (2)</td>
<td>6.1% (87)</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>10.8 ± 9.7</td>
<td>11.2 ± 10.3</td>
<td>10.4 ± 11.8</td>
<td>9.5 ± 9.1</td>
</tr>
<tr>
<td>Age at disease onset</td>
<td>44.4 ± 13.1</td>
<td>37.1 ± 12.7</td>
<td>44.4 ± 15.0</td>
<td>45.7 ± 13.7</td>
</tr>
<tr>
<td>Disease subsets</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limited, N (%)</td>
<td>68.8% (33)</td>
<td>83.3% (15)</td>
<td>69.2% (18)</td>
<td>60.7% (897)</td>
</tr>
<tr>
<td>Diffuse, N (%)</td>
<td>31.3% (15)</td>
<td>16.7% (3)</td>
<td>30.8% (8)</td>
<td>39.3% (580)</td>
</tr>
<tr>
<td>Clinical variables</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified Rodnan skin score, mean ± SD</td>
<td>10.6 ± 8.8</td>
<td>8.1 ± 11.3</td>
<td>9.1 ± 9.0</td>
<td>11.5 ± 10.3</td>
</tr>
<tr>
<td>Inflammatory myositis</td>
<td>5.3% (2)</td>
<td>0.0% (0)</td>
<td>36.0% (9)</td>
<td>8.9% (118)</td>
</tr>
<tr>
<td>Calcinosis</td>
<td>36.2% (17)</td>
<td>33.3% (6)</td>
<td>42.3% (11)</td>
<td>25.3% (371)</td>
</tr>
<tr>
<td>Arthritis</td>
<td>27.1% (13)</td>
<td>27.8% (5)</td>
<td>42.3% (11)</td>
<td>28.0% (414)</td>
</tr>
<tr>
<td>GI symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GERD/reflux</td>
<td>85.4% (41)</td>
<td>61.1% (11)</td>
<td>57.7% (15)</td>
<td>82.0% (1211)</td>
</tr>
<tr>
<td>Dysphagia</td>
<td>57.4% (27)</td>
<td>50.0% (9)</td>
<td>32.0% (8)</td>
<td>52.4% (764)</td>
</tr>
<tr>
<td>Antibiotics for bacterial overgrowth</td>
<td>4.5% (2)</td>
<td>0.0% (0)</td>
<td>4.3% (1)</td>
<td>7.0% (91)</td>
</tr>
<tr>
<td>Episodes of pseudo-obstruction</td>
<td>8.3% (4)</td>
<td>0.0% (0)</td>
<td>0.0% (0)</td>
<td>2.6% (38)</td>
</tr>
<tr>
<td>Fecal incontinence</td>
<td>26.2% (11)</td>
<td>13.3% (2)</td>
<td>11.1% (2)</td>
<td>17.6% (202)</td>
</tr>
<tr>
<td>Hyperalimentation</td>
<td>0.0% (0)</td>
<td>0.0% (0)</td>
<td>0.0% (0)</td>
<td>2.7% (23)</td>
</tr>
<tr>
<td>Number of GI symptoms (0-6)</td>
<td>1.8 ± 1.0</td>
<td>1.2 ± 0.9</td>
<td>1.0 ± 1.0</td>
<td>1.6 ± 1.0</td>
</tr>
<tr>
<td>Scleroderma renal crisis</td>
<td>2.1% (1)</td>
<td>5.6% (1)</td>
<td>4.0% (1)</td>
<td>3.9% (57)</td>
</tr>
<tr>
<td>Interstitial lung disease</td>
<td>48.9% (23)</td>
<td>11.8% (2)</td>
<td>42.3% (11)</td>
<td>35.4% (512)</td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td>17.5% (7)</td>
<td>0.0% (0)</td>
<td>14.3% (3)</td>
<td>13.6% (162)</td>
</tr>
<tr>
<td>Lab tests</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline visit</td>
<td>96.0 ± 52.5</td>
<td>84.5 ± 35.5</td>
<td>176.8 ± 232.4</td>
<td>108.8 ± 167.0</td>
</tr>
<tr>
<td>Percentage with CK&gt;3x normal baseline</td>
<td>0.0% (0)</td>
<td>0.0% (0)</td>
<td>5.0% (1)</td>
<td>1.4% (17)</td>
</tr>
<tr>
<td>Highest CK during follow up</td>
<td>160.1 ± 288.2</td>
<td>99.8 ± 54.8</td>
<td>159.2 ± 139.3</td>
<td>153.4 ± 405.2</td>
</tr>
<tr>
<td>Percentage with CK&gt;3x normal in f/u</td>
<td>2.2% (1)</td>
<td>0.0% (0)</td>
<td>4.5% (1)</td>
<td>2.3% (32)</td>
</tr>
<tr>
<td>Serology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANA positive</td>
<td>93.6% (44)</td>
<td>100.0% (18)</td>
<td>100.0% (26)</td>
<td>94.3% (1396)</td>
</tr>
</tbody>
</table>

ACA: anti-centromere antibodies; ATA: anti-topoisomerase I antibodies; ARNAP: anti-RNA polymerase III antibodies; SD: standard deviation; NA: not available; GI: gastrointestinal; GERD: gastroesophageal reflux disease; HRCT: high resolution computed tomography scans of the lungs; CXR: chest X-ray; CK: creatinine kinase; ANA: anti-nuclear antibody.
ACA (20/425, 4.7%), ATA (22/221, 10.0%) and ARNAP (18/183, 9.8%) (Table 1; differences between monospecific anti-PM/Scl groups and all other groups not significant, Supplementary Table 1). On the other hand, the highest prevalence of inflammatory myositis (9/25, 36%) was among the subjects with both anti-PM75 and anti-PM100 antibodies (vs. 120/1374 [8.7%]) of all other patients, odds ratio 5.9, 95% confidence interval 2.5, 13.6, \( p = 0.0002 \); Table 2).

In the monospecific anti-PM75 group, a trend towards relatively high rates of calcinosis (37.5%) and gastrointestinal symptoms (gastroesophageal reflux disease [GERD] 87.5%, dysphagia 68.8%, antibiotics for bacterial overgrowth 14.3% and fecal incontinence 28.6%) was seen (Table 1). ILD was also common (50.0%), second only to the ATA group (56.1%), and pulmonary hypertension (21.4%) was most frequent in this antibody group. However, probably due to the low numbers, few of the comparisons between the monospecific anti-PM75 and all other groups reached statistical significance (Supplementary Table 1).

The monospecific anti-PM100 group also showed a relatively high rate of calcinosis (36.4%) but low rates of gastrointestinal symptoms (mean number of symptoms 1.1, range 0–6). ILD was less common compared to the anti-PM75 and other antibody groups, and none of the subjects had pulmonary hypertension. Again, only a few of the comparisons reached statistical significance (Supplementary Table 1).

In unadjusted survival analysis (Figure 2), anti-PM100 was associated with a significantly better survival compared to ARNAP (log rank \( p = 0.0369 \)) and there was a trend toward better survival compared to ATA (log rank \( p = 0.0681 \)) and anti-PM75 (log rank \( p = 0.0922 \)).

Discussion

We sought to describe the distinct clinical phenotypes associated with anti-PM75 and anti-PM100 antibodies in SSC patients, autoantibodies directed against different antigens on a common molecular target. In this international cohort of 1574 subjects, only 16 (1%) had monospecific anti-PM75 antibodies and 11 (0.7%) monospecific anti-PM100 antibodies. Monospecific anti-PM75 and anti-PM100 had common (e.g. calcinosis) and distinct (anti-PM75 more...
Table 3. Summary of the literature on clinical associations of anti-Pm/Scl antibodies in SSc.

<table>
<thead>
<tr>
<th></th>
<th>Anti-PM75</th>
<th>Anti-PM100</th>
<th>Anti-PM/Scl</th>
<th>Anti-PM1-alpha</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monospecific</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Detection method</td>
<td>LIA</td>
<td>LIA</td>
<td>LIA</td>
<td>LIA</td>
</tr>
<tr>
<td>Total study population</td>
<td>1574</td>
<td>280</td>
<td>210</td>
<td>1574</td>
</tr>
<tr>
<td>Subpopulation positive for antibody (percentage of total)</td>
<td>16 (1%)</td>
<td>29 (10.4%)</td>
<td>14 (6.7%)</td>
<td>11 (0.7%)</td>
</tr>
<tr>
<td>Comparison group</td>
<td>Negative for anti-PM75 and anti-PM100</td>
<td>Negative for anti-PM75 and anti-PM100</td>
<td>Negative for anti-PM100</td>
<td>Negative for anti-PM/Scl</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Diffuse SSc</td>
<td>4</td>
<td>18</td>
<td>NA</td>
</tr>
<tr>
<td>Overlap</td>
<td>12</td>
<td>3</td>
<td>NA</td>
<td>10</td>
</tr>
<tr>
<td>Age at onset of disease</td>
<td>45.7 vs 45.7</td>
<td>44.2 vs 50.4</td>
<td>43.5 vs 45.7</td>
<td>48.3 vs 49.8</td>
</tr>
<tr>
<td>Comparison</td>
<td>--</td>
<td>--</td>
<td>NA</td>
<td>--</td>
</tr>
<tr>
<td>Muscle (%)</td>
<td>7.7 vs 8.9</td>
<td>65.5 vs 44.2</td>
<td>3.5 vs 11.5</td>
<td>51 vs 14</td>
</tr>
<tr>
<td>Gastrointestinal (%)</td>
<td>10.8 vs 11.5</td>
<td>9.0 vs 7.2</td>
<td>4.4 vs 11.5</td>
<td>NA</td>
</tr>
<tr>
<td>Skin (mRSS)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Comparison</td>
<td>--</td>
<td>--</td>
<td>NA</td>
<td>--</td>
</tr>
<tr>
<td>Lung (%)</td>
<td>50 vs 35.4</td>
<td>55.2 vs 32.7</td>
<td>20.0 vs 35.4</td>
<td>55.0 vs 33.5</td>
</tr>
<tr>
<td>Comparison</td>
<td>--</td>
<td>--</td>
<td>NA</td>
<td>--</td>
</tr>
<tr>
<td>Arthritis (%)</td>
<td>31.3 vs 28.0</td>
<td>36.4 vs 28.0</td>
<td>36.4 vs 28.0</td>
<td>36.4 vs 28.0</td>
</tr>
<tr>
<td>COMPARISON</td>
<td>--</td>
<td>--</td>
<td>NA</td>
<td>--</td>
</tr>
</tbody>
</table>

Tri-nation refers to the current study.
Table 4. Definitions of variables among the studies being compared.

<table>
<thead>
<tr>
<th></th>
<th>Anti-PM75</th>
<th>Anti-PM100</th>
<th>Anti-PM/Scl</th>
<th>Anti-PM1-alpha</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Detection method</strong></td>
<td>Euroimmun line immunoassay</td>
<td>Euroimmun line immunoassay</td>
<td>Euroimmun line immunoassay</td>
<td>Double immunodiffusion</td>
</tr>
<tr>
<td><strong>Comparison group</strong></td>
<td>Patients negative for anti-PM75 and anti-PM100</td>
<td>Patients negative for anti-PM75</td>
<td>Patients negative for anti-PM/Scl</td>
<td>ID for PM/Scl or ELISA for PM1-Alpha</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Overlap</strong></td>
<td>NA</td>
<td>SSC with other connective tissue disease</td>
<td>NA</td>
<td>SLE, RA, PM, DM</td>
</tr>
<tr>
<td><strong>Age on onset</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at symptom onset</td>
<td>Not defined</td>
<td>No clinical data present</td>
<td>Age at symptom onset</td>
<td>Percentage of patients with onset below 50 years</td>
</tr>
<tr>
<td><strong>Muscle</strong></td>
<td>Presence on physical exam by study physician</td>
<td>Muscle atrophy</td>
<td>CK elevation</td>
<td>Proximal muscle weakness, myopathic changes on electromyogram, abnormal biopsy</td>
</tr>
<tr>
<td><strong>Calcification</strong></td>
<td>Calcification on physical exam by study physician</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Skin</strong></td>
<td>mRSS</td>
<td>mRSS</td>
<td>mRSS</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Lung</strong></td>
<td>ILD</td>
<td>ILD</td>
<td>ILD</td>
<td>ILD</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td>Presence of GERD and/or reflux as per patient survey</td>
<td>Colon involvement</td>
<td>Esophageal dysmotility or stricture</td>
<td>Esophageal involvement</td>
</tr>
<tr>
<td><strong>Arthritis</strong></td>
<td>Presence on physical exam by study physician</td>
<td>NA</td>
<td>Physical and radiographic joint involvement</td>
<td>Synovitis</td>
</tr>
</tbody>
</table>

*DOI: 10.3109/08916934.2015.1077231*
commonly associated with GI and lung disease than anti-PM100 antibodies; anti-PM100 associated with better survival] clinical profiles. Other features previously associated with anti-PM/Scl antibodies such as higher rates of myositis were only observed in subjects with both anti-PM75 and anti-PM100 antibodies. These results suggest that various disease features associated with anti-PM/Scl antibodies may in fact depend on particular and possibly multiple antigen specificities. However, due to the small samples, these results need to be interpreted with caution.

Of particular importance, this dataset highlights the very low prevalence of the monospecific anti-PM75 and anti-PM100 antibodies in SSc. This underscores the importance of international collaborations to assemble sufficiently large cohorts to understand the clinical profiles of relatively uncommon antibodies in SSc.

In addition, little was known to date on the distinct clinical correlates of anti-Pm/Scl antibodies in SSc. We performed an extensive review of the literature (Table 3). All except one of the reported studies [14–16] of anti-PM/Scl antibodies in SSc examined the clinical correlates of those antibodies without excluding subjects with concomitant SSc-specific antibodies, in particular ACA, ATA and ARNAP. Thus, the variable profiles associated with those antibodies may in fact have been confounded by the presence of other antibodies known to have distinct clinical profiles. The only study examining monospecific anti-PM/Scl antibodies was recently reported and was done on a subset of the subjects included in the current study but using a different assay, an ELISA with the synthetic peptide PM1-Alpha, PM100’s major epitope [17]. In that study, monospecific anti-PM1-Alpha antibodies were present in 3.4% of the cohort and were associated with younger age at disease onset, more limited skin disease, skeletal muscle involvement, calcinosis, inflammatory arthritis and overlap disease, and less ILD and gastrointestinal symptoms (Table 4). It is noteworthy that this profile is similar to that of anti-PM100 in the current study, with the additional feature that anti-PM1-Alpha antibodies were also associated with muscle disease (whereas anti-PM100 was only associated with muscle disease in the presence of anti-PM75 antibodies). This suggests that testing both anti-PM75 and anti-PM100 antibodies or anti-PM1-Alpha antibody alone is necessary to cover the spectrum of the anti-PM/Scl antibodies. Of note, a novel anti-PM/Scl-100 antibody immunoassay has recently been developed and found to have good performance characteristics [18]. This immunoassay was used to test 223 Japanese SSc sera and found to be positive in only one (0.4%), a patient with lcSSc and pulmonary hypertension. The presence of concomitant SSc-specific antibodies in this patient was not reported, although the patient was said to have a positive ANA (titer 1:320) with nucleolar staining. Although anti-Pm/Scl antibodies are thought to be rare in Japanese patients, that proportion is consistent with the one reported for anti-PM100 in this study.

This study is not without limitations. In particular, variables including inflammatory myositis and calcinosis were not defined using specific criteria. Instead, a study physician reported their presence or absence. However, the fact that all study physicians were experienced rheumatologists supports the validity of these diagnoses. Similarly, defining ILD in the context of a longitudinal observational cohort studies is very complex, given issues of missing data and verification bias. We defined ILD using a clinical decision rule that was recently published [12]. Data on right heart catheterization was not systematically collected in all patients. Nevertheless, in those without right heart catheterization, we defined pulmonary hypertension using a high cutoff for pulmonary systolic pressure on echocardiogram that has been shown to correlate strongly with right heart catheter studies [13]. Still, we acknowledge that pulmonary hypertension based on echocardiogram is not synonymous with pulmonary arterial hypertension and that some of those with pulmonary hypertension based on echocardiogram may have had other causes of pulmonary hypertension such as left heart disease. Thus, measurement error may have contributed to some of the negative findings of the study. On the other hand, when dealing with relatively uncommon autoantibodies (there were only 16 subjects with monospecific anti-PM75 and 11 subjects with monospecific anti-PM100 antibodies in a cohort of 1574 subjects), large well-phenotyped cohorts are required. In the end, the limitations of our data are counter-balanced by its strengths, which include large sample size and detailed clinical phenotypic data.

This study aimed to identify clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies. These antibodies were uncommon in isolation and this points to the need for international collaborations to fill important knowledge gaps in SSc. Monospecific profiles of each autoantibody included more calcinosis. An increased frequency of myositis was only seen in subjects positive for both anti-PM75 and anti-PM100 antibodies. Lung disease was only associated with anti-PM75 and subjects with anti-PM100 antibodies had better survival compared to other antibody subsets. Disease features associated with anti-PM/Scl antibodies may depend on particular and possibly multiple antigen specificities. However, due to the small numbers of subjects with monospecific antibodies, these results need to be interpreted with caution and replicated in other studies.

Declaration of interest

The authors report no conflicts of interest.

The CSRG received funds and/or gifts in kind from the Canadian Institutes of Health Research (CIHR) (grant #FRN 83518), the Scleroderma Society of Canada and its provincial Chapters, Scleroderma Society of Ontario, Scleérodermie Québec, Cure Scleroderma Foundation, INOVA Diagnostics Inc. (San Diego, CA, USA), Euroimmun (Lubeck, Germany), Fonds de la recherche en santé du Québec (FRSQ), the Canadian Arthritis Network (CAN), the Arthritis Society Research Chair (University of Calgary) and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC. The CSRG has also received educational grants from Pfizer and Actelion pharmaceuticals. Dr. Hudson is funded by the Fonds de la recherche en Santé du Québec. Dr. Nikpour holds an NHMRC research fellowship (APP1071735). ASIG receives unrestricted grants from Actelion, Pfizer and GSK, and is also supported by Scleroderma Australia. Dr. Assassi is funded by the NIH/NIAMS K23AR061436. Dr. Mayes is funded by NIH/NIAMS.
AR055258. The GENISOS cohort receives funding from DoDW81XWH-13-1-0452. The funding sources had no role in the design of the study, analysis of the data, preparation of the manuscript and decision to submit for publication.

References


Supplementary material available online

Supplementary Table 1
Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival

M. Wodkowski¹, M. Hudson¹-³, S. Proudman⁴-⁵, J. Walker⁶, W. Stevens⁷, M. Nikpour⁷, M. D. Mayes⁸, S. Assassi⁹, M. Baron¹-³, M. J. Fritzler¹⁰, and the Canadian Scleroderma Research Group (CSRG), the Australian Scleroderma Cohort Study (ASCS), and the Genetics versus Environment in Scleroderma Outcome Study (GENISOS)

¹Dept. of Medicine, McGill University, Montreal, Quebec, Canada; ²Division of Rheumatology and ³Lady Davis Institute, Jewish General Hospital, Montréal, Canada; ⁴Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia; ⁵Discipline of Medicine, University of Adelaide; ⁶Department of Allergy and Immunology, Flinders Medical Centre, South Australia; ⁷Department of Rheumatology, St Vincent’s Hospital Melbourne, Victoria, Australia; ⁸Department of Medicine, The University of Melbourne at St. Vincent’s Hospital, Melbourne, Victoria, Australia; ⁹Division of Rheumatology and Immunogenetics, University of Texas Health Science Centre at Houston, Houston, Texas, USA; ¹⁰Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.

M. Hudson, MD
J. Walker, MD
W. Stevens, MD
M. Nikpour, MD
S. Proudman, MD, MPH

Please address correspondence and reprint requests to: Dr Marie Hudson, Jewish General Hospital, Room A-725, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec H3T 1E2, Canada. E-mail: marie.hudson@mcgill.ca

Received on March 17, 2015; accepted in revised form on July 6, 2015.


© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2015.

Key words: systemic sclerosis, autoantibodies, anti-Ro52/TRIM21 antibodies, interstitial lung disease, cohort study

Funding information and competing interests on page S-135.

ABSTRACT

Objective. Autoantibodies directed against Ro52/TRIM21 are common in systemic sclerosis (SSc) but their clinical significance remains uncertain. The aim of this study was to assess the clinical correlates and survival of subjects with monospecific anti-Ro52/TRIM21 antibodies, i.e. anti-Ro52/TRIM21 antibodies in the absence of other SSc-related antibodies.

Methods. A tri-nation (Canada, Australia, USA) cohort of 1574 SSc subjects was formed, demographic and clinical variables were harmonised and sera were tested using a common diagnostic platform. Statistical analyses were performed to determine associations between the presence of monospecific anti-Ro52/TRIM21 antibodies and outcomes of interest, including interstitial lung disease (ILD) and survival.

Results. 103 (6.5%) had monospecific anti-Ro52/TRIM21 antibodies, 324 (20.6%) had anti-Ro52/TRIM21 antibodies overlapping with other SSc-related antibodies and 1147 (72.9%) were negative for anti-Ro52/TRIM21 antibodies. Monospecific subjects were less likely to be White compared to negative subjects (68% vs. 82%, odds ratio (OR) 0.48, 95% confidence interval (CI) 0.30–0.75, p=0.0011). ILD was the only clinical variable significantly associated with monospecific anti-Ro52/TRIM21 antibodies compared to negative subjects (adjusted OR 2.70, 95% CI 1.75–4.14, p=0.0001). Subjects with monospecific anti-Ro52/TRIM21 antibodies were at significantly increased risk of death compared to subjects without anti-Ro52/TRIM21 antibodies (log rank p=0.0003; adjusted hazard ratio (HR) 1.87, 95% CI 1.24–2.82, p=0.0029).

Conclusion. The results obtained from this unique tri-nation cohort represent the strongest evidence to date that anti-Ro52/TRIM21 antibodies are independently associated with the presence of ILD and poor survival in SSc. These data provide strong support for the predictive and prognostic value of this serological biomarker in SSc.

Introduction

Two main types of SS-A/Ro autoantibodies have been described. One is directed at a 60 kDa protein known as SS-A/Ro60, which is a component of a small cytoplasmic ribonucleoprotein (scRNP) macromolecular complexes. Another, that often coexists with SS-A/Ro60 autoantibodies, is directed against a 52 kDa (Ro52) protein that is normally part of the scRNP complex but is an E3 ubiquitin ligase and member of the tripartite motif (TRIM) family of proteins known as TRIM21 (1, 2); hence, the preferred terminology of Ro52/TRIM21 will be used in this report.

Anti-Ro52/TRIM21 antibodies have been reported in a wide variety of autoimmune diseases, often overlapping with other autoantibodies (3-5). Hence, they have often been considered non-specific markers of autoimmune inflammation. The fact that these autoantibodies have also been detected in sera of patients with neoplasia (6), viral infections or even healthy individuals who later developed auto-immune diseases (7) has provided further support for this. In SSc, a recent report on a Spanish cohort of 132 consecutive SSc patients did not find any clinical associations with anti-Ro52/TRIM21 (8).

On the other hand, anti-Ro52/TRIM21 antibodies have been reported to be as-
associated with interstitial lung disease (ILD) in various autoimmune diseases (9, 10), in particular in association with anti-Jo1 antibodies (11), which are well known to be associated with ILD. We previously reported an association between anti-Ro52/TRIM21 antibodies and ILD in SSc where, if present, ILD was 1.5 times more likely (12). However, the relationship between anti-Ro52/TRIM21 and ILD in SSc (and other autoimmune diseases) may have been confounded by the presence of concomitant antibodies known to be associated with ILD, particularly antitopoisomerase I in SSc (13). We have previously shown that overlap with SSc-specific autoantibodies can confound the associations with other autoantibodies (14). The aim of this study was therefore to assess the clinical correlates of monospecific anti-Ro52/TRIM21 antibodies, i.e. anti-Ro52/TRIM21 antibodies in the absence of other SSc-related antibodies.

Materials and methods

The Tri-Nation cohort comprises SSc subjects included in the Canadian Scleroderma Research Group (CSRG), the Australian Scleroderma Cohort Study (ASCs) and the American Genetics versus Environment in Scleroderma Outcome Study (GENISOS) cohorts. Ethics committee approval for this study was obtained at McGill University (Montreal, Canada) and at all participating CSRG, ASCs, and GENISOS study sites. All subjects provided informed written consent to participate in the study. Selection of study subjects in and harmonisation of clinical variables between the 3 study cohorts have been described (15). Briefly, over 98% of the CSRG (16) and ASCs subjects, and all GENISOS subjects meet the 2013 ACR/EULAR classification criteria for SSc (17). Demographic information regarding age, sex and ethnicity was collected by subject self-report. Disease duration was recorded by study physicians and defined as the interval between the onset of the first non-Raynaud disease manifestation and baseline study visit. Skin involvement was assessed using the modified Rodnan skin score. Limited cutaneous disease (lcSSc) was defined as skin involvement distal to the elbows and knees with or without facial involvement; diffuse cutaneous disease (dcSSc) was defined as skin involvement proximal to the elbows and knees and/or of the trunk. A history of inflammatory myositis, calcinosis, inflammatory arthritis and scleroderma renal crisis was recorded by a study physician.

To assess gastrointestinal involvement, subjects answered yes/no to 6 questions concerning gastroesophageal reflux disease, dysphagia, antibiotics for bacterial overgrowth, episodes of pseudo-obstruction, fecal incontinence and hyperalimentation. The presence of interstitial lung disease (ILD) was determined using a clinical decision rule that was recently published (18). Using this algorithm, ILD was considered present if a high resolution computed tomography (HRCT) scan of the lung was interpreted by an experienced radiologist as showing ILD or, in the case where no HRCT was available, if either a chest x-ray was reported as showing either increased interstitial markings (not thought to be due to congestive heart failure) or fibrosis, and/or if a study physician reported the presence of typical “velcro-like crackles” on physical examination. Pulmonary hypertension was defined as an estimated systolic pulmonary artery pressure (sPAP) ≥45 mmHg measured using the Doppler flow measurement of the tricuspid regurgitant jet on cardiac echocardiography (an estimate that correlates strongly with right heart catheterization studies) (19) for CSRG and GENISOS subjects, or mean pulmonary artery pressure (mPAP) ≥25 mmHg with a pulmonary capillary wedge pressure (PCWP) <15 mmHg on right heart catheterisation for ASCs subjects.

Statistical analysis

Subjects were divided into those exclusively positive for anti-Ro52/TRIM21 antibodies (i.e. monospecific anti-Ro52/TRIM21 antibodies subjects), those with anti-Ro52/TRIM21 antibodies overlapping with other measured antibodies (i.e. overlapping anti-Ro52/TRIM21 antibodies subjects), and those altogether negative for anti-Ro52/TRIM21 antibodies. Descriptive statistics were used to compare 20 selected variables between 1) monospecific anti-Ro52/TRIM21 antibody positive versus negative subjects and 2) overlapping anti-Ro52/TRIM21 antibodies versus negative subjects. Adjusting for multiple comparisons, p<0.00125 was considered statistically significant. Multivariate logistic regression adjusting for baseline differences in age and ethnicity was used to determine the association between anti-Ro52/TRIM21 antibody groups and ILD. Kaplan Meier analysis and Cox proportional hazard models adjusting for baseline differences in age and ethnicity were used to compare survival between autoantibody subsets. p-values <0.05 were considered statistically significant for these 3 latter analyses. All statistical analyses were performed with SAS v.9.2 (SAS Institute, USA).

Results

A total of 1574 SSc subjects were included in this study, of whom 103 (6.5%) had monospecific anti-Ro52/TRIM21 antibodies, 324 (20.6%) had anti-Ro52/TRIM21 antibodies overlapping with other SSc-related antibodies and 1147 (72.9%) were negative for anti-Ro52/TRIM21 antibodies (Table 1). Monospecific subjects were less likely to be White compared to negative subjects (68% vs. 82%, odds ratio (OR) 0.48, 95% confidence interval (CI) 0.30–0.75, p=0.0011). Subjects with overlapping anti-Ro52/TRIM21 anti-

Anti-Ro52/TRIM21 antibodies in SSc / M. Wodkowski et al.

S-132
In unadjusted survival analysis (Fig. 1), a higher frequency of ILD in univariate or multivariate analysis.

subjects with monospecific anti-Ro52/TRIM21 antibodies were at increased risk of death compared to negative subjects (log rank p=0.0003). Again, after adjusting for differences in baseline demographic characteristics, subjects with monospecific anti-Ro52/TRIM21 antibodies were still at significantly increased risk of death compared to subjects without anti-Ro52/TRIM21 antibodies (hazard ratio (HR) 1.87, 95% CI 1.24–2.82, p=0.0029; Table III).

**Discussion**

Although anti-Ro52/TRIM21 is the second most common autoantibody in SSc sera (12, 20), the prevalence of monospecific anti-Ro52/TRIM21 antibodies in this large SSc cohort was less than 10%. Nonetheless, leveraging this large unique tri-nation dataset using a common serological platform, we found strong evidence that monospecific anti-Ro52/TRIM21 antibodies are independently associated with ILD and increased mortality in SSc. Currently, there are few robust clinical biomarkers in SSc-ILD aside from C-reactive protein, which has been shown to be associated with worse pulmonary function (21) and anti-topoisomerase I (Scl-70) with ILD (22) and worsening forced vital capacity (23). Our data provide evidence for a novel predictive and prognostic biomarker in SSc. Of note, though, subjects with overlapping anti-Ro52/TRIM21 antibodies did not have a higher frequency of ILD. It is possible that the presence of other SSc-related antibodies modifies the association between anti-Ro52/TRIM21 and ILD. The role of anti-Ro52/TRIM21 in the pathophysiology of autoimmune diseases remains largely unknown.
Table II. Logistic regression model to estimate the association between the presence of anti-Ro52/TRIM21 antibodies and ILD, adjusting for baseline demographic differences.

<table>
<thead>
<tr>
<th></th>
<th>β Odds ratio</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>-0.23</td>
<td>0.80–0.60</td>
<td>1.06</td>
</tr>
<tr>
<td>Age</td>
<td>0.01</td>
<td>1.01–1.01</td>
<td>1.02</td>
</tr>
<tr>
<td>Monospecific vs. negative anti-Ro52/TRIM21 subjects</td>
<td>0.99</td>
<td>2.70–1.75</td>
<td>4.14</td>
</tr>
<tr>
<td>Overlapping vs. negative anti-Ro52/TRIM21 subjects</td>
<td>0.05</td>
<td>1.05–0.80</td>
<td>1.37</td>
</tr>
</tbody>
</table>

Nevertheless, some reports suggest a pathogenic role. In general, the autoantibody binding target, Ro52/TRIM21, is a regulator of type I interferon (IFN) and proinflammatory cytokine production (2). In turn, IFNα upregulates Ro52/TRIM21 and promotes its nuclear translocation to apoptotic blebs (24). This self-perpetuating process has the potential to contribute to the inflammatory cascade. In tissue, Ro52/TRIM21 expression is increased in cutaneous lupus erythematosus and ultraviolet light-induced skin lesions and translocation to apoptotic blebs has been hypothesised as a mechanism for its immunogenicity (25). Evidence also exists to support a similar mechanism occurring during cardiomyocyte apoptosis, as well as direct cross-reactivity with cardiac membrane proteins involved in the control of electric signal generation and/or conduction, as in congenital heart block (26, 27). Finally, in primary Sjögren syndrome, a single nucleotide polymorphism in the Ro52 gene has been shown to be associated with anti-Ro52/TRIM21 autoantibodies (28). Although anti-Ro52/TRIM21 autoantibodies have been shown to be associated with severe disease refractory to steroids in auto-immune hepatitis, the pathogenic mechanisms, if any, are not known (29). Similarly, the pathogenic role of anti-Ro52/TRIM21 and other autoantibodies associated with interstitial lung disease is not known (30).

This study is not without limitations. In particular, defining ILD in the context of longitudinal observational cohort studies is very complex, given issues of missing data and verification bias. We defined ILD using a clinical decision rule that was recently published (18). Still, measurement error may have contributed to some of the negative findings of the study. On the other hand, when dealing with relatively uncommon serological profiles (there were only 6.5% of subjects with monospecific anti-Ro52/TRIM21 antibodies, large well-phenotyped cohorts are required to obtain robust estimates. Thus, the limitations of our data are counter-balanced by its strengths, which include large sample size and detailed clinical phenotypic data. Finally, subjects identified as having “monospecific” anti-Ro52/TRIM21 antibodies may in fact have had other autoantibodies that are undetected by the immunoassays employed in this study. This might include some associated with connective tissue disease-related ILD such as anti-Jo1, which were not included among those tested for this study. However, we have previously reported a very low prevalence of anti-Jo1 antibodies in the CSRG SSc cohort (approximately 1%) (12). Thus, the presence of these autoantibodies is unlikely to have influenced the results of this study in a meaningful manner.

We found that monospecific anti-Ro52/TRIM21 antibodies were strongly associated with ILD and an independent predictor of mortality in this large SSc cohort. This provides the strongest evidence to date for the predictive and prognostic value of this serological biomarker in SSc and contributes important clinically meaningful data.

Investigators of the Canadian Scleroderma Research Group

J. Pope, London, Ontario
M. Baron, Montreal, Quebec
J. Markland, Saskatoon, Saskatchewan
D. Robinson, Winnipeg, Manitoba
N. Jones, Edmonton, Alberta
N. Khalidi, Hamilton, Ontario
P. Docherty, Moncton, New Brunswick
E. Kaminska, Calgary, Alberta
A. Masetto, Sherbrooke, Quebec
E. Sutton, Halifax, Nova Scotia
J-P. Mathieu, Montreal, Quebec
M.D. Mayes is funded by NIH/NIAMS AR05528.
M. Fritzler is a paid consultant, has received honoraria or has received gifts in kind from Inova Diagnostics (San Diego, CA) and Euroimmun GmH (Lübeck, Germany).

The funding sources had no role in the design of the study, analysis of the data, preparation of the manuscript and decision to submit for publication.

References

M.D. Mayes is funded by NIH/NIAMS AR05528.
M. Fritzler is a paid consultant, has received honoraria or has received gifts in kind from Inova Diagnostics (San Diego, CA) and Euroimmun GmH (Lübeck, Germany).

The funding sources had no role in the design of the study, analysis of the data, preparation of the manuscript and decision to submit for publication.

References